The analytical land and biological enantioselectivity of substituted 2-aminotetralins. by Wood, Stephen A.
U N IV E R S IT Y  OF SU R R E Y  L IB R A R Y
ProQuest Number: 10131025
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10131025
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
THE ANALYTICAL AND BIOLOGICAL 
ENANTIOSELECTIVITY 
OF SUBSTITUTED 2-AMINOTETRALINS.
Stephen A. Wood
Submitted for the degree of Doctor of Philosophy. 
Robens Institute of Health and Safety 
University of Surrey 
1996
ABSTRACT
The enantiomeric discrimination properties of a number of commercial chiral HPLC 
stationary phases have been examined using a series of 2-aminotetraiin analogues. The 
mobile phase conditions for each column were varied in order to optimise the separation for 
the largest number of analytes. Factorial experimental design techniques were used to test the 
empirically derived mobile phase combinations. A primary limitation o f factorial design 
optimisation strategies, the number of experiments required, was overcome by the 
development of a simultaneous factorial design method utilising the selectivity of mass 
spectrometric detection. This enabled the optimisation of the separation o f the enantiomers 
of 12 compounds, using Chiral AGP, to be carried out concurrently. None of the columns 
tried was able to separate the enantiomers of more than half the analytes.
The retention mechanism of the Chiral AGP column was shown to be via cation exchange 
and non-polar interactions. The ability to form a hydrogen bond between the carbon 8 
substitution (acceptor) o f the analyte and the stationary phase (donor) was found to be a 
prerequisite for the separation of enantiomers using Chiral AGP and Chiralcel OD. Neither a 
rule based nor a mathematical model constructed from calculation derived physicochemical 
and molecular data were sufficient to describe the enantioselectivity of the Chiral AGP 
stationary phase. A molecular graphics template model was used to demonstrate the 
importance of the spatial position of the hydrogen acceptor to the enantioselectivity o f the 
column.
Two 2-aminoteralins substituted at the carbon 8 position with a keto-pyrrol function were 
found to be enantioselectively cleared from in-vitro rat liver preparations dependent upon the 
substitutions attached to the carbon 2 nitrogen. Differences between these closely related 
structures were shown to be related to the hydroxylation of the parent molecule, probably, 
although not exclusively, via the cytochrome P450 isozyme CYP2D6. An in-vivo study using 
an intravenous dose route showed no sign of enantioselectivity or evidence of the major 
in-vitro metabolite.
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GENERAL INTRODUCTION
CHIRAL COMPOUNDS
Scientists have been aware of the chiral nature of natural and synthetic compounds for over a 
century. Today, issues relating to chirality have reached a wider audience. Many media 
articles appeared prior to the floatation in February 1994 of the biotechnology company, 
Chiroscience. The financial press have focused on the commercial
merits of converting racemic drugs into "new" single enantiomer medicines as distinct from 
new chemical entities which were single enantiomers. In addition, the national press used its 
science and health care columns to inform the
general public about the drug safety and efficacy issues that relate to chirality.
The increased awareness of chirality and drug safety has found its way into popular fiction. In 
the novel "Body of Evidence" a non-toxic single enantiomer found in an "over
the counter" medicine was used to mask the presence of its other, highly toxic enantiomer, 
thereby diverting the investigators attention from the possibility of poisoning.
Stereochemical definitions.
Isomers.
Isomers can be defined as molecules which closely resemble one another but are not identical 
due to a single difference in their chemical structure. A pair of constitutional isomers share 
the same molecular formula but the arrangement of the atoms is different, for example 
propan-1-01 and propan-2-ol. When the difference is due to spatial arrangement of atoms the 
molecules are said to be stereoisomers.
Stereoisomers can be subdivided according to two distinct criteria, namely geometry or 
energy The geometry criterion classifies stereoisomers into enantiomers and
diastereomers. If  stereoisomers are related to each other as object and non-superimposible 
mirror images they share an enantiomeric (chiral) relationship. These are also termed optical
isomers because they show optical rotations of plane polarised light of opposite sign and 
equal amplitude. Stereoisomers that are not enantiomers are diastereomers. The definition 
implies that they are mutually exclusive.
The alternative classification, according to energy, is less well defined. The stereoisomers 
can be discriminated on the basis of the energy needed to convert one isomeric form to the 
other.
Enantiomers.
A chiral molecule must contain one or more elements of asymmetry. The molecule may be 
unsymmetiical about a centre, axis or plane. Carbon is the most frequently encountered 
asymmetric centre but other chiral tetracoordinate centres are possible, including quaternary 
nitrogen and phosphonium salts. Some configurationally stable tricoordinate centres are also 
possible, for example, chiral sulfoxide, where the lone pair of electrons is treated as the 
fourth ligand. The tricoordinate derivative of nitrogen undergoes fast inversion and is 
therefore not geometrically stable.
Plane polarisation of light.
A chiral compound possesses the unique ability, first demonstrated by Biot in 1838, to rotate 
plane polarised light. Plane polarised light can be regarded as consisting of two kinds of 
circularly polarised light. It can be visualised as two helixes, one left handed the other right 
handed, propagating along the axis of motion When the light encounters a chiral
agent each helix (wave) is presented with a different path which, if it were possible, would 
result in the two circularly polarised components propagating at different speeds through the 
chiral molecule. However the two components of the same light cannot travel at different 
speeds and the faster wave "pulls" the slower towards it. The result of this, vector addition, is 
that the plane of the light is rotated. The amount of rotation can be very small and is 
dependent on a number of factors; path length, temperature, solvent and concentration 
(solutions) or pressure (gasses). To remove external influences the specific rotation (a) is 
defined as equation 1 ;
Equation 1
P 100a[ a l =  —
where a  = measured rotation, X= wavelength (nm), T = temperature (°C), 1 = cell path-length 
(cm), c = concentration of compound (g 100 ml'^)
Classification.
Identifying the rotation of plane polarised light does not allow the molecule to be modelled 
with the correct spatial arrangement of atoms. However, the absolute classification of the 
arrangement of atoms at a chiral centre is most important chemically, pharmacologically and 
for identification purposes. The need to assign absolute configuration to enantiomers was 
addressed by Rosanoff who arbitrarily assigned the label D to a given configuration of 
glyceraldehyde (the alternative configuration was labelled L). Compounds synthetically 
related to this compound were also assigned the D configuration. Similarly, compounds 
linked to these where also assigned ‘D ’. It is possible to have two compounds related in this 
way to rotate plane polarised light in different directions. This nomenclature is limited to 
asymmetric carbon atoms and is now used mainly for carbohydrates and amino acids
(March, 1985]
A more generally applicable nomenclature is that of Calm, Ingold and Prelog The (R) 
and (S) description allows the absolute configuration to be reconstructed. It does not however 
have any relationship to the optical rotation of the two isomers. The nomenclature is based 
upon a sequential rule which arbitrarily assigns a value (value in this context is related to 
molecular mass, for example, H<CH3 <C2 Hs) each of the four constituents (a, b, c and d) of 
the chiral centre. The asymmetric centre is placed with the lowest value ligand (labelled d) 
pointing away from the viewer and the highest (labelled a) uppermost. If the sequence a - b - 
c runs clockwise it is designated (R) (rectus) if it runs anticlockwise it is assigned the (S) 
configuration (sinister), figure 1.
Figure 1
Conformation determination by Cahn. Ingold and Prelog.
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Chirality in nature.
Despite a high degree of external anatomical symmetry the animal body is, at the chemical 
level, an intensely chiral environment where biochemical reactions exliibit specific 
handedness. Proteins, for example, are almost exclusively built from L-amino acids (same 
configuration as L-glyceraldehyde). Very few exceptions to this rule are found in living 
organisms. A rare example is the capsular substance of Bacillus anthracis which
contains D-amino acids. Carbohydrates consist of sugar units whose conformation is spatially 
related to D-glyceraldehyde.
Possible origins of biological handedness.
A question arises as to why do living organisms use L-amino acids and D-sugars? The 
‘common ancestor effect’ provides a plausible answer. The current chiral
composition found in living creatures arose because it was the composition used by the 
organism at the root of the ‘evolutionary tree’. Therefore, as the common ancestor used 
L-amino acids to construct its proteins, so do all of its descendants. The common ancestor 
effect does not address the question of how the first organism came to use L-amino acids. A 
possible biological answer to the question, is natural selection. If both D and L amino acids 
were available in abundance, the gradual prevalence of L over D form amino acids in the 
interests of biological efficiency may have occurred.
A number of non-symmetrical physical forces have been proposed to show that prebiotic 
substances could have been homochiral Solar radiation has a circular polarisation
of very low magnitude at certain times o f day. The irradiation of racemic substrates with 
circularly polarised light may have lead to enantiomeric photochemical synthesis. Other 
theories relate to the non-conservation o f parity in the electroweak interaction (mediator of 
P-radioactivity). These theories predict very small differences in photolysis and binding 
energies which results in one enantiomer becoming the energetically preferred state. The 
1.4% enantiomeric excess of morphologically (-)-quaitz crystals is evidence of a 
non-heterogeneous distribution of chiral structures in the natural world.
The impact of these “chiral physical forces” are vanishingly small. Chiral amplification 
mechanisms have been proposed which account for the minor enantiomeric excess reaching a 
point where biological evolution could take over. These theories involve either a gradual (a 
reaction where the very small enantiomeric excess for the substrates is amplified in the 
product) or a catastrophic (minor alteration of the substrates of a metastable reaction triggers 
a non-racemic production of the product) kinetic process.
ANALYSIS OF CHIRAL COMPOUNDS
Non-separation techniques.
Optical rotation (polarimetry):
The unique property of enantiomers is the ability to rotate plane polarised light in equal but 
opposite directions, and this can be used to measure enantiomeric purity. Polarimetry is a 
simple method of measuring the amount of an antipode present, for example, in a new 
chemical synthesis. However, the maximum rotation for the pure enantiomers, [aj^ax., must 
be known. The optical purity, P(%), of a sample can then be calculated using equation 2;
Equation 2
[“ L »
Where: a  = optical rotation measured for the mixture.
The optical rotation is dependent upon the solvent used, the wavelength chosen, and assumes 
there is no molecular association between the enantiomers in solution, or with the sample 
matrix. These conditions preclude the measurement of the enantiomeric ratios of small 
synthetic chemicals in biological samples, for example plasma.
Nuclear magnetic resonance (NMR):
Chiral recognition with “magnetic” methods requires the formation of 
diastereomers l®*®smann, 19931 may be formed by derivatisation with an optically pure
reagent, or more usefully, by interaction with a chiral environment during NMR 
determination. Chiral solvents, for example, (R)-(-)-2,2,2,-trifluro-1 -phenylethanol induce a 
chemical-shift difference between the enantiomers resulting in two peaks which can be 
measured by integration. The purity of the solvent does not alter the peak area ratio, just the 
separation of the peaks. This separation, caused by the preferential interaction of one 
enantiomer with the solvent, is often too small to enable discrimination.
An improvement in the separation of NMR peaks split in this way can be obtained using 
optically active lanthanide-shift reagents. These result in both higher resolution (from pseudo 
contact downfield shifts) and the splitting of the resonance lines by enantioselective 
interaction. Integration of the NMR spectra results in the concentration ratio (r) of the 
enantiomers and the enantiomeric purity or enantiomeric excess is given by equation 3;
Equation 3
( 1 - r )enantiomeric.excess   -xlOO%(1 + r)
Immunoassay:
Stereoselective antibodies, for example for propranolol I®“hui-Gnassi, 1 9 9 3 ]^  possible. In this 
case the binding measured for antibodies raised to the enantiomerically pure hapten was 
twenty times greater than seen for its antipode. Plasma protein binding of propranolol is high 
(>90%) and stereoselective with higher binding for the (S) enantiomer through interaction 
with a ra c id  glycoprotein. This selectivity might affect the assay if free drug only can be 
measured. The cross reactivates of the antibodies to metabolites and structural analogues was 
similar to antibodies raised to the racemate. Similarly propranolol can be measured using a 
radio recep+''’* assay where K, values of 8 x 10‘*° for the (S) enantiomer and 6 x 10'® M for the 
(R) can be obtained using bovine lung preparations However, both immunoassay
and radioreceptor assays measure biological activity and cross reactivity of endogenous 
compounds and metabolites must be established before use.
Isotope dilution:
To use isotope dilution both the specific rotation and the isotope content of the sample must 
be determined. The latter can be measured using mass spectrometry, or if the sample contains 
a radioisotope, scintillation counting. To measure the concentration of an unknown sample, 
an aliquot of the sample is added to a solution of an isotopically labelled racemate of the 
same compound. The new sample is recrystallized and the isotopic content and optical 
rotation measured. This information can be used to calculate the [a]max. which when 
substituted into equation 1.2 will yield the optical purity of the original sample. This 
technique requires high concentrations and is useful for the determination o f enantiomer 
purity.
Enzyme assays:
Some enzyme reactions are highly stereoselective, and this property can be used to measure 
optical purity of samples. Both L- and D- amino acid oxidases are available commercially 
(Sigma Chemical Company, Poole, UK) and allow quantification of 0.1% of one enantiomer 
in the presence of its antipode. The applicability of these assays is limited by the specificity 
of the enzyme.
Summary of non-separation techniques.
The non-separation techniques listed above work well in specific cases but have 
shortcomings with samples of biological origin, particularly those containing close structural 
analogues, such as metabolites. Enantiomerically pure compounds, or at least compounds of 
known purity, are needed for polarimetry. The optical rotation would be affected by any other 
optically active substances in the sample, and polarimetry is therefore only useful for pure 
substances. NMR improves upon polarimetry in that specific parts o f a molecule can be 
examined. If  this signal is unique to the compound under test then the sample matrix does not 
need to be pure. However, with the exception of techniques such as fluorine NMR, this is 
rarely the case. Immunoassay techniques require the production of a stereoselective antibody 
which ideally does not cross react with either the antipode, metabolites, or the sample matrix. 
Whilst production of antisera is time consuming, high binding values, and therefore a 
sensitive assay, is not guaranteed.
To improve the applicability of the above techniques, analytes can be extracted from the 
sample matrix. Extraction from complex matrices such as plasma and urine is rarely 
completely selective and some physicochemically similar co-extracts will be present in the 
sample. Achiral chromatography can be used to prepare a pure sample of the test compound 
by collection of the appropriate mobile phase fraction. However, only immunoassay of the 
techniques described, could offer superior sensitivity to on-line measurement of resolved 
enantiomers. To meet the needs of the in-vitro screening projects, on-line procedures are 
necessary.
High Performance Liquid Chromatographic theory.
There are a great variety of chromatographic techniques. Some require little equipment such 
as paper or thin layer chromatography where others such as capillary gas chromatography, 
require sophisticated engineering in order to work at their best. The utility of a 
chromatographic method often rests upon the extent of commercialisation. Capillary 
electrophoresis, for example, has been the focus of considerable commercial development in 
recent years. This is the combination of electrophoresis, where migration of analytes is 
dependent upon their overall molecular charge and liquid chromatography, because the 
conducting buffer flows through the fused silica capillary. A thorough explanation of 
capillary electrophoresis and gas chromatographic (GC) technique is beyond the scope of this 
introduction. High performance liquid chromatography (HPLC) is the technique of choice for 
many bioanalytical applications particularly those were versatility and speed of development 
are important.
Chromatography is the separation of molecules by their differential migration within a 
matrix. This very broad description also encompasses, for example, electrophoresis. Liquid 
column chromatography is described by the partition of a compound (the solute) between two 
phases, one stationary (packed into a silica, glass or steel tube, the column) and the other (the 
mobile phase) moving at a constant rate through the column. A solute which has a high 
affinity for the stationary phase may never elute from the column. Conversely a solute which 
is excluded from the stationary phase will travel through the column at the same rate as the 
mobile phase. The latter compound is said to be unretained.
The discussion which follows has been compiled from two sources ^nox. 1978]
It is assumed for the purpose of the following discussion that the unretained molecule has 
access to the total swept volume of the column, that it is small enough to enter the pores of 
the stationary phase. At equilibrium a solute (i) distributes itself between the two phases, 
resulting in a total quantity qj ^ present in the mobile phase (m) and qj s in the stationary 
phase (s). Molecules when dissolved in the mobile phase will be transported through the 
column at the same speed (u, the linear velocity of the mobile phase through the column) as 
the mobile phase molecules. However because the solute is constantly being adsorbed and 
desorbed by the stationary phase, the migration of the solute through the column is only a 
fraction of the mobile phase velocity, u, as given by equation 4:
Equation 4
y  _   film— y _    ----------------------------- u
qim+qù i+(q«/qi,) (i+k)
where V, is the migration speed of the solute band through the column.
The ratio qim/qis is known as the capacity ratio and denoted by k'. The time taken for the band 
to elute from the column (the retention time tn) is determined by the column length L and the 
migration speed, equation 5;
Equation 5
L
= -
Also important is the time taken for a mobile phase molecule to travel through the column 
(to), equation 6;
Equation 6
The combination of the three equations results in, equation 7:
Equation 7
trt = ( l  + k '> o
Equation 7 is the best description of retention as it is independent of the variables for mobile 
phase velocity and column length. A rearrangement of the above gives, equation 8:
Equation 8
, _  t r i - tok’ =
Using equation 8, it is possible to measure k' directly from the chromatogram.
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A chromatographic peak should be eluted from the column in the smallest possible volume of 
mobile phase. A typical HPLC solute may elute from the column in 1 ml of mobile phase, 
however, it was introduced on to the column in only 10 pi of solvent. This increase in volume 
is due to peak dispersion. Peak dispersion results in the dilution of the analyte concentration 
in the mobile phase (relative to the concentration of the analyte when it was injected) as it 
moves through the column. Dispersion arises from the following process;
1) A multi path route through the stationary phase bed. This form of dispersion is 
affected to a small degree by mobile phase velocity.
2) Molecular dispersion is dependent upon the total time spent by the solute in the 
column. This form of dispersion is most important at low mobile phase flow rates.
3) Slow equilibration between the mobile and stationary phases leads to peak 
dispersion which is directly related to flow rate.
The dispersion of the analyte increases with the square root of the distance travelled through 
the stationary phase and results in a Gaussian disti ibution of molecules in the eluted peak.
The extent of the dispersion is a measure of the column’s efficiency. Column efficiency, N, 
(number of theoretical plates), is related to the standard deviation (s) of the disti ibution, 
equation 9:
Equation 9
N = ( t , / s )
The column efficiency can be measured directly from the chromatogram using the peak width 
at half height (W]/2 ), equation 10;
Equation 10
N = 5.54(,/W|/,)
The theoretical plate height is expressed as the column length, L, divided by the efficiency,
N, equation 11 ;
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Equation 11
H = L /N
Plate height plotted against mobile phase velocity (u), known as a Van Deemter plot, will 
show an optimum mobile phase flow rate which produces the minimum plate height for a 
given stationary phase and particle size.
Chromatography is carried out to affect the separation of different analytes. The separation 
achieved can be expressed in a variety o f ways. The simplest description is the relative 
retention of the analytes, known as a . Alpha is the ratio of the capacity factor of the two 
peaks, k'2 /kV No separation is therefore equal to a= l .  A more complete description of 
resolution, Rg, of two different solute peaks is defined by equation 12;
Equation 12
R. = 2At,/(w,+Wj
As the baseline width of a Gaussian distributed solute band is equal to 4 standard deviations 
(a), it follows that a delta( A X  equal to 4a  is equivalent to Rg = 1.0. This means that there is 
a peak overlap of only 2%. For Rg = 1.5 (6a separation) there is complete baseline separation.
Rearrangement of the above equation and the addition of the average capacity factor k  -  (k| 
+ 1(2 ) / 2  gives equation 13;
Equation 13
a  -  1 , k , Vn
= * ____ -k.
i + k  2
As can be seen from the above equation, there are three factors affecting Rg. Efficiency is the 
least powerful due to the effect of the square root. The average capacity factor has a 
significant effect on the resolution. The effect of increasing the value is greater at lower 
retention times, therefore little is to be gained from highly retained analytes. The most 
important factor is the selectivity parameter a . A change in this parameter has a greater effect 
on resolution than a similar magnitude of change in either of the other two.
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Development strategies for achiral analysis.
The development of achiral separations, particularly reversed phase separations, can follow a 
well defined path. Briefly, a column chemistry is chosen to match the polarity of the 
compound. The mobile phase strength is adjusted to give adequate retention (k' 3-5). If  the 
selectivity of the chromatography is not adequate then the mobile phase composition can be 
altered by selecting a different organic solvent and using a concentration calculated to be of 
equal strength to the initial solvent. If  this is still inadequate mixtures of these solvents can be 
tried. This optimisation strategy is based on the use of the solvent selectivity triangle 
(Giajch, 1993. Synder, 1987] fjes^ription of solvent properties.
Further optimisation can be achieved by altering the stationary phase. A similar approach to 
the solvent optimisation can be taken with column choice The bonded phase
packings, for example C8, nitrile (CN) and phenyl (PH) may result in large selectivity 
differences, if not for the analyte, then for the co-extracted matrix components. The same 
chromatographic optimisation of solvent and column choice can be applied to normal phase 
systems Both of these strategies lend themselves to computational techniques to
find the optimum solvent / column combination I®®"*®®»
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CHIRAL CHROMATOGRAPHY.
Chromatographic analysis of enantiomers.
As stated earlier, chromatographic separation arises from the differential partition of the 
analytes between the mobile and stationary phases. In achiral chromatography, the 
differences which result in separation are physicochemical, for example, degree of 
lipophilicity or differences in charge upon the analytes. The separation of such analytes can 
be achieved by optimising the mobile phase strength or pH. No physicochemical differences 
exist between enantiomers and therefore a separation cannot not be achieved using achiral 
phases.
The separation of enantiomers using chromatography can be achieved in two ways. The 
classical and still popular method of resolving enantiomers is via derivatisation. The addition 
to each of the analyte enantiomers of a second chiral centre results in the diastereomeric 
products having different physicochemical properties. The alternative approach is to conduct 
the chromatography in a chiral environment.
Formation of covalent diastereomers.
The reaction between a pair o f enantiomers and an optically pure derivatisation reagent 
produces a pair of diastereomers which, because of their different physicochemical 
properties, can be separated using achiral stationary phases. For gas chromatography, 
derivatisation o f the analytes may be required to improve their volatility. The incorporation 
of an additional chiral centre during this process does not make the method significantly 
more time consuming or difficult There are however important implications when
using this form of analysis for the quantitative measurement of enantiomers. If  the 
derivatisation reagent is not pure then the diastereomers produced do not represent the 
absolute ratio of enantiomers in the sample, figure 4. This is due to the achiral stationary 
phase's inability to separate the enantiomers generated by the impurity in the derivatisation 
reagent.
14
Figure 4
Products of derivatisation with an impure chiral reagent.
(H-)-B (+)-A-(+)-B (i)
-------------> (.)-A-(+)-B (ii)
main reaction
(±)-A
(-)-B (+)-A-(-)-B (iii)
 > (-)-A-(-)-B (iv)
minor reaction
A = analyte B = derivatisation reagent
The four products represent two pairs of enantiomers i, iv and ii, iii respectively. The 
enantiomeric ratio can be determined if the optical purity of the reagent is known, but this 
relies on a number of assumptions. The reaction rates may be different for each enantiomer 
which will produce different yields if the reaction does not go to completion, or racemization 
(epimerization) may take place.
Chiral chromatographic environment.
It is the geometry of an enantiomer that distinguishes it from its antipode. The first chiral 
recognition theory was put forward by Dalgliesh He proposed the need for a 'three point 
interaction' after studies of the chromatography of amino acids using paper chromatography. 
He believed that the hydroxyl groups of the cellulose (a chiral macromolecule) stationary 
phase were hydrogen bonding to the amino and carboxyl groups of the amino acid. The third 
interaction he assumed to be due to the steric effects of the aromatic substituents.
It can be seen that to affect the recognition of a chiral molecule by matching it to a selector 
molecule, three geometrically important interactions are necessary. It is important to 
understand that these need not be attractive interactions and that purely steric factors could 
lead to chiral recognition. However in adsorption chromatography some kind of binding must 
exist with the stationary phase. The type of interaction will be influenced by the mobile phase 
environment. In non-polar solvents hydrogen bonding, ionic or dipole interactions may occur.
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Hydrophobic interactions may be additionally important in aqueous environments
[Allcnmark, 1988]
The more stable enantiomer-selector complex will be the enantiomer most retained when the 
selector is bound to, or is, the stationary phase. The reverse will be true if the selector is 
added to the mobile phase. The antipode of the selector can be used to reverse the elution 
order of the analyte enantiomers. Elution reversal may be very important if trying to quantify 
samples with a large enantiomeric excess.
Mobile phase additives.
When a chiral selector is added to the mobile phase the analyte and selector may form a 
diastereomeric complex. The strength of the complex will depend upon the degree of 
interaction. The types of interaction include ionic, hydrogen bonding, dipole interactions, n-n 
(primarily between aromatic rings) and steric limitations.
Diastereomeric ion-pairs of can be formed with, for example, P-blockers and 
N-benzoxycarbonyl-glycyl-proline (ZGP, figure 5) *^ **1. 10-Camphorsulphonic acid
may also be used for this class of compounds.
Figure 5
N-CBZ-GLY-PRQ rZGPV
\  — /  H COOH
An alternative chiral additive method, ligand exchange, involves the use of an amino acid 
chiral selector (commonly L-proline). The additive is able to form labile co-ordinate bonds 
with electron donating hetroatoms via copper (II) ions in the mobile phase (further details are 
given later). The ternary complexes formed with each of the analyte enantiomers have 
different stability’s resulting in different chromatographic retention. This technique has been 
used for the analysis of underivatised amino acids A complex is formed between
an amino acid chiral selector (L-proline) and copper acetate in the mobile phase and the 
enantiomers of the analyte. A similar approach has been used for the separation of dansyl 
amino acid derivatives using thin layer chromatography 1^®"*®*®'"'
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The retention and selectivity behaviour of chiral mobile phase additives is analogous to that 
of the same selector used as the stationary phase. Conceptually all the chiral selectors that are 
bound to a support surface in chiral HPLC columns can be used as a mobile phase additive, 
for example, human aj-acid glycoprotein (Hermansson, i984a] Difficulties o f additive solubility 
and detection, however, limit the use of mobile phase additives.
Direct methods -classification of stationaiy phases.
A classification of chiral stationary phases (CSPs) was proposed by Wainer in 1987. There were 
by 1993 500 CSPs l^oppcnhoefer, 1993] g u s  chromatography and 400 for liquid and
supercritical fluid chromatography) either commercially available or described in the 
literature. Whilst many of these phases are minor variations on a common theme, newer 
commercial products are attempting to incorporate diverse functionality i99i]
these circumstances a CSP may work as one Wainer column type for one separation and a 
different mechanism may be dominant for another when used with different mobile phase 
combinations. The Wainer classification can be used as a general grouping of CSPs and as 
such remains a useful aid.
Wainer type I. Stationary phases where "attractive" forces are the primary retention 
mechanism.
Wainer type II. Stationary phases where inclusion into chiral cavities and attractive 
forces are the primary retention and selectivity factors.
Wainer type ITT. Stationary phases where the inclusion of part of the analyte into a 
cavity of the stationary phase is the significant factor in the enantiomer separation.
Wainer type IV. Metal complexing stationary phases where a metal complex is 
formed between the analyte and the stationary phase.
Wainer tvpe V. Stationary phases which consist of a protein coated onto a support 
matrix, usually silica. The analyte interacts with binding sites on the protein coat.
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Theory and optimisation of the different CSP types.
Two of the above column types warrant close investigation. The first is the Wainer type I 
phases because the binding site is known explicitly and the analyte stationaiy phase 
interactions can be postulated in the light of this knowledge. In addition the functional groups 
of these phases appear in phases of different CSP types. The second column type worthy of 
more in-depth study is the protein based columns, Wainer type V. With these CSPs, and the 
protein a ra c id  glycoprotein is the most studied, the tertiary structure of the stationary phase 
as attached to the column support (usually silica) is unknown. Interactions between the 
analyte and type V CSPs is inferred from the experimental results.
Brush phases fPirkle or Wainer type I CSPs).
Structure:
The Wainer type I phases are “brush type” phases where the analyte interacts with an
optically pure moiety linked to an achiral support matrix. The early commercial phases were
developed by Pirkle and co-workers using NMR studies of diastereomeric complexes. These
phases consisted of optically pure amino acids which had been derivatised to include a 7t
accepting group, dinitrobenzoyl. The chiral selector was either covalently bound to the silica
support or prepared using an ionic interaction (figure 6) with a charged function bound to the 
silica |D«PPe»,1986]
Figure 6
Ionic linked N-(3.5-dinitrobenzoynphenylglycine.
NO.
HDOC N
IO2
Other amino acid derivatives were also used such as leucine. Variations of the phenylglycine 
phase were developed. A second chiral centre and different bonding chemistry produced a 
stationary phase for the separation of derivatised chiral acids The amino acid
derivatives have been replaced with synthetic variants such as
dimethyl N (3,5-dinitrobenzoyl)-a-amino-(4-allyloxy)benzylphosphonate If  a
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single enantiomer of a chiral selector has different affinities for the enantiomers of another 
substance, then a single enantiomer of the latter will have different affinities for the 
enantiomers of the initial selector. This affect is known as reciprocity The Tt-donor
CSPs are developments of this idea. To improve the applicability of the Wainer type I 
columns selectors have been developed that contain both 7i-acceptor and Tt-donor 
g r o u p s f i g u r e  7.
Figure 7
fS.Sl Whelk-O 1.
NH
NO.Si
NO
The ideal Pirkle stationary phase would be made with optically pure materials. However, in 
contrast to derivatisation, the presence of the opposite enantiomer merely reduces the 
observed separation. When the stationary phase comprises of an equal proportion of the two 
enantiomers then no separation of the analyte enantiomer will occur.
Recognition mechanism:
The structure of the Wainer type I stationary phases is well defined by the chemistry used to 
make it. It is therefore possible to determine what interactions may occur between the CSP 
and the analyte. However, how these interactions occur and the relative importance of each of 
them to any given separation is less obvious. The types of interaction possible include 
hydrogen bonding, dipole, n-n and ionic interactions as shown in figure 8 below. Steric 
hindrance is also important.
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Figure 8
Interactions possible when using the Pirkle type phases. 
amide dipoles
Pi bonding 
interaction
steric interactions
hydrogen bonding
The interaction between the CSP u-electron acceptor group (also known as a 7i-acid) and a 
7i-electron donor (xc-base) function of the analyte may be face to face or face to 
edge Alternative ideas exist as to the most important positional
orientations between the CSP and the analytes. The key point, however, is that the separation 
is a result of a variety of possible interactions.
Examples of bioanalytical assays:
Few analytes have groups with strong %-electron donator or acceptor functionality. To 
achieve a separation using this class of CSPs it is possible to add such functionality via 
derivatisation. Because the selector (the CSP) is chiral the derivatisation reagent may be 
achiral. An example is the method for ibutilide^”®“’ . 1-Napthyl isocyanate was used to 
add both a xc-donator and carbamate function to ibutilide enabling it to be separated using the 
Tc-acceptor Pirkle phase 3,5-dinitrobenzoy 1-D-phenyIglycine. Initial results required extended 
chromatographic run times in order to resolve the analytes form the co-extracted endogenous 
plasma constituents. To overcome this difficulty, column switching was used. The initial 
separation of the analyte and plasma components was carried out using an achiral stationary 
phase. The analyte peaks were switched, essentially free from co-extracted interference’s 
(heart cutting) to the chiral column where they were resolved into their enantiomers. The total 
analysis time for this assay was shorter when using column switching.
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Polymer Phases tWainer type II and Wainer type III CSPsT
The polymer phases can demonstrate both inclusion and attractive interactions. There are 
several approaches to their generation. A polymer can be constructed from subunits incubated 
with an optically pure template (one enantiomer of the intended analyte) which are then 
polymerised. The polymerisation forms pockets around the template with spatially located 
complimentaiy functionality, a Wainer type II CSP. The polymer is ground and sifted to a 
uniform particle size and packed to form the column. The template molecule is desorbed with 
an appropriate mobile phase. This type of polymer phase is created for a given analytical 
problem so that specificity is the aim, and the columns may be used for preparative 
separations.
An alternative group of phases can be constructed from optically pure derivatised vinyl 
polymers without the use of a template molecule The steric effects of the bulky
derivatives result in a handed helical polymer. These can be packed into chromatographic 
columns or, alternatively the polymer can be coated onto silica which is
subsequently packed into columns.
The chiral nature of the naturally occurring carbohydrate polymer lactose was used in 
1938 to obtain a partial separation of a racemic camphor, but possibly the most
widely used polymer is derivatised naturally occurring cellulose. Cellulose is a linear 
polysaccharide consisting of poly-[3-D-l,4,glucoside forming chains of at least 1500 
(+)-D-glucose units per molecule. Each unit contains five chiral centres and three hydroxyl 
groups.
The first derivatised cellulose was cellulose triacetate. This could be formed without loss of 
microcrystal 1 inity, and provided good stereoselectivity. The loss of the microcrystalline 
structure was found to be less important when cellulose triacetate was adsorbed onto the 
surface of silica gel. Analyte retention and stereoselectivity using these columns was less 
than that seen previously, however, greater column efficiency significantly improved 
resolution. The silica supported phase was more robust, allowing higher mobile phase flow 
rates and thereby shorter chromatographic run times. The mode of retention and selectivity 
of this stationary phase is unclear. A mechanism has been proposed based upon inclusion into
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chiral cavities formed by the handed nature of the polymer. This was concluded from the fact 
that non polar solutes with no functional groups can be resolved
Other derivatised cellulose phases are commercially available. Chiralcel CD (Daicel, JT 
Baker, Reading, UK) is cellulose derivatised with 3,5 dimethylphenyl carbamate. These CSPs 
act via attractive interactions and inclusion into the chiral structure imposed by the cellulose 
backbone, Wainer type II phases.
Examples o f bioanalytical assays:
The Chiralcel range of columns are popular choices of CSPs for bioanalysis. Separations 
have been reported for, warfarin*^ "'*®*^ ®™’ (Chiralcel DC), almokalant 
(Chiralcel CD) and aminoglutethimde (Chiralcel OD and OJ). Long retention
times (>20 minutes) and slow flow rates (<0.7 ml min"') were common features of these 
assays. The measurement of saterinone (Chiralcel OD) used an off-line coupled
column method to overcome the poor separation of the analyte enantiomers with the 
enantiomers of the internal standard. This approach could have been automated via column 
switching as shown by the analysis of lifibrol 1'''“**®'*®’ (Chiralcel OD-H).
Cyclodextrin based CSPs (Wainer type II and Wainer type III CSPsV 
Structure:
Cyclodextrins are produced by the partial degradation o f starch and the enzymatic coupling 
of cleaved glucose units. They form circular structures of which those consisting o f 6 (a), 7 
(P) and 8 (y) glucose units have been characterised for use as chiral stationary phases. The 
most common cyclodextrin used for chiral chromatography is the p. The 7 glucose units form 
a bucket 15.3 A wide and 7.8 A deep. The central cavity is 7.8 A wide 1'^ ®*'"®’ and is high 
in electron density arising from the glycosidic oxygen bridges. The “upper” rim of the bucket 
is lined with secondary hydroxyl groups giving rise to a polar region capable of hydrogen 
bonding. The “lower” rim of the bucket contains primary hydroxyls which are used to link 
the cyclodextrin to a silica support matrix. A new generation of cyclodextrin columns 
(Cyclobond II, Tecnicol, Lancs., UK) use a high purity silica support to improve 
reproducibility between columns.
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Recognition mechanisms:
For cyclodextrin based CSPs, in aqueous environments (reversed phase chromatography), 
inclusion into the cavity o f a non polar portion of the analyte displaces the aqueous solvent. 
Given the correct orientation and functional groups the analyte can hydrogen bond with the 
secondaiy hydroxyls at the rim. The difference in the stability of the diastereomeric 
complexes formed result in the stereoselectivity of the phase. Bonded cyclodextrin can also 
be used as a reversed phase matrix with retention via hydrophobic interactions i990i
A number of papers describing the structural requirements for stereoselectivity using the 
cyclodextrin phases have been published. Maguire used analogues of 5-phenylhydantoin 
to conclude that in addition to the “included” phenyl substitution two further sites of 
interaction were required. Evidence was also presented for the formation of hydrogen bonds 
with the primary hydroxyls at the base of the cyclodextrin bucket. A molecular modelling 
study by Camilleri showed that the molecular electrostatic potentials of the included 
aryl ring of the enantiomers of phaclofen were not symmetrical and correlation between the 
asymmetry and the resolution of enantiomers could be demonstrated.
The secondary hydroxyls of the cyclodextrin molecule can be derivatised. The addition of a 
hydroxypropyl group to the outer rim of the cyclodextrin gives greater flexibility
to the position of the hydrogen bonding functionality relative to the rigid hydroxyl orientation 
o f the native cyclodextrin. The addition of functionality similar to those used in Wainer type I 
phases allow the cyclodextrin phase to be used in either reversed or normal phase systems 
such as the addition of 3,5-dimethylphenyl carbamate to cyclodextrin i993] ^  y^riety
of similar phases are commercially available. The mechanism of separation for these columns 
is more complex than for the native cyclodextrins. The cyclodextrins derivatised with Pirkle 
type functional groups are best classified as Wainer type II CSPs. Berthod used the 
molecular structure of 121 racemic compounds to produce a database of substituents and their 
contribution to the observed stereoselectivity for a naphylethyl isocyanate derivative of 
P-cyclodextrin. For each substituent of the chiral atom a free energy contribution was 
assigned. The summation of these contributions for the substituents of a new analyte would 
reveal whether sufficient adsorption energy difference would be available to achieve 
resolution.
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The size of cyclodextrin (a, p or y) is the first consideration when attempting a reversed 
phase separation by inclusion. The cavity of P-cyclodextrin is large enough for the inclusion 
of phenyl, napthyl and biphenyl rings but steroid like structures with multiple rings would 
better fit the larger y-cyclodextrin. The choice of organic solvent has a significant effect upon 
the observed selectivity. Acetonitrile is a strong solvent, able to displace analytes from the 
cyclodextrin cavity, whereas methanol although “weaker”, is able to disrupt the hydrogen 
bonding at the rim. The pH of the mobile phase is important as is the buffer salt used. 
Triethylammonium acetate, ammonium nitrate or citrate are preferred^
An alternative for both native and derivatised cyclodextrin is the use o f a non aqueous polar 
mobile phase such as acetonitrile No inclusion is believed to take place because
the acetonitrile resists displacement from the cavity by the analyte. Retention and 
stereoselectivity are controlled by the addition of acid and base. These are commonly acetic 
acid and triethylamine, but different acids and bases can have significant effects upon the 
resolution of some enantiomers^. Interaction with the rim hydroxyls and steric effects are 
presumed to be the mode of interaction.
In the normal phase mode alteration of the solvent strength modifier, for example, 
acetonitrile, propan-2-ol or butan-l-ol and the addition of acid and or base are the variables 
for optimisation.
Examples of bioanalytical assays:
Whilst many compounds have been separated using bonded cyclodextrins, few methods have 
been reported as validated bioanalytical assays. Krstulovic used a commercial 
P-cyclodextrin column to produce an assay for an oxodibenzoxepin analogue extracted from 
rat plasma. A 15 minute total run time produced near baseline resolution with a limit of 
quantification of 0.08 |Lig ml’’ . Stalcup prepared cyclodextrin phases and investigated 
their use for direct injection of human serum. Long retention times were required for the 
analytes to clear the large solvent front caused by the endogenous matrix components.
Astec Inc, manufacturers literature, 1995.
Work by the author, poster presentation: p 
separation strategy for a diastereomeric mixture, U-96988. Wood S.A. and Liddicoat T.N.
 ^ P-Cyclodextrin and the polar organic mode - A novel
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An unusual application of cyclodextrin as a mobile phase additive was that used to improve 
the separation of a diastereoisomer derivative o f Baclofen
Crown Ether.
The chiral crown ether CSP marketed by Daicel is, in the main, intended for the separation 
of analytes containing a primary amine group at or near the asymmetric centre. The amine is 
fixed by hydrogen bonding with the oxygen’s of the cyclic ether to form a host-guest 
(inclusion) complex, Wainer type III CSP. Stereoselectivity arises from the interaction 
between other groups attached to the analyte and the crown ether. These interactions can be 
steric, further hydrogen bonding, dipole interactions or n-% bonding. The largest group of 
CSPs, however, to use inclusion complexing are the cyclodextrins.
Ligand exchange (Wainer type IV CSPsT 
Recognition mechanism:
Ligand exchange chromatography occurs through the process of the formation of labile co­
ordinate bonds. To form the co-ordinate bond the compound must contain electron donating 
hetroatoms, lor example, nitrogen, oxygen or sulphur, or 7i-electron donating double bonds 
which can be incorporated into the metal ion co-ordination sphere to complete its electron 
shell. The chelating metal ions are able to form ternary complexes with a pair of amino acids. 
Copper forms the most stable complexes but other bivalent cations such as zinc or nickel can 
be used. The kinetics of the reaction are important as the separations achieved using ligand 
exchange tend to be of low efficiency due to the slow exchange processes involved.
Ligand exchange chromatography was first reported by F.G. Helfferich and used for the 
separation of enantiomers by Davankov To effect the chiral separation of a number of 
amino acid anions L-proline was immobilised on a polymer support and Cu (II) ions were 
added to the mobile phase. Both polymer and silica have been used as supports for ligand 
exchange selectors.
Alpha - amino acids which form 5 membered rings with the copper ion are the most stable, 
p-amino acids which favour 6 membered rings are less stable and consequently show less 
chiral discrimination. The discrimination between enantiomers can be aided by the presence
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of other interactions. Aspartic and glutamic acids are examples of tridentate amino acid 
ligands capable of the displacement of water from the axial position of the co-ordination 
complex. The L-confîguration is more stable. Where the water molecule is not displaced it 
may provide a steric or repulsive interaction.
Examples of bioanalytical assays:
Many examples have been published for the analysis of both derivatised and underivatised 
amino acids.
Protein based CSPs ^Wainer type V CSPV
Proteins are macromolecules constructed from chiral subunits, L-amino acids. In the native 
state, their tertiary structure gives rise to binding sites of varying spatial character and 
functionality. For chromatographic use the protein is adsorbed or bonded onto a silica 
support. A number of protein based CSPs are available commercially. Human a,-acid 
glycoprotein (AGP, described in detail below) was one of the first and is possibly the most 
widely used protein CSP. Other CSPs derived from human or bovine serum albumin, egg 
ovomucoid, cellulase and cellobiohydrase are also available.
Structure:
Human a^acid  glycoprotien (AGP) is a small plasma transport protein of 41,000 Daltons. It 
contains two disulphide bridges, 14 sialic acid residues and 45% of the protein is 
carbohydrate The isoelectric point of AGP ranges from 1.8 to 2.7 and so has a
net negative charge at the pH values used (6 and above) for most chromatographic 
applications. The first AGP columns ^^ *^ 1 were made using silica with pore sizes of
both 100 A and 300 A (wide pore). The amount of AGP bound to the wide pore silica was 
over 10 times that bonded to the 100 A silica, indicating that the AGP was excluded from the 
narrower pores.
The AGP column was developed further I**®™®"®®®"» i984bi foPoYvjj^g investigation of the effect 
of the amount of protein loaded onto the silica support. The highest protein load used was 
185 mg AGP g'  ^ o f silica. Retention increased with increasing AGP content but no additional 
selectivity was obtained for the analytes studied when compared to a column loading of only
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75 mg g ''. However the higher loading was advantageous for the analysis of hydrophilic 
drugs.
The first commercially available column, EnantioPac, was made by adsorption of the AGP 
protein on a 10 fxm, large pore diethylaminoethyl silica followed by cross linking of the 
protein. A second generation o f AGP column. Chiral AGP, was produced by covalent 
bonding to 5p,m spherical silica with a small pore size followed by cross linking adjacent 
protein molecules IHcrmanasson, 1989] binding process results in the protein unfolding, 
revealed by a shift in the fluorescence spectrum due to the exposure of the AGP
tryptophan residues onto the surface of the protein. The stability of the protein conformation 
is important to the understanding of stereoselectivity. Circular dichroism spectroscopy has 
shown that the protein conformation on the silica support was stable in the presence of at 
least 40% propan-2-ol
Recognition mechanism:
The early AGP columns successfully resolved the enantiomers of a number of 
compounds IHermansson, 1983] mobile phases used consisted of phosphate buffers with low 
(1-2%) concentrations of propan-l-ol. The addition of the organic solvent reduced both 
retention times and stereoselectivity. The pH of the mobile phase was found to have a 
significant effect upon the retention and stereoselectivity of all the compounds tried. The 
selectivity measured with increasing pH increased for some compounds, decreased for others. 
This was thought indicative of either multiple binding sites or multiple interactions in a single 
binding site. One of these sites might contain a hydrophobic core which would explain the 
strong retention of some hydrophobic analytes. The propan-l-ol would be expected to 
compete for this site and thereby reduce the retention of these analytes. A number of 
obseiwations were made regarding solute structure and stereoselectivity by comparing the 
resolution of close analogues, for example, the presence of an hydrogen acceptor and a 
degree of flexibility about the chiral carbon.
The peak capacity of the Enantiopac CSP was low with a loss of both retention and
peak symmetry as the amount of injected sample increased. Different effects upon 
chromatographic performance relating to column loading were seen when using mobile 
phases additives. For example, the use of diol organic modifiers (butane-1,2-diol in place of 
propan-2-ol) reduced the sample capacity of the column. This study re-enforced the
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dependence upon the presence of hydrogen bonding groups for selectivity with either large 
subsituents or cyclic structures attached to an ammonium ion and/or the hydrogen bonding 
group. The bulk of the molecule was considered of vital importance to a successful 
separation. It was noted, however, that the applicability of the Enantiopac column was wide 
and more specific rules could only be given for closely related compounds. Some 
consideration was given to the relevance of the degree of flexibility that the AGP protein 
might exhibit whilst bound to the silica support, and to the fact that selectivity for a broad 
range o f molecules may be modified by alteration of the mobile phase constituents, although 
in the light of later work conformational changes appear unlikely with the later
Chiral AGP CSP.
The stereoselectivity of the Enantiopac CSP was studied by Schill Efficiency was found 
to be dependent upon temperature and flow rate. Flow rates of 0.3 ml min’’ were advised to 
allow for the slow mass transfer of the analytes. The effect of anionic modifiers added to the 
mobile phase led Schill to conclude that the retention mechanism was not a function of 
binding to anionic sites on the protein. An ion-pair process was therefore proposed. The 
addition of charged modifiers to the mobile phase resulted in a change in the 
stereoselectivity. The structural characteristics required for stereoselectivity were examined. 
The distance between the and hydrogen bonding moieties, the substitution and the 
spatial arrangement of these atoms were important. An increase in steric bulk at the was 
generally desirable but the “ideal” distance between the and the HB groups was dependent 
upon the compound class.
The retention mechanism was examined further by Arvidsson Using the coefficients 
generated by a 2  ^factorial design experiment, it was demonstrated that retention took place at 
cation-exchange sites on the protein and that at the pH values used (6.0 and 7.5) 
cation-exchange dominated. Little anion-exchange activity was expected from the negatively 
charged protein stationary phase. The coefficient for propan-2-ol effects on retention were 
negative, increasing concentration of propan-2-ol resulting in reduced retention. A small 
negative influence on stereoselectivity was observed, suggesting that the solvent blocked 
interaction at an uncharged binding site. The coefficients for the action of octanoate (ion-pair 
additive) were generally small but had positive or negative effects upon both retention and 
stereoselectivity depending upon the analyte. The positive effect on retention was due to an 
ion-pair interaction. Other charged mobile phase additives were investigated. Atropine was
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resolved in the presence of 2-phenylbutyric acid and the degree of resolution was dependent 
upon which enantiomer of the additive was used. In the absence of the additive atropine was 
not resolved. This was taken as an example of a separation taking place at an uncharged 
chiral site. This view might be a simplification as the relevance of the chiral nature of the 
additive and its interaction with the CSP was not known.
Hermansson investigated the separation of chiral acids. Uncharged acids in the presence 
o f the positively charged dimethyloctylamine (DMOA) were eluted more rapidly. As no 
possibility of an ion-pair exists for these compounds the DMOA was assumed to be 
competing (as an ion-pair with the phosphate buffer mobile phase) for an uncharged chiral 
site. Charged acids could also be resolved by the addition of DMOA. The retention of the 
analytes increased with increasing additive concentration indicating an ion-pair relationship. 
The selective increase in retention seen with charged acids and DMOA suggests that there are 
steric differences between two analyte enantiomer DMOA ion-pair complexes at the 
uncharged site. Further evidence of the dual nature of both retention and selectivity is 
provided by Hermansson using non-steroidal anti-inflammatory drugs. This work 
revealed an interesting difference between the ion-pair effects of hydrophilic counter-ions 
such as sodium and additives such as DMOA, which are able to compete for both the 
negatively charged protein sites and adjacent hydrophobic sites. The response to the charged 
modifier DMOA on the selectivity of fentiazine IHcrmansson, 1989] (jgj-jvatives was the same for 
immobilised AGP or AGP used as a complexing agent in the mobile phase.
Whilst the AGP stationary phase can be shown to have multiple binding sites, both charged 
and uncharged, the structure of these sites is unknown. Some general rules for solute structure 
characteristics that lead to chiral discrimination have been put forward in some o f the work 
described above. More detailed investigation has been carried out by a number of groups, for 
example, Hermansson
Examples o f Bioanalytical assays:
AGP CSPs have been used for a wide variety of routine bioanalytical methods.
Hermansson reported a method for disopyramide in human plasma using Enantiopac. 
The higher efficiency and improved stability of the 2nd generation. Chiral AGP, column was 
used by Krstulovic to measure alfuzosin in rat plasma using flurometric detection to aid 
both selectivity and sensitivity.
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Chiral AGP was used for the analysis of medetomidine by Orn During the optimisation 
o f the chromatography very limited effects upon the separation of the enantiomers were seen 
by varying the column temperature, mobile phase flow rate, propan-2-ol content or buffer 
concentration.
Chiral AGP has been used for the analysis of in-vitro metabolism samples of
oxamniquine. Incubates of rat and mouse liver microsomal preparations were extracted with 
ether. After evaporation the residue was reconstituted in mobile phase and filtered prior to 
injection. The column was reported to be stable after 100 injections of extracted incubates, 
although no information was given on extended use.
Compared to achiral chromatographic phases the protein based chiral stationary phases are 
not robust. Selective extraction techniques are helpful, but still not sufficient if many samples 
of biological origin are to be analysed economically. A strategy used to provide very clean 
samples is chromatography. Achiral chromatography can be linked off-line 
[Wei, 1994. Beresford, 1992] oj|-line An off-line coupled column allows the
development of two independent chromatographic systems but requires additional operator 
input compared to on-line coupling. The speed and automation of the on-line approach is 
offset by the more complex equipment required and the necessary compatibility of the two 
analytical systems. A completely different approach to on-line coupled columns was taken by 
Walhagen The initial separation was carried out using AGP where co-eluting 
endogenous analytes made quantification impossible. Each enantiomer window eluting from 
the chiral column was trapped on a separate column and then sequentially eluted onto an 
achiral column for separation from the co-eluting components and quantification. The system 
used four columns, three valves and two pumps. This approach appears to have little to 
recommend it apart from a degree of peak compression to improve sensitivity.
Macrobiotic phases (Wainer type II CSPV
A recent class of CSPs, the macrocyclic antibiotics, vancomycin (Chirobiotic V) and 
teicoplanin (Chirobiotic T) are marketed by Astec (Technicol). These are Wainer
type II CSPs with chiral cavities and attractive functionality provided by the large cyclic 
structure of the antibiotic. They contain ionizable groups and the mobile phase pH may affect 
both the stereoselectivity and the conformation of the molecule. Column efficiency falls with
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increasing flow rate indicating that the rate of equilibrium between the analyte CSP (mass
transfer) is slow. The importance of hydrophobic interactions were demonstrated with
organic analytes The CSPs could also be used successfully in the polar organic
mode ITnng. 19941
Confirmation of a chiral separation.
Without optically pure standards the confirmation of a chiral separation may be difficult. 
During column screening experiments it may be sufficient to conclude that a separation has 
occurred if two peaks of equal area are recorded by the detector. If  two peaks are not obvious, 
then partially resolved peaks may be taken to be enantiomers if their areas can be judged to 
be equal. Additional evidence would be required before further analytical development is 
embarked upon and may be considered as part of method validation.
UV detection.
Enantiomers have identical UV spectra. Data generated by UV diode array detectors can 
provide useful evidence for a chiral separation. For two resolved chromatographic peaks the 
spectra can ..e normalised (for concentration) and compared. A ratio between two 
wavelengths descriptive of the spectra (for example, an absorption peak and trough) can be 
used to highlight chromatographic peaks with very similar spectra. The ratio remains constant 
regardless of the concentration of the enantiomers.
Mass spectrometry.
The molecular ion and fragmentation pattern of enantiomers are identical. The additional 
selectivity of the mass spectrometer provides good evidence that two peaks in a suspected 
chiral separation are the same structure. However, it does not provide evidence of an 
enantiomeric relationship.
Circular dichroism.
UV diode array spectra and the very selective mass spectrometry fail to provide complete 
evidence that two peaks are enantiomers. That the two seemingly identical peaks do not co­
elute using a chiral chromatographic system points to a fundamental difference not related to
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the molecules chemical structure, but optical rotation can provide the unassailable proof o f an 
enantiomeric relationship between two chromatographic peaks.
The optical rotation detector provides the evidence of optical activity required. However, the 
amount of rotation may be small, and the low sensitivity of available on-line detectors 
usually require preparative chromatography and off-line spectroscopy. Circular dichroism 
spectrophotometers measure the rotation of plane polarised light over a range of wavelengths 
producing a spectrum for a single enantiomer which may have both positive and negative 
optical rotations apparent at different wavelengths.
It is possible assign an optical rotation to a chemical structure 9^95] assign
absolute conformation to an analyte by reference to a close analogue.
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CHIRAL CHROMATOGRAPHIC ANALYSIS.
Development strategies for chiral analysis.
The number of commercially available CSPs is consistently increasing and with this the 
complexity in selecting the best possible CSP for a given separation. A number of strategies 
for developing a chiral chromatographic separation have been reported.
When faced with a new separation, the analyst can search the literature for similar 
compounds that have been successfully analysed. All manufacturers of CSPs provide an 
application guide showing the published separations that have been achieved using their 
stationary phase. A French group have taken this idea further by combining all reported chiral 
separations in a database called CHIRBASE l^ ®PP®"hoefcr, 19931 ^he database allows the user to 
search for similar separations using a sub-structure search technique, which would be familiar 
to analysts who have used commercial chemical structure database programs, for example 
MACCS (by MDL, San Leando, USA). If  a match is found the database provides details of 
the CSP used, the separation achieved, the order of elution and a reference to the original 
report.
When similar compounds have not been reported another approach must be used. A selection 
of chiral stationary phases may be kept and each tried with each new compound. Many CSP 
manufacturers or suppliers provide a flow chart showing how a nominal method may be 
developed. To rigidly follow each of these experimental designs for every compound would 
not meet the needs of many analytical problems. It would be more efficient to focus upon 
those separation systems that offer the best chance of success with a given compound or 
compound class. In one such strategy key racemates were selected from the
compound classes under study. Physical data for these racemates was determined, for 
example, structure, octan-l-ol water partition (log P), pK^ and solubility. These data were 
used to determine the likely interactions that may take place with a number of commercial 
CSPs and chiral counter ions. Those interactions which appeared favourable were 
investigated experimentally.
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Having found a partial separation, further optimisation can be carried out as for achiral 
separations. The nature of chiral separations is more complex than that for achiral 
separations. A small change in the mobile phase pH may lead to significant changes in the 
selectivity between the enantiomers and the stationary phase. Statistical experimental design 
strategies have been developed (not exclusively for chiral analysis) to examine the 
contribution of individual chromatographic variables to the overall system performance
{Berriage, 1985. M organ, 1991]
Automated techniques of chromatographic optimisation are not commonly used in routine 
bioanalytical development where the unknown biological components of the mixture are 
numerous and their abundance and behaviour difficult to predict. This unpredictability is also 
true for chiral separations where the sample matrix is of biological origin. However, the 
initial exercise of understanding and optimising the resolution of a pair or pairs of 
enantiomers may be expedited by the use of empirical or search directed chemometric 
optimisation techniques
Factorial designs explore a defined parameter space. Figure 9 below shows the space 
investig 
design.
i ated for a factorial design exploring three variables at two different levels, a 2^
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Figure 9
The experimental space explored by the 2~ factorial design experiment.
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There are eight experiments required to carry out the above factorial experiment. Each corner 
represents an experiment with the variables A, B and C at either the high or low level, (see 
table 1). The calculations required to find the variable effects are shown in table 2. The 
number of experiments required is one of the drawbacks of this type of optimisation process. 
If np parameters are investigated at I levels, then the number of experiments required (Ug) is 
equal to equation 14;
Equation 14
n =  I
If  the number of levels is equal to two, then four variables require sixteen experiments and 
five variables require thirty two experiments.
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Table 1
Conditions for each of the ei ght experiments required for the three factor, 
two level (2~) factorial experiment.
Experiment Factor A Factor B Factor C
1 1 1 1
2 1 1 0
3 1 0 1
4 1 0 0
5 0 1 1
6 0 1 0
7 0 0 1
8 0 0 0
Table 2
Calculations required to find average effect of factpr (or factor combinationV
Factor
combination
Calculation 
(result o f  experiment number)
A 74(1+2+ 3+4)-(5+6+7+S)
B 74 ( 1+ 2+ 5+6) - (3+4+7+B)
C V4 (1+3+5+7) - (2+4+6+S)
A and B 74 (1+2+7+8) - (B+4+5+6)
B and C 74( 1+4+ 5+8) - (2+3+Ô+7)
A and C V4 (1+3+6+8) - (2+4+5+7)
The central composite design is a modification to the factorial design which, via
the inclusion of additional points, allows non-linear effects to be approximated. It is 
important to remember that these techniques can only predict effects within the boundaries of 
the experiments carried out, and that the optimum conditions found are only a local optimum 
and not a global optimum, that is, the optimum for all possible conditions.
A different strategy to the optimisation of a particular separation is to ask the question, will 
system X separate the enantiomers of compound Y? This is also different from finding the 
‘best’ separation. It involves building a model of the separation for a specific CSP and 
applying the model to new compounds to determine whether they have the structural 
characteristics necessary to differentiate between their enantiomers. With a model for each 
CSP the column screening process becomes a paper, or computer, exercise. Having identified
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a suitable column from the models, optimisation using any of the previously mentioned 
approaches can be used to find the local optimum separation.
The relationship between solute structure and enantioselectivity using Chiral AGP was 
investigated for a series of N-aminoalkylsuccinamides (figure 10) and
1-alkyl-2’,6’-pipecoloxylidides (figure 11) [Hermansson, 1987]
Figure 10
General structure of N-aminoalkvlsuccinimides,
Figure 11
General structure of 1-alkyl-2’.6’-pipecoloxylidides. 
CH3 O
H
OH
The chromatographic data generated from the two series of compounds (7 
1 -alkyl-2%6'-pipecoloxy 1 idides and 38 N-aminoalkylsuccinamides) was used to determine 
what structural characteristics resulted in improved or reduced chromatographic 
enantioselectivity. This model consists of a set of rules, for example, type of substitution on 
the basic nitrogen, which would allow an assessment of the likelihood of a separation being 
possible using AGP for a new analogue of the two compound classes examined.
A further study N-aminoalkylsuccinamides (figure 10) and Chiral AGP
sought to create a mathematical model of the enantioselectivity. To do this a number of 
physicochemical variables, for example, Hammett constant, and Hansch aromatic fragment 
constant, were assigned to positions on the molecules. Additional variables were included to 
define the presence or absence of substitutions or the length of an alkyl chain. In all 50
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variables were used to describe each of the 35 analogues. A principle component analysis 
(PCA) technique was used to determine which variables were the most important. The 
mathematical model described 85% of the variance in the data.
The two studies above have investigated a series o f analogues with relatively minor changes 
or differences between each successive structure. This had allowed the authors to propose 
rules for the structural characteristics that resulted in a chiral separation. They have not, in 
general, produced models which would allow the prediction of the separation of a structurally 
diverse chemical. No data for the models was obtained directly from the binding site on the 
CSP. All the data was inferred from the chromatographic results.
A different strategy can be taken where the chiral selector structure is known. Computational 
chemistry techniques are used for the design of new chemical entities A computer
model of an as yet unsynthesized chemical can be compared and contrasted with existing 
drugs and conclusions drawn as to how the new chemical would behave in a given system. 
The algorithms (programs) used predict the three dimensional shape of the molecule and 
information about the electronic nature of the atoms within it. The shape of a molecule can be 
experimentally determined from x-ray crystallography, however, the crystalline shape may 
not be that which the molecule takes up in solution or as it interacts with the biological 
receptor.
/
The computational analysis of shape is performed with molecular mechanics (MM) 
programs. These treat the molecule as a series of balls attached to springs and subjected to 
intermolecular forces. An approximate geometry is submitted to the program which then 
twists and stretches the molecule to achieve the lowest energy conformation, assumed to be 
that conformation in which the molecule spends most time. Molecules are not static and can 
take up different conformations. The probability that the molecule will be in any one 
conformation is described by the Boltzmann distribution. The parameters for the forces are 
held in a table created from experimental data. Parameters do not exist for all atoms or groups 
of atoms and the relaxation calculation is normally conducted in the gas phase. These force 
field programs are under continual development, for example, including variables to allow 
for solvent effects. The electronic information is generated using molecular orbital (MO) 
calculations. The electrostatic molecular potential of the surface o f a molecule can be used to
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investigate structure activity relationships. Information is also generated about the hydrogen 
bonding potential or the reactivity o f particular atoms in the molecule.
Computational chemistry can be used to build models of CSP and analyte structures and 
allow investigation of how these structures might interact. A study of the conformation of a 
Pirkle CSP ( analogue of N-3,5-dinitrobenzoylamino acid) was carried out using the Allinger 
MM2 force field a  number of compromises were made in order to model the
CSP. No force field information was available for aromatic nitro groups and these were 
replaced with CHO, see figure 12.
Figure 12
Pirkle type CSP as modelled.
HOC CHO
The silica support was not included and it was assumed that it didn’t influence either 
conformation or stereoselectivity. The torsional angle of the two bonds indicated was set in 
20° steps, and the molecular energy minimised using the MM2 force field with these angles 
fixed. This study found that the CSP could exist in five low energy conformers. The global 
minimum was arbitrarily set to zero, a second set of conformers were found approximately 
0.3 kcal m of' above the minimum and a further set o f conformers at approximately 
0.77 kcal m of’ greater than the minimum. Under normal chromatographic conditions all 
these energy levels were expected to be populated, as interconversion between conformations 
would be rapid given that the energy barriers between these conformers were less than 
5 kcal moF^.
Lipkowitz developed the approach to include the analyte Computer models of
the CSP (figure 13) and the analyte, 2,2,2-trifluro-1 -(9-anthryl)ethanol, were generated.
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Figure 13
CSP
HOC •CHO
Analyte
HO
Models were arranged in space and brought together along an axis connecting the centre of 
mass o f the two molecules. The energy of the complex was minimised using MM2. The 
molecules were separated and their conformation altered by a fixed increment. The two new 
confirmations were brought together and the energy minimised again. This was repeated for 
all conformation increments, and the lowest energy value obtained recorded. The angle of the 
axis between the two compounds was altered and the process repeated until the analyte had 
approached the CSP from all directions. The result was a map of the intermolecular energy of 
the two molecules as the analyte was “tumbled” ovdr the Van der Waals surface of the CSP. 
The (R) and (S) enantiomer of the analyte were treated identically.
Plots o f the energy differences between the (R) and (S) analyte complexes with the CSP 
revealed an energy difference between the two global minima of 0.3426 kcal mol'^ in favour 
of the (S) enantiomer. Chromatographically the (S) enantiomer elutes last and resolution from 
the (R) enantiomer was a=1.33 which was considered to be in good agreement with the 
computer model. The separation factor is linked to the thermodynamic quantities as follows, 
equation 15
Equation 15
Where A(Ap) 
R 
T 
a
A(A\x) = RT lna  
difference in global minima 
gas constant (1.988 cal mol ' K) 
temperature in K 
separation factor
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When the constrained CSP torsional bond angles in the minimum energy complex were 
relaxed and the CSP allowed to form a lower energy diastereomeric complex with the analyte 
the difference between (R) and (S) was larger, though the (S) enantiomer complex still 
formed the lowest energy complex.
A similar study was carried out using a number of different CSPs and analytes 
The minimum energy conformation of the analyte was interacted with the CSP in a similar 
manner to the first study. It was found that the elution order obtained from chromatographic 
analysis agreed with that implied by the model. A separation was predicted when the global 
energy minimum between the two enantiomer complexes was different, although how 
different was not clearly stated. The magnitude of the difference, however, did not appear to 
correlate with the observed chromatographic separation
These three studies started with molecules in artificially
fixed conformations. An infinite number of torsional angle increments would be equivalent to 
using flexible molecules but is impractical. An alternative method of producing
conformations for analysis is to apply heat energy to the computational model. As the energy 
rises so the rnolecule may occupy more structural conformational space. Samples of these 
structures are taken as the energy is increased and these new structures are then minimised.
These studies have used computational chemistry to explore the energy of structural 
conformation of molecules and the interactions of those structures with each other. MO 
algorithms have been used to calculate a number of quantum parameters for each atom in the 
molecule, for example, partial charge or the highest occupied (HOMO) and lowest occupied 
(LOMO) molecular orbitals. This is analogous to the physicochemical data used for the 
Chiral AGP mathematical model described earlier 1^®*''"**®''’ These calculations have been 
used to investigate retention mechanisms in gas chromatography
[Garcia-Raso, 1984. Osmilniowski, 1985]
It must be stressed that the computational models are approximations of the chromatographic 
environment and the limitations of the technique must be borne in mind. However, the 
models do allow the analyst to view the three dimensional environment and to see how the 
shape and electrostatic potential of molecules change with the addition o f new functional 
groups. The models of the Pirkle type CSP do represent universal models in the sense that
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any enantiomeric pair can be presented to the CSP and the energies of the resulting 
diastereomeric complexes compared. The same technique can be used in reverse to predict 
the stereoselectivity of new CSPs. To use these models the analyst must have access to 
considerable computing power.
Characteristics required for bioanalytical assays.
The general requirements for achiral bioanalytical assays are; selectivity and sensitivity for 
the analyte of interest; reproducibility and repeatability of quantification and robustness. The 
requirements for chiral bioanalytical assays are no different in these respects. Modern achiral 
chemistries are reproducible from batch to batch and column packing techniques have also 
improved. High efficiencies (for example, 5 pm spherical particle size approximately 70,000 
plates m"' and 3 pm particle size approximately 115,000 plates m“')^ and longevity are the 
norm for achiral chromatography. Chiral column chemistries are less reproducible and less 
robust. Column efficiencies obtained with CSPs are generally poorer when compared to 
reversed phase bonded silica columns (particularly protein based CSPs), which compromises 
both resolution and sensitivity. The reduced peak capacity of CSPs increases the need for 
efficient sample preparation. Cleaner samples will also improve column lifetimes. A number 
of studies Waihagen, 1989] used achiral chromatography (coupled
column or off-line) as the sample preparation technique prior to analysis on a CSP.
Validation of chiral bioanalytical assays is identical to that for achiral assays. Additional 
experiments may be required if, for example, quantification of an enantiomer is important in 
the presence of a high enantiomeric excess of its antipode. Particular care must be taken when 
trying to quantify small peaks which occur on the tail of an earlier eluting peak. It is possible 
to under or over estimate the area of the poorly resolved peaks when using the standard 
“dropped line” integration procedure Peak pairs (enantiomers) are often not fully
resolved by the CSP and peak tailing may be more pronounced than when using achiral 
stationary phases. Peak height determination may be better for poorly resolved peaks in the 
absence of significant peak tailing. Validation should address the issue of how little of the 
enantiomer can be accurately and precisely measured in the presence o f its antipode. This 
type of experiment may be more important for assays measuring enantiomeric purity than 
assays o f biological samples.
 ^Hichrom, manufacture’s literature, 1995.
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Most detection techniques used for chromatography are achiral, for example, UV absorbance. 
Without optically pure standards, it is important to determine the optical nature of the 
analytes to prove that a chiral separation has occurred. On-line polarimetry based optical 
detectors have been developed. The sensitivity of these detectors is poor requiring 
microgram amounts of analyte and therefor are of little use for bioanalysis. For analytes 
which show significant optical rotations, these detectors are useful for preparative 
chromatographic separations.
On-line detectors based upon circular dichroism spectroscopy have been proposed. These 
detectors are more sensitive than polarimeter detectors, but complexity and expense still 
result in limited application for bioanalysis. However, used off-line with peaks collected from 
semi-preprative chromatography or multiple injection, these spectrometers can provide 
excellent data to demonstrate optical activity.
Sample preparation for chromatography.
The application of chiral chromatography to in-vitro or in-vivo metabolic studies involves the 
resolution of the analytes of interest from a complex biological matrix. In achiral 
chromatography separation takes place with phases that have generally robust and 
reproducible column chemistries of high peak capacity (the total number of peaks that can be 
resolved in unit length), which are compatible with various forms of sample preparation. Few 
stationary phases are robust enough to allow repeated direct injection o f biological fluids 
such as plasma, though an exception is the Pinkerton type column with a porous hydrophobic 
coating designed to allow plasma to be injected directly onto the column, and further sample 
preparation is normally required.
A simple form of sample preparation is plasma protein precipitation with injection of the 
supernatant. The achiral chromatographic support of the in-vitro metabolic screening of
2-aminotetralin analogues used protein precipitation without difficulties arising
from poor column performance or co-elution of matrix or metabolites.
There are, however, situations where extraction of the sample is desirable, for example, to 
concentrate the sample. A large sample volume can, by extraction be reduced to a few 
microlitres, most or all of which can be for injection into the chromatographic system. Other 
reasons to use an extraction procedure are the removal of components of the sample matrix
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which interfere by co-eluting with the analyte o f interest, or for the removal of highly 
retained components. There are, of course, circumstances where selective extraction may be 
undesirable, for example, metabolite profiling and quantification.
Extraction is an important tool in the optimisation of a chiral chromatographic assay. An 
immediate difficulty experienced when using chiral stationary phases is that the analyte, 
ideally, is resolved into two chromatographic peaks thereby reducing the sensitivity of the' 
assay by a factor of two relative to analysis using an achiral stationaiy phase. The sensitivity 
of the method is further reduced by the lower column efficiencies generally seen with CSPs, 
particularly the protein based stationary phases. Some of the flexibility o f separation 
optimisation is lost, comparing method development strategies for chiral analysis to analysis 
using achiral stationary phases. For achiral chromatographic analysis the resolution of the 
analyte from an interfering peak may be achieved by changing the organic modifier used in 
the solvent system, for example methanol for acetonitrile. The same alteration of column 
selectivity might also occur when using a CSP but the chiral selectivity may be adversely 
affected by the change in solvent. In a similar way the mobile phase pH range possible when 
using a CSP tends to be limited. An additional difficulty is limited peak capacity. This is 
particularly true of the protein based columns. Sample extraction reduces the overall column 
loading by removing matrix related components. For all these reasons extraction may be 
necessary to provide additional selectivity, capacity and sensitivity for a chiral assay.
Two types of extraction are common for biological fluids. The classical technique o f liquid / 
liquid (solvent) extraction involves the use of an immiscible organic solvent into which the 
analyte of interest will partition favourably compared to the aqueous (sample matrix). Solvent 
extraction can be efficient and give excellent sample clean up with careful choice of 
extraction solvent, sample pH, and the use of back extraction. There are, however, a number 
o f drawbacks. Good recovery of the analytes may require repeated extraction, and to obtain 
clean extracts back extraction is commonly used. These techniques lead to methods which are 
labour intensive, and the high solvent use raises environmental issues. To overcome these 
difficulties a system for liquid / liquid extraction, the Toxilute system was introduced. An 
inert support (Fuller’s earth) is packed into a disposable plastic column (syringe barrel), the 
aqueous sample is added to the Toxilute column and allowed to adsorb on to the support. To 
extract the analytes of interest the column is flushed with a suitable water immiscible solvent
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and collected. The advantage o f this approach is two fold, i, the large surface area made for 
efficient extraction and ii, the sample matrix remained on the column.
Solid phase extraction (SPE).
SPE is a development of the Toxilute principle, and solid phase extraction is now common in 
all areas of chromatographic analysis. The solid phase is usually a wide pore silica of large 
particle size (70-100 pm). Bonded to the silica are phases familiar to achiral chromatography, 
non-polar phases such as C l8, C8 and phenyl, polar phases, for example, nitrile and diol and 
ion exchange phases such as the sulphonic acid phase, SCX. The phase is packed into a 
polypropylene syringe barrel cartridge of various geometry’s and bed volumes held in place 
with polypropylene or stainless steel frits. New technologies involve low masses of small 
particle size silica held in either a glass fibre (SPEC, Hypersil, Cheshire, UK) or PTFE fibril 
(Empore, Anachem, Beds., UK) mesh. The SPE system is intended for, and performs best 
when each cartridge is used just once.
The mechanism of solid phase extraction is analogous to that of chromatography. The aim is 
to choose a stationary phase which will retain the analyte of interest, and little o f the matrix 
components. The cartridge is rinsed to remove as much of the retained sample matrix or 
impurities as possible. The final elution step selectively removes the analyte from the 
cartridge into a collection tube. In theory, some highly retained components can be left on the 
cartridge, although, with the commonly reported elution solvents, it is doubtful that this is 
often the case in practice.
A number of approaches to developing a SPE method can be taken A cartridge can
be chosen which is similar in polarity to the analytical column and the mobile phase is then 
used to elute the analyte. A different strategy specifically uses the residual silonol 
functionality of the silica support matrix of the non polar SPE phases. Used in this way the 
interaction between the analyte and the SPE is ion exchange. This method works well for 
small amines, for example, many pharmaceutical compounds. A further option seeks to find I
the best phase for the analyte by empirical experiment, a cartridge screen analogous to the I
analytical column screen used to find the best chiral separation.
Assay sensitivity enhancement.
Due to the generally low efficiency and the limited peak capacity of chiral columns and the 
fact that the analyte is separated into two peaks, any improvement in the sensitivity and
45
selectivity of a chiral method is beneficial. As the detection technique becomes more 
selective it follows that the method becomes applicable to fewer analytes. The following is a 
necessarily limited discussion of each o f the common on-line HPLC detection 
techniques
UV Detection.
UV absorption detectors respond to substances that absorb light in the UV region (180 to 
350 nm). Many compounds absorb UV light and this detection technique is the most popular 
method of on-line detection. Compounds with one or more double bonds (tc electrons) and 
analytes with unshared (non bonded) electrons, such as, aromatics, >C=0, -N =0 and -N=N- 
groups. The relationship between analyte concentration and UV light transmission is given by 
Lambert-Beer’s Law. Absorbance is proportional to the analyte concentration, the light path 
length and the extinction coefficient. The latter is a property of the analyte and the path 
length is limited by practical considerations, mainly peak dispersion characteristics.
The selectivity of UV absorbance detection increases with increasing wavelength. The 
sensitivity achievable is dependent upon the extinction coefficient o f the analyte. The correct 
choice of light source (mercury, deuterium etc.) is important for maximum sensitivity at a 
given wavelength. A number of types of UV detector are available; fixed wavelength, 
variable wavelength, multiple wavelength (scanning) and diode array detection (DAD).
The UV DAD is the most versatile of the UV detectors. The sample is irradiated with a wide 
spectrum light which after passing through the sample is split using a holographic diffraction 
grating. The light from the grating falls upon a linear array of light sensitive diodes which 
measure the amount of energy in that part of the spectrum. The number of diodes in the array 
determines the spectral resolution of the detector. The DAD is thus able to continuously 
monitor a wide range of wavelengths throughout the chromatogram. Readings can be taken 
from all the electrodes at narrow time intei*vals or be triggered by a peak exceeding a 
predetermined threshold value for a monitored wavelength.
A number of different data treatments are possible when using detectors of the DAD type. 
Spectra through the start, apex and tail of a peak can be compared. Differences between these 
spectra after normalisation for the differing intensities indicate that the measured peak is not
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pure. The spectra of two different peaks can be compared. A further treatment takes two 
different wavelengths and outputs the ratio of the two, a ratiogram.
UV absorption is a robust on-line detection method, the sensitivity of which is dependent 
upon the analyte. Routine bioanalytical assays can be developed to measure of the order of 
1 - l O n g  ml'* of analyte. UV DAD detectors are less sensitive than an equivalent variable 
wavelength detector.
Fluorescence detection.
Fluorescence detection is generally more sensitive and selective than UV adsorption. When 
light is absorbed by a molecule, a transition to a higher electronic state takes place, this is 
analyte and wavelength specific. When electrons are raised to an upper excited single state, 
this results in the characteristic UV / visible absorption spectra for the compound. If  the 
electron returns to it’s ground state (not lost in collision with other molecules) then the 
energy is released in the form of electromagnetic radiation, resulting in fluorescence. Some 
energy is always lost and the emission wavelength is always longer than the excitation. If  the 
release of energy persists after the removal of the excitation, then the sample is said to be 
phosphores''°nt. The excitation can be induced chemically rather than by light. This 
technique is called chemiluminescence.
The emission of fluorescent light by an analyte in solution is proportional to; the sample 
concentration, the intensity of the excitation source, volume of sample irradiated and the 
quantum efficiency of the fluorescence of the sample (ratio of radiating to non-radiating 
transfer energy from excited to ground state). The construction of the cell and optics of the 
detector are quite different from UV detectors. Light is radiated from the sample in all 
directions and collected by spherical mirrors. The fluorescence detector is more sensitive than 
UV absorption and with ideal flurophores (for example, napthyl groups, often used as 
derivatisation reagents) concentrations of less than a pg ml * can be detected. With the 
increase in sensitivity comes a decrease in robustness. Dissolved oxygen, impurities in the 
mobile phase and stray light reduce sensitivity by quenching the light emitted.
Fluorescence detection can be applied to a wider range of analytes by using low wavelength 
excitation Excitation wavelengths down to 190 nm may be used with some makes
of detector, for example, Perkin Elmer (Beaconsfield, Bucks, UK). The fluorescence outputs
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obtained by this approach were small and had not significantly improved upon the UV 
adsorbence response. However, where excitation at low wavelength did produce a 
fluorescence response the increase in selectivity over low wavelength (210 - 220 nm) UV was 
significant.
Electrochemical detection tECDL
Electrochemical detection can be more sensitive than UV and equal to fluorescence detection. 
ECD utilises oxidisable (or less often, reducible) functional groups within molecules to 
provide selective detection of HPLC analytes. There are a number of basic types of 
electrochemical detector available. The ESA Coulochem detector (ESA, Massachusetts,
USA) uses two serially aligned porous carbon electrodes through which the mobile phase 
passes. The mobile phase contains an electrolyte which allows a standing current to pass 
between the carbon electrode and an auxiliaiy electrode. The analyte eluting from the 
column, reacts at the electrode surface, the oxidation reaction releasing hydrogen and an 
electron, figure 14. A complementary reduction occurs at the auxiliary electrode.
Figure 14
Oxidation of hydroquinone to quinone.
O
O
+ 2H+ + 2e-
In theory, the very high surface area of the porous carbon electrode results in all of the 
analyte being oxidised, known as coulometric detection. This is in contrast to the more 
common electrochemical detection method known as amperometric detection. These 
detectors use a glassy carbon electrode where the mobile phase passes over the surface of the 
electrode and only the analyte at the surface is available for oxidation. The efficiency of the 
glassy carbon electrode can be improved by altering the mechanical arrangement of the cell 
such that the mobile phase is sprayed at the electrode surface. These are known as wall jet 
electrodes. Other electrode materials can be used, for example, a gold amalgam or compacted
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carbon paste. The different electrode materials and configuration can result in a different 
selectivity for the reaction with the analytes. A further ECD type is the dropping mercury 
electrode. Mercury, held in a burette type reservoir is allowed to form a drop which is then 
used as the electrode surface. To replace the electrode the reservoir is opened allowing the 
old drop to fall and the formation of a new electrode. These detectors are not common.
Electrochemical detector types show different characteristics. The coulometric designs are 
generally nosier and have higher background currents when compared to the amperometric 
detector. Robust and sensitive ECD requires high purity reagents and steps to limit dissolved 
gases in the mobile phase.
Liquid chromatography with mass spectrometry detection. fLC-MS and LC-MS-MS).
Potentially mass spectrometry is the most sensitive and selective detection technique 
available to the bioanalyst. The essential difficulty is the removal o f the solvent component of 
the LC eluent and the interfacing of HPLC systems to the high vacuum environment of the 
mass spectrometer. This has developed through a number of distinct phases. The moving belt 
interface ^^ ^^ 1 was the first interface design. The first of these (1974) used a continuous
wire loop, replaced in 1976 by a polyamide belt. The mobile phase (or a portion of it via a 
stream splitter) was directed to the belt, and solvent evaporated by a heater before the belt 
passed through a series of evacuated chambers before entering the source o f the mass 
spectrometer. The dried sample was vaporised from the belt, ionised (by chemical ionisation 
or electron impact) and the ions passed into the mass spectrometer. The belt moved out o f the 
source through a heater and wiping mechanism to clean up the belt surface. High sensitivity, 
in the order of pg ml'*, was achievable with the moving belt interface system but it required 
careful setting up, belt replacement was cumbersome and carry over from the belt was a 
problem.
The thermospray interface was introduced commercially in 1983. Flow rates of up to 2 ml 
min * could be introduced directly into the source, removing the need for miniaturisation of 
the chromatographic system or stream splitting. In the interface a jet of vapour is formed 
from the mobile phase in a heated tube. Ionisation takes place via chemical ionisation and ion 
evaporation. The ionisation is achieved by the use of a reagent gas or by the addition of a 
volatile buffer in the mobile phase. To remove the large quantities of solvent vapour 
powerful vacuum pumps are required.
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Atmospheric pressure chemical ionisation is an alternative approach, and mass spectrometry 
instruments using this hardware are now popular, particularly for quantitative bioanalysis. 
Vaporisation of the mobile phase and ionisation of the analyte takes place at atmospheric 
pressure. The solvent vapour is drawn off by pumps less powerful than are required for 
thermospray. The ions enter the mass spectrometer via a small orifice (protected by a curtain 
gas of nitrogen) or capillary tubing.
Ionisation at atmospheric pressure can be achieved in two ways. Chemical ionisation arises 
from the transfer of a charged species from a reagent ion to the analyte molecule 
The column eluent is vaporised using a heated nebuliser. The mobile phase is mixed with a 
nebulizer gas (air or nitrogen) and flows down a heated tube. The heated gas, solvent, and 
analytes are swept into the atmospheric pressure interface which has a corona discharge 
needle. Positive ionisation results in adducts such as or or, in negative mode, from 
losses o f protons or electron capture to give, for example NO2 ' . By the correct choice of 
conditions a high degree of ionisation can be achieved with very little fragmentation of the 
analyte. The corona discharge (at approximately ±6,000 V, 3 - 5  pA) provides energy for the 
ionisation of, primarily, the reagent molecules. The charge can be transferred to the analyte 
via charge transfer (R^+ T = T^ + R) or proton transfer (RH + T = TH^ + R). Negative 
ionisation of the analyte occurs similarly.
An alternative method of ionisation is ion evaporation or electrospray. The mobile phase 
entering the source is disrupted to form droplets by a high velocity jet of air. The tip of the 
nozzle is charged, and this assists the dispersion of the droplets and provides each droplet 
with a net charge. The distribution of charge within the droplet is not uniform, the excess 
charge residing at the surface of the droplet. As the droplet evaporates the surface charge 
increases until the electrostatic charge overcomes the surface tension of the droplet 
(Matthews, 1994) this happens fine droplets are ejected. This process continues producing
ever finer droplets, presumably until no charge difference remains. An advantage of this 
ionisation technique is that more than one charge can be added to the analyte, which extends 
the application of electrospray to larger molecules (Mr=l 00,000) than by the other techniques 
described above.
Two detection modes are possible. Single ion monitoring where commonly the molecular ion 
(mol. wt. +1, for molecules with a single charge via proton transfer) is measured and the
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more selective technique of daughter ion monitoring (LC-MS-MS), For LC-MS-MS ions 
equivalent to the molecular ion of the analyte are focused by the first quadropole (acts as a 
lens) into the collision cell. Here the molecules collide with argon and fragment in a 
reproducible way. The final quadropole of the mass spectrometer is used to focus a fragment 
ion of the analyte on to the detector. The combination of the two ion selection mechanisms 
provides very selective detection and the absence of ions other than the analyte (very low 
noise levels) allows high sensitivity to be achieved.
Quantification of analytes.
The quantification of analytes can be accomplished in a variety o f ways. In some situations 
comparison with an injection of a known concentration of standard may be adequate, for 
example, when using protein precipitation. More commonly, one or more blank matrix 
samples fortified with known amounts of analyte (calibration standards) which are then 
treated in an identical manner to the unknowns are used. The detector response to the 
calibration standards can then be used to quantify the response from the unknowns. There are 
a number of problems with this approach. Variability during the extraction process, variation 
of sample injection volume and drifting detector response will all be manifest in the apparent 
precision and accuracy of the quantification. The use of an internal standard (IS) can 
compensate for some of these difficulties. A compound similar in structure, extraction 
efficiency and chromatographic behaviour to the analytes under test is added tq all samples 
and calibration standards. The detector response to the internal standard is then used to 
normalise the response to the analytes. In this way sources of variability can be compensated 
for. For example, the peak height or area ratio between the analyte and internal standard will 
be the same for any given sample regardless of the amount injected and quantification is 
achieved by comparing the peak height ratio of the unknowns with those of the calibration 
standards.
The choice of an internal standard for use with chiral methods is not as straight forward as 
that for achiral chromatography where a close analogue of the analyte can normally be used 
with little difficulty. Small changes in analyte structure may require optimisation of the 
mobile phase conditions to achieve a separation from the analyte to be measured and these 
changes may adversely effect the resolution o^ the analyte enantiomers. The chromatographic 
behaviour of CSPs is less predictable than for achiral stationary phases.
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Poor peak capacity (protein CSPs in particular) make the placing of an internal standard in 
the chromatogram particularly difficult. A possible advantage using a chiral IS would be that 
it would allow the use of either enantiomer of the IS to be used, although that would require 
stereochemically pure standards. In a reversed phase type separation such as Chiral AGP the 
internal standard would ideally be placed such that it eluted after the analyte enantiomers, 
thereby minimising the risk of the internal standard co-eluting with metabolic products o f the 
analyte which are normally more polar than the parent. If  the extraction method used 
provides very high recoveries, the possible variation due to extraction is thereby limited. By 
fixing all transfer volumes further reduction in variation is achieved and an internal standard 
may not be required.
A variety of calibration functions can be used with or without the presence of an internal 
standard. The most common bioanalytical calibration uses multiple standards of known 
concentration. Normally, a straight line is fitted to the absolute peak height or area (ratio for 
internally standardised assays) using least squares linear regression (y=mx+c). The slope of 
the line (m) and the intercept (c) are used to quantify the detector response to the unknown 
(y). The statistical errors in chromatographic calibration are not necessarily related to 
concentration, but are dependent upon the manual steps taken to present the sample to the 
detector. These steps include the sampling errors, extraction differences between cartridges, 
imprecision in reconstitution the sample prior to injection and the injection volumes. All o f 
these errors are independent of concentration, resulting in measurements with a constant 
coefficient o f variation (CV). In these circumstances a weighted regression is more 
appropriate. The function required is 1/variance of the measurement. This is rarely available 
for routine bioanalytical calibration data (where single or duplicate measurements are used at 
each concentration level) and the common functions used are 1/y^, 1/y, 1/x  ^or 1/x . If  these 
functions are not available, forcing the calibration line through zero results in generally 
similar calibration data assuming that the chromatography is specific for the analyte being 
measured. The use of a linear regression assumes that the detector and integrator are working 
within their region of linear response.
As the amount of analyte nears the limit of the detector’s sensitivity, the CV increases until it 
becomes unacceptable This point defines the limit of quantification of the method.
The upper limit of the calibration range is determined by the linearity of the detector and / or 
the amount of “carry-over” seen with subsequent extractions and injections. In practice there
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is no upper limit for the quantity that can be measured because the sample may be diluted 
until it falls within the practical calibration range.
Quality control of analytical techniques.
Quality control (QC) samples, which are usually control biofluids fortified with known 
concentrations o f analyte, are used to provide information about the long terra performance 
of an analytical method. QCs can also provide information to enable comparison of the 
method under varying conditions, for example, a new operator, or in a different laboratory. 
Generally, QC samples are prepared in bulk, dispensed into aliquots and stored in conditions 
approximating to that used for the study samples. A number of QC samples are removed and 
analysed with each batch of samples. Common practice is to use two or three QC samples at 
low, medium and high concentration, relative to the calibration range The
application of QC samples to the analysis of in-vitro metabolism or exploratory in-vivo 
pharmacokinetics is limited due to the essentially “one o ff’ nature of these studies.
53
DRUG METABOLISM
In-vivo metabolism.
Many critical features of the pharmacology and toxicology of exogenous organic molecules 
(xenobiotics) arise from their interaction with highly chiral endogenous compounds present 
as receptors and enzymes A fundamental principle of pharmacodynamics, as
formulated by Paul Erlich, is that compounds do not act unless bound. This applies to both 
pharmacodynamic events (for example, drug-receptor binding) and pharmacokinetic 
processes (for example, metabolism) Drug disposition and metabolism may
involve binding to endogenous macromolecules. The energies involved range from a few 
kcal mof* (weak reversible bonds) to 1 0 0  kcal mof* or more (covalent bonds).
The stereoselectivity of xenobiotic pharmacokinetic events can be classified into two groups. 
The first as a result of absorption, distribution, binding and excretion, which corresponds to 
one type of stereoselectivity, namely the differential disposition / interaction displayed by 
stereoisomers. This is comparable to the situation found in pharmacodynamic events. The 
second in contrast, is a result of metabolism (biotransformation), and displays two basic types 
of stereoselectivity, substrate stereoselectivity and product stereoselectivity, which is not 
unique to xenobiotic metabolism. The different rates at which the enantiomers o f a chiral 
substrate are metabolised is the result of substrate selectivity. It is also possible for an 
asymmetric centre to be created at different rates, which is, product
stereoselectivity Although the focus of much of the published work in the area of
chiral interactions relates to drugs, the areas discussed here are equally relevant to other 
xenobiotic compounds such as pesticide residues, residues of compounds used to treat 
livestock, and environmental pollutants.
Possible routes o f enantioselective metabolism:
In producing its expected biological effect a drug undergoes a number of complex 
interrelated biochemical processes. There are two distinct processes of interaction, the 
pharmacokinetic, what the body does to the drug and the pharmacodynamic, what the drug 
does to the body. The pharmacokinetic process is where the drug is absorbed (in the case of 
an oral or topical preparation), distributed (delivered to the target organ or receptor).
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metabolised (detoxified) and eliminated from the body. The pharmacodynamic process is a 
result o f the drug interacting with the target organ or receptor. The pharmacodynamic phase 
also includes non-therapeutic interactions between the drug and the body. At each stage there 
is the opportunity for chiral sensitive mechanisms to differentiate between enantiomers.
There is little evidence that drugs are absorbed in humans by processes other than passive 
diffusion However the presence of membrane transport proteins suggests that in
theory at least, it would be possible for stereoselective absorption to occur. A possible 
example is that of a-methyldopa. The fraction of a radiolablled dose of a-methyldopa 
excreted into faeces was found to be different for D-a-methyldopa (70-80% unchanged drug) 
from that of its enantiomer L-a-methyldopa (35-60% unchanged drug) The
assumption was that the fraction absorbed was dependent upon the stereochemistry of the 
compound.
The fraction of the absorbed dose of a drug which is available for metabolism, excretion or
interaction with the target organ is affected by the extent of plasma protein binding, since
only free drug can interact at the receptor site. An example of enantiospecific drug-plasma
protein interaction is arotinolol The differences in pharmacokinetics of the
enantiomers o f mexiletine in humans has also been attributed to serum protein binding 
differences Hg^ 'cmezie, 19S9]
There is a variety of possible stereochemical routes of metabolism for xenobiotic compounds. 
A prochiral compound can undergo metabolism resulting in a chiral product. This can occur 
at the prochiral centre (for example, hydroxylation of aliphatic chains), or remote from the 
prochiral site (as in the hydroxylation of phenytoin see figure 2 ).
Figure 2
Structure of phenytoin. 
pro-S
pro-RHN
H
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The latter is an example of product specificity because, in man, para-hydroxylation of the 
phenyl ring, attached to the prochiral carbon occurs, which results in greater than 95% of the 
(S) enantiomer being produced. The reverse is seen in the dog, where, predominately 
meta-hydroxylation is seen.
Further differences can occur during chiral-chiral transformations. The same metabolic 
transformation can occur but at different rates. This is an example of substrate selectivity. 
Indacrinone a uricosuric - diuretic agent, is metabolised by para-hydroxylation.
There is a 40 fold difference in metabolic clearance via the hydroxylation route resulting in 
the (R) isomer being eliminated much faster than the (S) isomer.
There are examples of different metabolic routes being used to eliminate different isomers of 
a chiral compound. The oral anticoagulant, warfarin, has been well studied. Two routes of 
metabolism are observed, aromatic oxidation of the coumarin ring, and ketone reduction in 
the side chain ^^ **1. The ketone reduction results in a second asymmetric centre and
therefore a diastereoisomeric product. The relative extent of metabolism via these pathways 
varies between species. In man the major metabolite is 7-hydroxywarfarin and the preferred 
substrate for the enzyme is the more pharmacologically potent (S) enantiomer. In the rat, the 
(R) enantiomer of warfarin is metabolised preferentially compared to its antipode.
Metabolism of a chiral compound away from the asymmetric site can result in a 
diastereoisomeric product, as in the ketone reduction of warfarin. The "reverse" is possible, 
where a chiral compound is metabolised to an achiral product, for example, the deamination 
of amphetamine.
Chiral inversion is a rare metabolic transformation. The 2-arylpropionic acids, a group of 
non-steroidal anti-inflammatory compounds (for example, ibuprofen), are able to undergo 
inversion of the R-acid to the antipode without further alterations to the structure. The (S) 
isomer is the pharmacologically more active and the (R) to (S) conversion results in 
metabolic activation, the rate of which varies between species
The excretion of a compound or its metabolites may be affected by its stereochemistry. Hilary 
excretion of xenobiotics may occur via an active, carrier mediated process, however, 
selectivity due to structure (other than size) is rare ^^ *'*1,
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The pharmacodynamic (i.e. pharmacological and toxicological) consequences of drug 
metabolism are significant. Biotransformation may cause inactivation or activation of 
metabolites responsible for some, or all, of the subsequent clinical response. The extent of 
chiral specificity observed can be dependent upon the probe used to investigate it, for 
example achiral analysis of the propionic acids is insufficient to explain the observed 
pharmacodynamic events caWweii, i98si requires chiral analysis to correlate
pharmacokinetics and pharmacodynamics.
An example of the importance of chirality in therapeutics:
The cytostatic agent Ifosfamide (IFO), a compound containing a chiral phosphorous atom 
(figure 3), was patented by Astra in 1968 and it is still in use today.
Figure 3
Structure of Ifosfamide.
7' - n h c h , c h x iN  ^ ^'^CHgCHgCl
IFO is a prodrug which undergoes metabolic activation, by ring hydroxylation at 
carbon-4 *^ ^^ 1^  to the cytostatically active metabolite 4-hydroxyifbsfamide. Oxidation
of the side chain (which inactivates the drug) liberates chloroacetaldehyde which was 
presumed to be responsible for the neurotoxicity seen with therapy. The study 
of 11 subjects dosed daily for 5 days with IFO demonstrated a reduced terminal half life and 
area under the blood level / time curve (AUC) of approximately 30% by day 5 compared to 
day 1. This data was consistent with induction o f hepatic enzymes responsible for the 
biotransformation of IFO. Both parent compound and metabolites were measured using 
achiral analytical techniques and therefore no information was generated regarding the 
possible enantiosf^lectivity of these processes. The study concluded that the toxicity was dose 
dependent and would increase during prolonged exposure to IFO.
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These findings were confirmed by other workers, for example, Boddy A reproducible 
variation in metabolism between subjects was observed. A further study showed
that the observed variation was not linked to genetic polymorphism.
To investigate the metabolism of IFO, in-vitro experiments using human liver microsomes 
were conducted i^9 3 . waikcr, i9 9 4 i cytochrome P450 isozyme family CYP3A (sub 
types CYP3A3 and CYP3A4) was shown to activate IFO (4-hydroxylation) and to be capable 
of the N-dechloroethylation of IFO. The isozyme CYP2B was also shown to catalyse the 
activation of IFO. The possibility of inducing these P450 forms to improve activation and 
therefore the efficacy of IFO was proposed in the earlier study In  contrast, the
later study had shown that it was not possible to inhibit the pathway leading to the
toxic metabolite, whilst maintaining activation. Both studies used achiral analytical 
techniques to quantify both the prodrug and its metabolites.
The separation of the enantiomers of the prodrug and metabolites is possible A
study of 14 patients demonstrated that IFO was excreted in urine enantioselectively
and that the selectivity increased after repeated dosing. The (R) IFO always predominated.
(S) 2-dechloroethylated-IFO ((S) 2-DCE-IFO) was the main 2-DCE-IFO metabolite. For the 
3 position metabolites, (S) 3-DCE-IFO (from the (R) IFO'*) predominated in 6  of 14 patients 
whilst the (R) 3-DCE-IFO was in excess in the remaining 8 . The study concluded that no 
benefit would be obtained by “the therapeutic application of pure enantiomers”.
The efficacy of the enantiomers of IFO was examined by Wainer and co-workers 1^“'"®*'’
They found that enantiomers of IFO were equally effective anti-tumour agents, and that the 
(R) enantiomer was metabolised to a greater extent via the activation pathway. The 
neurotoxicity arises from the metabolism that occurs via the inactivation pathway and 
therefore the administration of (R)-IFO would result in a less toxic treatment.
Later work by Wainer (stereoselective pharmacokinetics conducted using 18 women
suffering from gynaecological cancers) found that the total clearance o f the (S) enantiomer 
was higher than that of the (R) enantiomer. Renal clearances of the two compounds were not
the change in labelling from (R) to (S) results from the Cahn, Ingold and Prelog assignment about the 
phosphonium atom, not a rearrangement of atoms.
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significantly different and therefore the non-renal clearance, in this instance, metabolism 
accounted for the difference. The observed neurotoxicity in these subjects correlated to the 
amount o f (R) 3-DCE-IFO present The conclusion to these studies was that (R) ifosfamide 
would result in a safer medicine than the racemic drug. The (R) enantiomer is now the subject 
of a patent for a new medicine.
Drug safety and regulatory issues regarding the use of chiral medicines:
Seventy percent of synthetic medicines available in 1994 were marketed as 
racemates News, 1 9 9 4] value of racemic drug therapies has been the subject of
much discussion by the pharmaceutical manufactures the clinicians who use
them and the government bodies that regulate that use
One representative view is that inactive isomers should be regarded as impurities, given the 
term 1^ '‘®‘®"®’ ^^^®1 “isomeric ballast” because they do not contribute to therapy and therefore 
only dosing of pure enantiomers can be justified. This view becomes less immoderate where 
two asymmetric centres are present, because now only 25% of the racemic formulation is a 
single isomer.
A more pragmatic approach is favoured by others because in practice the
concept of a 50% "impurity" is valid in only a limited number of cases. Totally different 
pharmacological or toxicological properties for enantiomers are
rare 1989. DeCUamp, 1989]
The Food and Drugs Administration, the government body responsible for the regulation of 
medicines in the USA, have published on the topic of the administration of racemates or 
unequal mixtures of enantiomer *^ ^^ 1. The government regulatory bodies of
other countries have similar guidelines.
The regulations and guidelines leave scope for the regulatory bodies to question the safety of 
racemic compounds. Experiments should not neglect the possibility o f a potential difference 
in action of enantiomers. None of the regulatory bodies has yet ruled that only enantiomericly 
pure synthetic compounds are acceptable.
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In-vitro metabolism.
As the understanding of the metabolic fate of pharmaceutical compounds grows, the 
knowledge gained will eventually lead to the faster development of safer medicines. The only 
model capable of providing information about both phase 1 and phase 2  metabolic reactions, 
and their interactions with other biological processes, (such as the distribution and excretion 
of the drug) is the in-vivo model. Metabolism in animals or human volunteers can be studied 
by the collection o f urine, blood and in more sophisticated studies, the collection of bile via 
cannulation of the bile duct ^^ *^ 1,
Sufficient toxicological data for a new chemical entity must be collected using animals prior 
to dosing human volunteers. The use of whole animals, however, can in some circumstances 
be inefficient. Studies involving whole animals are complex, labour intensive activities. New 
synthetic medicines are often the result of the investigation of a large number of chemical 
analogues with minor structural differences. In-vitro pharmacological models, for example 
cell binding, allow large numbers o f chemicals to be screened rapidly. The data obtained 
from these studies may then be used to predict new structures for testing using QSAR 
(quantitative structure activity relationship) techniques. However, a pharmacologically active 
substance is of little use if it cannot be delivered to the active site in sufficient quantity to 
elicit the desired response. Bioavailability dependent upon the metabolic stability of the 
active compounds can also be examined using in-vitro models.
A number of Ui-vitro systems are possible from purified enzymes, cell culture through to 
perfused organs Purified enzymes may be used to examine a specific reaction.
They may also be used to prepare antibodies to probe metabolism in more complex in-vitro 
studies. The purification procedures required are usually extensive and the micro 
environment of membrane bound enzymes, such as those of the cytochrome P450 group, is 
lost and needs to simulated. The turnover of substrate when using these preparations may be 
very low and not reflect the situation in-vivo. Subcellular fractions, though simpler to 
prepare, provide a more complex in-vitro preparation. The micro environment of the enzymes 
remains intact and for the study of metabolism the model is generally considered adequate. 
The preparation of these fractions is rapid and they remain stable when stored at -80 °C for a 
period of months with little loss of activity. The concentrations of co-factors and substrates
60
can be optimised for the study of enzyme kinetics, however, data generated by subcellular 
fractions and purified enzyme models may be different to that seen in-vivo.
Isolated intact cells are closer to the in-vivo environment. However, a number of new 
difficulties now need to be considered. For the substrate to be metabolised it must penetrate 
the cell and compete with endogenous substrates. The cell must be capable o f producing or be 
supplied with sufficient co-factors, for example, nicotinamide-adenine dinucleotide 
phosphate (NADPH), nicotinamide-adenine dinucleotide, uridine diphosphate-glucuronic 
acid and adenosine 3 '-phosphate 5 '-sulphate phosphate. Liver cells (hepatocytes) should 
contain sufficient glycogen stores for NADPH generation and adenosine triphosphate 
synthesis, but without the addition of inorganic sulphate to the incubation medium sulphate 
conjugation will not occur.
The interaction between metabolic pathways must also be considered. Phase 1 and phase 2 
reactions may be linked. The product of a P450 mediated oxidation of a substrate (phase 1 
reaction) may not be present in the incubation medium because of the rate of glucuronidation 
and sulphate conjugation reactions (phase 2). The isolated cell models may use either freshly 
isolated cells or those from a primary culture, and established cell lines have been used but 
possess limited drug metabolising activity Newly isolated hepatocytes have high
metabolic activity but are only viable for a few hours. A sufficient number o f cells is 
produced by a single preparation and this allows a number of different experiments to be 
conducted. Much work has been carried out tn increase the drug metabolising life of isolated 
cells.
Isolated cell systems still lack the structure of the whole organ. Liver slices are a model 
closer to the whole organ structure. A 0.8 cm core of liver tissue is cut into 250 p.m thick 
slices. Each slice is a set of intact cells, albeit with a damaged outer layer. The need to ensure 
sufficient co-factors is the same as for the isolated cell models.
Isolated organ models are the closest to the whole animal in-vivo environment. The perfused 
rat gut model involves the isolation of a piece of gut into which the compound
under test is added. The vascular supply to that region of gut is isolated and perfused with a 
blood substitute. The model was used to investigate metabolism of compounds absorbed 
through the gut wall. A similar preparation was used for liver
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Role of in-vitro metabolism models in pharmaceutical development.
Despite the caveats noted above, in-vitro models can be effectively used to screen large 
numbers of compounds for specific properties and to investigate a variety o f metabolic 
issues. The comparison of metabolic pathways and differences between species is essential if 
toxicological studies are to be meaningful. In-vitro models using human matrices can provide 
data about the suitability of animal species before human studies are underway. The 
generation and effect of toxic metabolites can be studied using in-vitro techniques. A simple 
screening application of in-vitro models is their use in the assessment o f the metabolic 
stability of a series of analogues, so that candidates which have acceptable pharmacological 
activity but better metabolic stability can be chosen for further development. In-vitro models 
can, of course, be used to investigate chiral metabolism, but in order to use these metabolism 
models to examine the fate of enantiomers, methods must be developed to separate and 
identify them, and measure their concentration.
Measurement of metabolic activity and pharmacokinetics.
In-vitro data.
When a test compound is incubated with a suspension of microsomes, tissue homogenate, 
hepatocytes, liver slices etc. the disappearance of the analyte from the incubation medium can 
occur only via its transformation to something else. Assuming the analyte is chemically 
stable under the conditions of the incubation (pH and temperature) then the loss may only 
arise from biological, enzymatic, action. The type o f biotransformations that may occur is 
dependent upon the model used. The microsomal preparations are predominately cytochrome 
P450 enzymes (bound to the endoplasmic reticulum) which give rise to oxidative phase 1 
reactions. The hepatocytes and liver slice models can, with appropriate co-factors, give rise to 
phase 2 , synthetic reactions such as conjugation.
Enzyme kinetics are described by the Michaelis-Menten equation, equation 16;
Equation 16
V =  ' ' M
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The velocity (v) of the reaction is controlled by the maximum velocity possible (V), the 
concentration of substrate ([S]) and the Michaelis constant Km. The Michaelis constant is the 
substrate concentration that produces half-maximal velocity. Since the Km is specific to each 
enzyme and substrate (and also to the conditions of the reaction such as pH) it can be used as 
a means of comparing metabolic stability. To measure V, and hence Km requires a large 
number o f experiments because the relationship is non-linear. This can be overcome by the 
application of the double-reciprocal plot or Lineweaver-Burk plot, which transforms the 
curve into a straight line requiring fewer points to describe. A development of the 
Lineweaver-Burk plot, the direct linear plot allows the estimation of V
and Km from incubations at only three concentrations. A measure of the intrinsic clearance 
rate (metabolic clearance without accounting for blood flow through the organ) is given by 
Vmax/Km mls uiin'^ 10  ^cells. The above approach to determining stability requires the 
measurement of the initial velocity, and requires sufficient data points to enable the initial 
velocity to be measured. For unstable compounds it can be difficult to equilibrate the 
incubation media and sample quickly enough to define the initial velocity accurately.
An alternative mathematical approach is the use a pharmacokinetic model Here,
the incubation medium represents the total volume of distribution of the drug and as the cell 
suspension is fortified it reaches equilibrium rapidly. This is analogous to the one 
compartment pharmacokinetic model, see figure 15.
Figure 15
One compartment pharmacokinetic model tintravascular bolus doseV
D -------------------[ > -------------------1>
^
Where;
D = dose
Kgj = elimination rate constant from compartment 
Vd = volume of compartment 
Cp = drug concentration
The only route of elimination is via metabolism, and therefore Kei is equal to the sum of all 
the rates of the metabolic processes occurring in the incubation mixture. The analyte
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concentration should decline according to first order (exponential) kinetics. When the data is 
plotted using logarithmic (log„) concentration the plot is transformed into a straight line. The 
analyte concentration is defined by equation 17;
Equation 17
Where;
Cp = concentration at time t 
Cp = concentration at time zero 
Kgj = elimination rate constant
A number of related parameters may be obtained from these plots. The elimination rate 
constant is equal to the slope of the line. A common pharmacokinetic parameter, tlie half life, 
the time taken for the concentration to reduce by half, is given by equation 18;
Equation 18
0.693
The total area under the time versus concentration curve extrapolated to infinity, AUCo.%, is 
given by equation 19;
Equation 19
C"A  = —— [concentration * time]
k . . ,
The AUCoc may then be used to determine the pharmacokinetic parameter, clearance, by 
equation 2 0 ;
Equation 20
Cl =  [volume * time]
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The elimination rate constant and the half life will remain constant (independent of 
concentration) if the enzymes in the incubation mixture are not saturated. These parameters 
can then be used to compare the relative metabolic stability of a number of compounds. 
Given a minimum of six concentration values over time, the measurement of the elimination 
rate constant will be quite accurate because minor inaccuracies in each measurement will be 
averaged out by the regression equation used to fit the line. However, to reduce the 
inaccuracy of “dosing” a number of incubations will be required. Likewise, to test that the 
enzyme kinetics at the chosen doses are linear, a number of concentrations are required.
In-vivo data.
The open pharmacokinetic model described above may also be appropriate to describe the 
kinetics of a compound in-vivo. The drug in the in-vitro incubation cannot distribute beyond 
the volume of the incubation medium. A drug may distribute in a number of ways in-vivo. If 
the analyte is highly protein bound, the drug may never distribute further than the volume of 
blood within the body. Some highly lipid soluble drugs will distribute widely as it can easily 
pass through cell membranes. The one compartment model above is valid for in-vivo 
situations where the distribution of drug rapidly reaches equilibrium. If  the distribution into 
tissues from the circulation does not reach equilibrium rapidly, then a biphasic elimination 
profile will result. This may be approximated using an open two compartment model.
This assumes that upon dosing the drug rapidly equilibrates into a central compartment (as 
for the single compartment model), from where it slowly distributes into a peripheral 
compartment. Equilibrium is reached some time after dosing where the initial rapid fall in 
plasma drug concentration (the a  phase) arises from the distribution into the peripheral 
compartment and some elimination of the drug. The decline of the later part of the plasma 
concentration curve (the |3 phase) is dependent upon the transfer of drug from the peripheral 
compartment back into the systemic circulation, metabolism of the drug and its excretion 
from the body. Where a drug has a high clearance rate, the a  phase may represent a 
significant part of the elimination phase of the drug concentration time profile. A typical 
blood level time cui've, with the a  and P phase drawn in (using curve feathering 
is shown in figure 16.
65
Figure 16
Blood level time curve representing an open two compartment pharmacokinetic model.
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The model can be described schematically as in figure 17. 
Figure 17
Open two compartment model.
Where;
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66
The rate constants for the model can be calculated using the following equations 21, 22 and 
23;
Equation 21
Equation 22
=  Ihr-'l
Equation 23
Where;
A
a
B
p
K.. c ;
y  axis intercept of a  phase 
slope of a  phase 
y axis intercept of p phase 
slope of p phase 
summation of A and B
[hr - 1
The concentration of drug in plasma at time t is given by equation 24;
Equation 24
C,, = B.e'"' + A .e -°’
The volume of distribution of a drug is not a real volume, but a theoretical value which 
provides a measure of the disposition of the drug within the body. If  a drug, administered as 
an intravenous bolus, has access only to the circulating blood then the concentration in the 
blood at time zero would be equal to the dose divided by the blood volume. To measure the 
volume of distribution at time zero for the open two compartment model, after intravenous 
bolus dosing, the equation 25, is used:
67
Equation 25
^  = [rnl]
S
Where;
Vc = volume of central compartment
D = dose administered
Other volumes of distribution can be calculated. The volume of distribution at steady state 
(Vdss) can be used to compare the pharmacokinetics of the analyte in different animals via the 
distribution coefficient. The distribution coefficient is simply the volume of distribution at 
steady state divided by the body weight. The definition of steady state is dependent upon the 
model used. For the open one compartment model it is the back-extrapolated time zero 
(Vdss= dose/C^p), for the open two compartment model it is defined as follows, equation 26;
Equation 26
= [ml]^oul
The volume of distribution can be normalised for different body weights using distribution 
coefficient, Ac, equation 27;
Equation 27
The distribution coefficient is only valid when comparing animals or subjects with normal 
body weight, stature and frame. Excess body fat would lead to a change in the distribution 
coefficient if the drug distributed into the lipid stores.
The total exposure of the drug to the body can be obtained by measuring the area under the 
blood level time cuiwe (AUC). By comparing the AUC obtained when the drug is given 
intravascularly with that obtained by any other dose route, the fraction of drug absorbed by 
that route can be calculated. The AUC can be calculated in a number o f ways, for example.
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the trapezoidal rule. An exact value can be calculated from the model fit as follows, 
equation 28;
Equation 28
A  =  —  + — [conc'time]p a
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PROJECT AIMS.
The aim of this project was to investigate the application of chiral chromatographic 
techniques to support in-vitro metabolism studies of some new analogues o f the SHTja 
receptor agonist 8-hydroxy-2-dipropylaminotetralin (8 -OH-DPAT). These compounds have a 
common 2-aminotetraIin substructure and similar 2-nitrogen substitutions. However, the C 8  
position was substituted to give a variety of chemical structures.
The 2-aminotetralins.
Serotonin (5-hydroxytryptamine, 5-HT) is found in many tissues of the body and
acts as a vasoconstrictor on pulmonary and renal blood vessels, but as a relaxant on cardiac 
and skeletal vessels. It is also found in the central nervous system where it acts as a 
neurotransmitter. The variety of serotonin actions point to multiple receptors and at least four 
sub types have been proposed each with variations of their own The 5-HTia sub
type, found primarily in the cranial vasculature, has been linked to the pathology of migraine. 
Prior to a migraine attack, plasma levels of serotonin fall. However, the use of serotonin as a 
treatment for migraine is restricted by its variety of systemic actions.
The 5-HT receptor agonist 8 -OH DP AT, figure 18, is a potent and selective agonist for the 
5-HT,a receptor type
Figure 18
8 -hydroxy-2 -dipropylaminotetralin.
OH 
N
The action of 5-HTla receptor agonists is to inhibit the synthesis of 5-HT The
accumulation of 5-hydroxytryptophan (5-HPT) can be used as an indicator of 5-HT synthesis 
rate Pharmacological screening tests for 5-HT receptor activity include in-vivo
5-HTP accumulation in various parts of the brain and displacement binding studies carried 
out in-vitro using brain homogenates. Marked differences in the 5-HTP accumulation activity
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of the individual enantiomers of 8 -OH DP AT and some close analogues have been 
demonstrated three dimensional aspects of the interaction of the
enantiomers of 8 -OH DP AT and similar compounds were explored using computer 
graphics When the coplanar rings of the (R) and (S) enantiomers of 8 -OH DP AT
are superimposed the two 2-nitrogen substitutions lie 1.48 Â apart. This may result in the less 
active (S) enantiomer having to take up a less energetically favourable position in the active 
site relative to the (R) enantiomer. Behavioural and motion observations are also 
studied Flat body posture, fore paw treading and increased locomotion are
indicative of 5-HT activity.
The poor oral activity of 8 -OH DPAT («2% bioavailability) is due to extensive first pass 
metabolism by the liver The two major routes of metabolism in the rat have
been shown to be glucuronidation and N-dealkylation of the parent compound 
The N-dealkylated metabolite is subsequently excreted as the glucuronic acid conjugate. 
Using rat liver microsomes the N-dealkylation of 8 -OH DPAT has been shown to
be the result of cytochrome P'^SO activity.
Analogues of 8 -OH DPAT were synthesised as part of a drug discovery project which was 
looking for novel, orally active centrally acting medicines. The relative metabolic stability of 
pharmacologically active structures was assessed by incubation with freshly isolated rat 
hepatocytes with analysis using a “core assay”
achiral chromatographic technique. This enabled many compounds to be screened quickly. 
The data generated by these studies was used to synthesise new structures that were 
metabolically stable whilst retaining biological activity.
Few compounds were produced as enantiomerically pure standards, consequently the 
incubations were carried out using racemic mixtures. The use of achiral chromatographic 
analysis resulted in only an estimate of the stability of the enantiomers being determined. It 
was not possible to determine if one enantiomer was significantly more stable than its 
antipode. If the development of a chiral assay could be achieved with greater speed, then 
information regarding enantiomeric stability might assist the development of new analogues.
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The present work.
The aims of the study reported here were to investigate the development of a “universal” 
chiral chromatographic methodology which could be applied to the analysis of samples 
generated by in-vitro metabolism and in-vitro pharmacokinetic studies of the new 
2-aminotetralin ananalogues. It was intended that the information generated by these studies 
could be used to assist the preparation of new analogues with desirable pharmacological 
activity and resistance to metabolic clearance.
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MATERIALS AND METHODS
TEST COMPOUNDS.
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* This structure can not be shown in full.
Table 3
Calculated octan-l-ol / water partition ratio 
rc  Log P) of the test compounds.
Test compound 
number C lo g P
I 3.637
I I 2.173
I I I 3.094
IV 2.020
V 1.360
VI 3.551
V II 3.556
V III 4.480
IX 3.963
X 3.968
XI 5.398
X II 5.418
X III 4.278
XIV 3.038
XV 3.048
XVI 3.244
Test compound 
number C lo g P
XVI 3.244
XVII 3.043
X V III 2,718
XIX 4.332
XX 4.103
XXI 4.093
XXII 5.435
X X III 3.299
XXIV 3.012
XXV 5.840
XXVI 5.652
XXVII 3.056
XX VIII 2.606
XXIX 2.020
XXX 4.352
8-OH DPAT 3.868
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CHROMATOGRAPHY METHODS.
AH solvents and chemicals used in HPLC mobile phases where obtained from Fisons 
(Loughborough, UK) unless otherwise stated. HPLC grade chemicals, or the highest 
specification grade available, normally Fisons A.R. grade, were used. All water was prepared 
in-house using a Waters Milli-Q water purification system (Waters, Watford, UK).
HPLC pumps such as the Waters 510 or 600, Hewlett Packard HP 1090 (Hewlett Packard, 
Wokingham, UK), Severn Analytical SA 421 OB (HPLC Technology, Macclesfield, UK) and 
Kratos SA400 (Perkin Elmer, Beaconsfield, UK) were used for mobile phase delivery.
Sample injection for HPLC was accomplished by autosamplers, chiefly 710 or 712 WISP 
from Waters, Hewlett Packard HP 1090 or Gilson Model 412 (Anachem, Luton, UK). Except 
where noted HPLC columns were maintained at a temperature above ambient using forced air 
ovens, either the Shimadzu CTA 6A (Dyson, Hetton, UK) or the Hewlett Packard HP 1090.
The detection systems used for ultra violet absorption were the Kratos Spectraflow 773, 
Hewlett Packard HP 1090, or Waters DAD 990-MS (part of the liquid chromatography / mass 
spectrometry (LC-MS) system) and for electrochemical detection, ESA Coulochem (ESA, 
Huntingdon, UK) or Altech (Presearch, Hitchin, UK). Analogue data from these detectors 
were collected using either a Spectra Physics SP4270 computing integrator, Hewlett Packard 
HP 1090 workstation, or the Waters 860 data system.
Screening of chiral stationary phases for gas chromatography was conducted using a Hewlett 
Packard 5880 GC with mass selective detection.
HPLC mobile phases were made freshly and purged with helium (BOG, Crawley, UK) for 
approximately 5 minutes to displace dissolved atmospheric gases prior to use.
HPLC systems were constructed carefully to reduce band broadening by using minimum 
lengths of narrow bore tubing (0.010 inch i.d., pre-cut if possible) and zero dead volume 
fittings. A short guard column consisting o f the same or similar packing material to that used 
in the analytical column was used to protect the analytical column from contamination by 
either the sample or debris from the HPLC system itself (for example, shavings from high
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pressure pump seals). The guard column was replaced by a 0.2 mm stainless steel frit for 
column screening and in other studies where biological samples were not used. HPLC pumps 
and autosamplers were flushed with solvent prior to attaching the analytical column. 
Columns were allowed to equilibrate with mobile phase for 15 to 20 minutes before use. 
Samples were filtered or centrifuged if necessary to remove particulates before injection.
The broad peak shapes commonly found when using some chiral LC stationary phases 
allowed detector response times to be set to 2 to 5 seconds, thereby damping detector noise 
when set at high sensitivity.
Solutions of test compounds were made in either water, 0.1% acetic acid in water or 
methanol. Material was accurately weighed and a variable volume of solvent added to 
achieve the desired concentration. Due to the small amounts of test article available amounts 
weighed were approximately 1 mg. An ultrasonic bath was used to aid dissolution of some 
compounds.
Integration of chromatographic peaks was carried out using the algorithms installed in the 
equipment used; Spectra Physics, Hewlett Packard or Waters. Each system allowed for a 
"manual" baseline fit using on-screen graphical manipulation. Peak area was generally used 
for quantification. Calibration of chromatographic data was achieved by external standard, 
either single (for most in-vitro data), or multi-point calibration using least squares linear 
regression, weighted least squares or linear forced through zero to calculate unknown values.
Liquid chromatography - mass spectrometry.
Qualitative metabolite identification was can ied out using a Finnigan Mat TSQ70 (Finnigan, 
Hemel Hempsted, UK) using a Waters M 6000-MS HPLC pump fitted with a manual 
injection system. A Waters diode array UV detection system was fitted in-line before the 
mass spectrometry interface.
The mass spectrometer was operated in the Q3MS mode (3rd quadropole) scanning the mass 
charge ratio (m/z) range 200 to 500 once every 2 seconds. The thermospray interface 
conditions were; source block temperature 200 °C, repeller voltage 5 volts and vaporiser 
temperature 100 °C.
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Daughter ion mass spectrometry (tandem LC-MS or LC-MS-MS) was carried out using argon 
gas in the collision cell. The 1st quadropole was set to pass only the molecular ion of the 
analyte under examination and the 3rd quadropole set to scan an appropriate m/z range to 
monitor the fragmentation pattern.
Quantitative analysis was conducted using a PE SCIEX API III+ Biomolecular Mass 
Analyzer (Perkin Elmer). The chromatographic system used with the SCIEX consisted of a 
Severn Analytical SA410B HPLC pump and a Waters 715 autosampler. The instrument was 
run in heated nebuliser mode with the nebuliser set at 500 °C. The curtain gas used was 
Helium. Data was collected in single ion monitoring mode.
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PREPARATION OF SAMPLES.
Biological samples.
A Denly BM402 bench top centrifuge was used (Denly, Billingshurst, UK) for sample 
preparation prior to chromatography. VacElut 10 place solid phase extraction manifolds were 
purchased from Varian (Varian, Henley-on-Thames, UK). Solid phase extraction cartridges 
(Bond Elut) were obtained from Varian, or Isolute by Jones chromatography, Hengoed, UK. 
Solvent evaporation was carried out using either a Gyrovap (Howe, Slough, UK) or Tubovap 
(Zymark, Birchwood, UK)
Various forms of sample treatment were used. The simplest was centrifugation of biological 
material after protein precipitation with an equal volume of methanol, followed by injection 
of the supernatant onto the HPLC system. If  a concentration step was required the sample 
was dried using the Gyrovap and reconstituted prior to injection. Where a reduction in 
biological material was required, either liquid / liquid (with an immiscible solvent) or solid 
phase extraction (SPE) was carried out.
For SPE, an appropriate number of 10 place VacElut manifold boxes were connected together 
via tee pieces to a vacuum supply. Unused positions were closed off using small plastic 
plugs. SPE cartridges containing 100 mg of packing material in either 1 ml or 3 ml reseiwoirs 
were primed with 2 ml of acetonitrile followed by 2 ml of water. The sample loading, 
cartridge rinse and analyte elution steps varied according to the experiment. Solvent was 
drawn through the cartridges by the application of partial vacuum (atmospheric pressure - 
5 mm Hg). The cartridges were not allowed to dry except prior to elution. Collected eluates 
were partially reduced in volume in-situ by the application of higher vacuum («25 mm Hg) or 
the sample removed to a vacuum centrifuge (GyroVap) or a sample concentration unit using 
compressed air (TurboVap) at elevated temperature (40 °C).
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Sample preparation for circular dichroism spectroscopy.
A Jasco J720 spectropolarimeter (Jasco, Essex, UK)was used for the spectral analysis. Data 
was collected, analysed and reported via an attached personal computer.
Dried HPLC fractions were reconstituted in methanol and diluted to give an analyte 
concentration of approximately 100 pg m l'\  The solution was added to a 1 cm path length 
cuvette and scanned from 185 - 380 nm with a band width of 1 nm. Multiple (2-4) scans were 
made and averaged to reduce noise. Data was generated using baseline subtraction and 
normalisation.
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IN-VITRO PREPARATIONS
Freshly isolated rat hepatocytes.
All chemicals were obtained from Sigma unless stated otherwise. Preparation of excised liver 
lobes: Heparin (sodium) solution for injection; 5000 units mf^ (National Veterinary Supplies, 
Stoke on Trent, UK.). Earles balanced salt solution (EBSS) was prepared by adding 100 ml of 
EBSS (lOx concentrate without Ca^^ and Mg^^ (Gibco, Life Technologies, Renfrewshire, 
Scotland) to 870 ml of water and 30 ml sodium bicarbonate (7.5% w/v; Gibco). The solution 
was adjusted to pH 7.4.
EBSS + ethyleneglycol-bis(P-aminoethylether) N,N,N’,N’-tetraacetic acid (EGTA) was made 
by adding 10 ml of EGTA solution (25 mM in NaOH) to 490 ml o f EBSS and the pH 
adjusted to 7.4.
The digestion medium was made by adding 0.3 ml of IM CaCl2  (anhydrous), 10 mg trypsin 
inhibitor and 12-15 units of collagenase (from Clostridium Histoyticum, Boehringer, Lewes, 
UK.) to 150 ml EBSS.
N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulphonic acid) buffer (HEPES) was made by 
adding 2.383 g o f HEPES (10 mM), 8.299 g NaCl (142 mM) and 0.522 g KCl (7 mM) to 
1 litre of water. After adjustment to pH 7.4 (at 4 °C), lOg of bovine serum albumin (BSA) 
was added.
Phosphate buffered saline A (PBS A) was made using PBS tablets diluted to 10 mM. To this 
solution 1 g of glucose was added, the solution cooled to 4 °C and adjusted to pH 7.4.
In-situ hepatocyte preparation: The pre-perfusion solution was made by dissolving 8.7 g 
NaCl (Fisons), 2.4 g Na HEPES, 3.0 g D-fructose, 0.19 g EGTA (solubilised in 0.2 - 0.3 ml 
conc., HCL), 0.6 ml 0.5 % phenol red (Fisons) and 10 ml heparin (National Veterinary 
Supplies) in 1 litre water, and adjusted to pH 7.5.
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The digestion medium was made by dissolving 0.5 g KCl (Fisons), 8.3 g NaCl (Fisons),
2.4 g Na HEPES, ), 7.4 g Ca2Cl2.2H20, 3.0g D-fructose, 6 ml 0.5 % phenol red, 93,000 units 
hyaluronidase, 1000 units collagenase H., 0.066 g trypsin inhibitor and 2 g BSA in 1 litre of 
water. Adjust solution to pH 7.5.
The Supplemented Dulbecco’s Modified Eagles Medium (DMEM) stock solution was made 
by dissolving 11.0 g NaHCOs (Fisons), 11.7 gN a HEPES, 10.0 g BSA, fraction V,
2.0 g D-fructose and 1 packet DMEM ( with 1000 mg glucose, without Na pyi'uvate, 
without NaHCOs; Gibco) in 5 litres of water and adjusting to pH 7.4.
The final suspension buffer was made by adding 1.0 g BSA, 0.0045 ml insulin solution (fatty 
acid free BSA : bovine pancreatic insulin : HCL (12M) (5 : 3.27 : 15 w/w/v) and 25 ml foetal 
calf serum to 500 ml DMEM stock solution and adjusting to pH 7.4.
The perfusion apparatus similar to that described by Chenery was built by engineers 
from Upjohn Ltd.
Two procedures for the isolation of rat liver microsomes were used, reflecting the standard 
practices of the laboratory at the time of preparation. The earlier technique where excised 
liver lobes were perfused with collagenase was replaced with an in-situ perfusion technique 
which produced larger cell yield and greater cell viability.
Method 1 : The outflows from three flasks were connected to a single tube via a three way 
fitting. Screw clamps were used to regulate the flow from each flask to the single line. The 
contents of each flask was purged with Carbogen (BOC) during the perfusion process in 
order to maintain the correct pH. The flow from the flasks was directed through a heat 
exchanger maintained at 43 °C by a water heater / circulator. After the heat exchanger the 
line was split into four, each line feeding a 23 gauge cannula. The flow from the cannulae 
was collected at the base of the perfusion apparatus and fed to waste or re-circulated by a 
peristaltic pump back to flask 3. The perfusion apparatus was maintained at 43 °C by 
circulating water between the inner and outer walls of the vessel. The heated perfusion 
reagent maintains the excised tissue at physiological temperature.
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A male rat (approximately 150 - 210 g) was injected (intraperitoneal) with heparin 
(0.1 ml 5,000 units ml '), and killed after 10 minutes by cervical dislocation. The liver was 
removed into ice-cold PBS A and the two largest lobes removed using a scalpel or razor 
blade. The lobes were placed onto the perspex platform of the perfusion apparatus. Two 
vessels exposed by the removal of the lobes were cannulated using a 23 gauge catheter.
Perfusion of the buffer in flask 1 (EBSS + EGTA) was started at a flow rate of approximately 
10 ml mill"'. The passage through the coil heated the perfusate to 37 °C at the catheters. The 
perfusate from flask 1 was fed to waste. After 5 minutes the perfusate from flask 2 (EBSS) 
was switched in-line (flow from flask 1 having been switched off) and allowed to flow for 10 
minutes to remove the EGTA from the tissue. The flow from flask 2 was stopped and the 
contents of flask 3 (digestion medium) allowed to start. The first 50 ml of the digestion 
medium was allowed to run to waste and then the perfusate was recycled for 30 minutes.
Upon completion of the perfusion process the lobes were placed in 20 ml o f HEPES buffer at 
4 °C. The liver capsule was cut and the cells gently teased out using a spatula. The 
suspension was filtered through nylon bolting cloth which was then rinsed with 20 ml o f 
HEPES buffer (4 °C). The filtered suspension was centrifuged for 2 minutes at 4 °C at 
approximately 50 g. The supernatant was discarded and the pelleted cells re-suspended in 
40 ml o f HEPES buffer (4 °C). The centrifugation and re-suspension steps were conducted a 
further two times. The final re-suspension was with 25 ml of PBS A at 4 °C.
Yield was estimated by taking an aliquot (0.25 ml) and adding trypan blue solution (0.1 ml, 
0.4 % w/v) and mixing. After 5 minutes an aliquot was taken and pipetted into a Neubauer 
counting chamber where the dead and viable (unstained) cells were counted. The cell 
suspension was diluted to 5 x 10  ^cells ml"' using incubation buffer.
Method 2: This method required only two flasks, the outflows from which were connected to 
a single line via a tee piece. Flow from each flask was controlled by a screw clamp. The 
perfusate was drawn from the flasks by a peristaltic pump. The same heat exchanger was 
used as for method 1.
A male rat (weight 230 - 250 g) was anaesthetised by intraperitoneal injection of 
Hypnorm/Hypnovel (Janssen Pharmaceutical Ltd.) at a dose of 3.0 ml per kg body weight
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and then placed dorsal side down on the perfusion plate. The body cavity was opened to 
expose the liver and intestines. The intestines were then drawn to one side to expose the 
hepatic portal vein. The blood flow to the liver was stopped by tying off the hepatic portal 
vein and a cannula was inserted into the vein towards the liver above this point. The cannula 
was held in place by two further sutures. When the cannula was secured the flow from flask 1 
(pre-perfusion) was commenced at 10 ml min"'. The rat was then killed by slitting the 
diaphragm and the ileo-lumber vein cut to allow drainage of blood and perfusate. After 1 
minute the flow rate was increased to 20 ml min"'. After 5 minutes the flow was switched to 
flask 2 (digestion medium) and the rate again increased to 30 ml min"'. Perfusion continued 
until the liver showed evidence of extensive dissociation (discoloration of tissue normally 
after 6 to 8 minutes).
The flow rate was reduced to 10 ml min"' to maintain back pressure when the liver was ready 
to be excised. It was placed in a weighing boat containing digestion medium at room 
temperature. The liver capsule was cut and the cells gently teased out. The resulting cell 
suspension was filtered through a 250 mm mesh followed by a 75 mm mesh. Each mesh was 
washed with digestion medium and the washings added to the filtrate. The filtered suspension 
was centrifuged and the pellet re-suspended as described for method 1 except that suspension 
buffer was used throughout. The number and viability of the recovered cells was measured as 
before.
An aliquot (5 ml) of the hepatocyte cell suspension was added to a 20 ml disposable glass 
screw top vial and placed in a shaking water bath at 37 °C. The incubation was started by 
adding an appropriate mount of test article solution. Aliquots (0.5 ml) were taken at timed 
intervals and placed immediately into methanol (0.5 ml).
Rat liver microsomes (fraction 9 and 100,000 g).
All chemicals were obtained from Sigma unless stated otherwise. Phosphate buffered saline 
(PBS) was prepared from PBS tablets (Fisons) diluted to the required concentration. The 
storage solution for 100,000 g microsomes was O.IM Tris buffer containing 20 % (w/v) 
glycerol. Incubation co-factor solution contained, 60 mg nicotinamide, 38 mg 
glucose-6-phosphate, 5 mgNADP^ in 30 ml of phosphate buffer (0.5M, pH 7.4). To incubate
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100.000 g microsomes, 20 units o f gIucose-6-phosphate dehydrogenase was added to the 
co-factor solution.
Excised liver tissue was homogenised using a shearing blender (MSE, Fisons). All 
equipment, such as containers and centrifuge rotors were cooled to 4 °C prior to use. Rats 
were killed by cervical dislocation and the livers removed into ice-cold 0.0IM PBS pH 7.4. 
The livers were blotted dry and weighed. Each liver was roughly chopped and homogenised 
in 3 volumes of PBS. The homogenisation vessel was kept in ice to reduce local heat build 
up. The homogenates were centrifuged in the Beckman L8-60M ultracentrifuge using a 55.2 
cm Ti rotor at 10,500 rpm (9000 g) for 20 minutes at 4 °C. Half the supernatant, representing 
the S9 fraction was then transferred to screw topped vials and frozen overnight at -20 °C prior 
to storage at -80 °C until required.
The remaining supernatant was used to prepare 100,000 g microsomes. S9 fractions (8 ml) 
were diluted with 8 ml of ice cold 0.05M phosphate buffer pH 7.4 and centrifuged at
44.000 rpm (100,000 g) for 1 hour at 4 °C. The supernatant was discarded and the pellet 
re-suspended in 16 ml of ice-cold 0.05M phosphate buffer before centrifugation as above.
The supernatant was again discarded and the pellet re-suspended in 3 ml of ice-cold 
0.05M phosphate buffer. The re-suspended pellet, representing the endoplasmic reticulum 
fraction, was further diluted with 10 ml of ice-cold O.IM Tris buffer pH 7.4 containing 20 % 
w/v glycerol. The microsomes were frozen overnight at -20 °C before storage at -80 °C prior 
to use.
Incubations were carried out using 20 ml disposable glass screw top scintillation vials placed 
into a shaking water bath. The bath temperature was set at 37 °C and 100 cycles min ' . The 
vials were fortified with an appropriate amount of test article solution, 0.5 ml phosphate 
buffer (0.5M pH 7.4), 0.5 ml magnesium chloride (5.06 g 1"') and 1.5 ml cofactor solution. 
This was left for 5 minutes to reach 37 °C. The incubation was started by adding 0.5 ml of 
microsomes which had been equilibrated to 37 °C. Aliquots (0.5 ml) were taken at timed 
intervals and placed immediately into methanol (0.5 ml).
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Rat liver slices.
All chemicals were obtained from Sigma Chemical company unless stated otherwise. 
Modified University o f Wisconsin Solution (MUWS, used for cold storage of slices): 25 mM 
phosphate buffer was prepared by mixing 0.07M KH2 PO4  with 0.07M Na2 HP0 4  in the ratio 
197 : 803 (v/v). This solution was further diluted to 25 mM by adding water 370 : 630 (v/v). 
The pH was adjusted to 7.4 with orthophosphoric acid if required. To 1 litre of buffer was 
added the following; 35.83 g lactobionic acid, 4.01 g potassium hydroxide, 0.6 g magnesium 
sulphate, 17.84 g D(+) raffinose, 0.92 g glutathione, 1.34 g adenosine, 0.14 g allopurinol,
100 U insulin and 8  mg dexamethasone.
Supplemented Dulbecco’s Modified Eagles Medium (used for incubation of slices): 100 ml 
o f DMEM (Life Technologies) plus 1.2 ml L-glutamine solution (200 mM), 1.2 ml MEM 
non-essential amino acids (lOOx), 22.8 pi gentamicin solution (10 mg ml"'),
25.2 pi hydrocortisone solution (33.7 pg ml"') and 4.5 pi insulin solution. The insulin 
solution was made by dissolving 5 mg of fatty acid free bovine serum albumin, 3.27 mg 
bovine pancreatic insulin and 15 pi of 12M HCl in 25 ml o f water.
A Krumdieck tissue sheer (Alabama Research and Development Corporation, Alabama, 
USA) was used for the preparation of rat liver tissue slices.
A male rat (weight between 200 and 300 g) was killed by cervical dislocation. The liver was 
immediately excised and perfused with MUWS (4 °C) using a syringe via the hepatic portal 
vein to remove blood from the tissue. The lobes of the liver were removed into MUWS prior 
to coring.
Cores were cut from the liver lobes with an 8  mm coring tool using the Krumdieck motorised 
press. The depth stop was set to stop at the units base. The liver lobes were placed under the 
raised coring tool and held whilst the coring took place.
The Krumdieck tissue sheer was stored in the refrigerator overnight and set up according to 
the instructions and filled with MUWS. A liver core was placed into the tissue holder. The 
liver was cut into 200 mm to 250 mm slices by the rapidly reciprocating (40 cycles min"')
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disposable microtome blade. Slices where recovered from the holding chamber into fresh 
MUWS by releasing the spring clamp.
When all the available cores had been sliced those that looked cleanly cut (without frayed or 
incomplete edges) were sorted into fresh MUWS.
Prior to incubation the slices were rinsed twice with DMEM and transferred to fresh DMEM 
for incubation.
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PHARMACOKINETIC STUDY IN RATS (BOLUS 
INTRAVENOUS DOSING).
All blood sampling was carried out using modified 1 ml syringes. To remove the dead space 
that would be created when using the syringes with normal Leur lock fitted hypodermic 
needles the Leur portion of the syringe barrel was filled with a pre-cut, de-barred length of 
narrow bore stainless steel tubing held in place by a small length of silicone tubing. The 
silicone and stainless steel tubing were pushed into the end of the syringe barrel with a steel 
rod equal to the internal diameter of the syringe. The use of these syringes reduced the dead 
volume of the syringe from approximately 100 pi to probably less than 10 pi.
The rats were dosed via a canula inserted into the inferior vena cava and blood samples were 
removed from a canula inserted into the superior vena cava.
Prior to surgery the rats were quarantined for a period of 5 days. The anaesthetic used for 
surgery was Halothane with oxygen : nitrous oxide (1 : 1, 1 ml min"') supplied to the animal 
throughout. For induction of anaesthesia halothane at a concentration of 4 % was used, 
maintenance was achieved with a concentration of 2 - 2.5 %. During surgery each rat was 
placed on a heated (36 °C) pad. After surgery the rats were kept in an incubator for 
0.5 - 2 hours to remove the risk of post operative hypothermia.
Each rat was treated prophylactically with Streptopen (Glaxovet Limited, Uxbridge, UK) at a 
dose level of 0.4 ml kg ' intramuscular for 3 days, day I being the day on which the surgery 
was carried out. Only rats which reached their pre-surgery weight within 5 days following 
surgery and were judged to be healthy (visual appearance and behaviour) were used for the 
study. The cannulae of each rat were tested with saline prior to the start of the study.
Each rat was weighed on the day of the study and its weight recorded. The dosing syringe 
was filled with the appropriate volume of dosing solution and weighed. To administer the 
dose the ivc canula was flushed with a small (200 pi) amount of saline to ensure that it was 
free flowing, the dose was then injected into the canula which was then flushed with a further 
200 pi of saline. The dose syringe was re-weighed and the difference taken to be the dose 
administered.
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Blood samples (150 pi) were taken using a similar procedure. The modified syringes were 
pre-washed with potassium ethylenediamine-tetraacetic acid, EDTA (Fisons), (2 g ml ' in 
water). The superior vena cava canula was flushed with saline, the blood sample withdrawn 
and the canula flushed again to avoid blood clotting in the tubing. The blood sample was 
dispensed into a micro centrifuge vial (Eppendorf, Fisons) and centrifuged in a bench top 
micro centrifuge for 2 mins at 12,000 rpm. The plasma was removed to a new tube and frozen 
until analysis.
At the end of the study the animals were killed using CO2 .
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CHROMATOGRAPHIC DEVELOPMENT
COLUMN SCREENING
Introduction.
There are a number of strategies available to the analyst who wishes to use chromatography 
to resolve and quantify enantiomers, some of which have been discussed. It would be 
impractical to investigate all of the possible options every time a new separation is 
undertaken, and some decisions as to methodology must be made before experiments are 
begun. In order to meet the objectives of this project, the development of each chiral 
separation had to be rapid, and, if possible, one methodology would be applicable to a 
number of compounds.
Results.
Gas chromp graphic column screening.
The innate resolving power of capillary gas chromatographic (GC) analysis made this an 
attractive option which was tried first, despite recognised problems of universal application. 
Capillary GC columns have high resolving power due to the number o f theoretical plates 
possible with this technology. The high efficiency can be used to turn a small difference in 
the adsorption of two enantiomers into a fully resolved pair of peaks. However, the 
commercial GC chiral stationary phases were not expected to be applicable to this project’s 
objectives because many of the analytes would require derivatisation to improve volatility 
and suppress polar functional groups. Nevertheless compound IX was adjudged to be suitable 
for GC analysis underivatised, and this was tried on two GC CSPs.
A 20 metre Chiraldex B-PH (p-CD) capillary GC column (0.25 mm i.d., supplied by Astec, 
Whippany, NJ, USA) and a 25 metre Chiralsil-Val capillary GC column (0.25 mm i.d., 
supplied by Alltech, Lancs, UK) were investigated. Both columns had a maximum 
temperature limit of approximately 200 °C, which was lower than for achiral GC columns. 
During the initial set up it was found that in order to elute IX from the column, the 
temperature needed to be raised above the safe, non-bleed, column temperature. Both
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columns produced a single peak for IX with no indication of chiral selectivity. This 
confirmed that GC methodology did not appear to offer a universal approach, and no further 
GC analysis was therefore conducted.
HPLC has few of the analyte limitations o f GC, but with very much lower column efficiency. 
To achieve comparable resolution of two analytes with liquid chromatography, requires 
greater selectivity (a) between the analytes (see equation 13). A large number of commercial 
HPLC CSPs are available and representative columns of the various types of CSP were 
chosen for investigation,
HPLC column screening.
Each column was used initially with a mobile phase combination suggested by the 
manufacturer’s literature, and the first experiments conducted with each column aimed at 
achieving a target capacity factor, k ', of between 2 and 10. The resolution of the enantiomers 
would then if possible be optimised. The test compounds were available only as racemic 
mixtures so that enantiomer separation, for the purpose of column screening, was deemed to 
have occurred if two peaks of essentially similar area were recorded. The lesser retained 
enantiomer was labelled “peak 1” and the later eluting enantiomer “peak 2”,
Phenylglycine.
A 250 X 4.6 mm i.d. covalently bound phenylglycine column (Hichrom, Reading, UK) at 
40 °C was used for screening. Because non-aqueous mobile phases only are compatible with 
the CSP, each test analyte was extracted as the free base from an aqueous standard after the 
addition of O.IM sodium hydroxide, with dichloromethane. Table 4 shows a representative 
selection of the results obtained.
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Table 4
Mobile phase optimisation of the separation of XX and 
8-OH DPAT using phenylglycine CSP.
Analyte Mobile phase Result
XX dichloromethane : hexane' 
(30 ; 70, v/v)
XX  not detected
XX dichloromethane : ethanol : hexane' 
(30 : 5 : 65, v/v/v)
XX  not detected
XX dichloromethane : trifluroacetic acid 
: hexane'
(30 : 0.05 : 69.95, v/v/v)
single peak 
k' = 1.33
XX dichloromethane : ethanol : 
diethylamine : hexane^
(30 : 5 ; 0.05 : 64.95, v/v/v/v)
single peak 
k' =  5.03
8-OH DPAT dichloromethane : ethanol : 
diethylamine ; hexane^
(30 : 5 ; 0.05 : 64.95, v/v/v/v)
single peak k' = 3.88
8-OH DPAT dichloromethane : ethanol : 
diethylamine: glacial acetic acid : 
hexane^
(30 : 5 : 0.05 :0.05 ; 64.9, 
v/v/v/v/v)
single peak 
k = 2 .7 8
 ^M obile phase flow  rate 2.0 ml min’*.
Without the addition of either acid or base to the mobile phase, XX was not eluted from the 
column. The addition o f ethanol in the absence of acid or base also failed to elute the analyte. 
The replacement of the ethanol with 0.05 % trifluroacetic acid resulted in a single peak with 
limited retention. The addition of both ethanol and diethylamine to the initial mobile phase 
(the flow rate was also increased) produced a single peak but with greater retention. The 
chromatographic efficiency was good (N=7000 per 250mm) with a symmetrical peak, but no 
enantioselectivity was seen, figure 19.
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Figure 19
Chromatogram of XX on phenylglycine CSP 
mobile phase = dichloromethane : ethanol : diethylamine : hexane 
(30 : 5 : 0.05 : 64.95. v/v/v/v^
A second analyte, 8-OH DPAT, was injected, also resulting in a single peak. The retention of 
8-OH DPAT was less than that seen for XX but with similar column efficiency. The addition 
of glacial acetic acid to the mobile phase reduced retention and did not give rise to separation 
o f the 8-OH DPAT enantiomers.
Cyclobond I.
A 250 X 4.6 mm i.d. column was used to carry out the screen. The mobile phase used was 
methanol : water (containing 0.1 % triethylamine, adjusted to pH 5.5 with glacial acetic acid) 
(20 : 80 v/v). The column oven was set to 30 °C and the flow rate used was 1 ml min'^.
Table 5 shows the results obtained.
Table 5
Separation of XVII. X XV. VIII and IX 
using native P-cyclodextrin - mobile phase as above.
Compound Retention 
k' 1st peak
Retention 
k' 2nd peak
a
VIII 5.82 1
IX 3.11 18.25 5.87
X 3.12 1
XV 1.44 7.51 5.22
XVII Ï.71 1
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The apparent enantiomeric separations recorded with both XV and IX were anomalous, being 
much greater than generally recorded for cylcodextrin (CD) separations in the scientific 
literature. Compounds IX and X have very similar structures and a separation for X was 
expected. The triethylamine content of the mobile phase was increased to 0.25 v/v (pH 5.5), 
with results as in table 6.
Table 6
Separation of XVTT. X and IX 
using native P-cyclodextrin - mobile phase as above.
Compound Retention 
k' 1st peak
Retention 
k' 2nd peak
a
IX 3.48 6 1.72
X 2.97 5.98 2.01
XVII 2 1
X
fresh solution
3.00 5.71 1.90
A number of inconsistencies were seen with this mobile phase composition. Peak 1 of IX was 
retained slightly longer with the increase in amine concentration, whereas the retention of 
peak 2 was reduced three fold. A separation was achieved for X, although the second peak in 
the earlier chromatogram may have been missed by using too short a run time. A freshly 
prepared standard gave two peaks whose areas differed by more than was expected, figure 20.
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Figure 20
Chromatogram of freshly prepared X using native (3-cyclodextrin.
The native p-cyclodextrin column was replaced with an acetylated p-cyclodextrin column 
using methanol : water (containing 0.1 % triethylamine, adjusted to pH 5.5 with glacial acetic 
acid) (20 : 80, v/v), table 7.
Table 7
Separation of XVII. IX. 8-OH DP AT. VHI and XVI using an acetylated 
P-cvclodextrin column.
Compound Retention 
k' 1st peak
Retention 
k' 2nd peak
a
VIII 3.47 1
IX 4.52 17.16 3.80
XVI 2.17 1
XVII 1.81 1
8-OH DPAT 2.58 1
The capacity factors and separations obtained using the acetylated stationary phase were not 
significantly different to those obtained using the bonded native cyclodextrin. However the 
difference by which the 1st eluting peak exceeded the area of the 2 nd peak had increased 
from 15 % to 20 %. The amine content of the mobile phase was increased to 0.2 % (pH 5.5) 
and the standards re-injected. The results were as previously noted for the native cyclodextrin 
with the retention of the second peak halved but again the difference in peak area rose to 
greater than 35 %. The test compounds were not pure and some process impurities and
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degradation products were inevitable. The second peak could therefore have been an 
impurity. The apparently high level of impurities might be the result of these having a 
stronger UV chromophore than that of the parent compound.
To investigate this further, the Cyclobond I column was connected to the Finnigen TSQ 70 
LC-MS system and IX re-injected. A molecular ion corresponding to IX (m +1) was recorded 
for the earlier eluting peak, however, no recognisable ion could be found for the later peak. A 
further injection using DAD UV detection confirmed that although the second peak had 
similar UV characteristics to IX at the monitoring wavelength of 250 nm, absorption over the 
range 200 to 350 nm was not consistent with that obtained for IX. Peak 2 was shown 
therefore to be a system peak (artefact of chromatography) arising from the use of 
triethylamine in the mobile phase.
Cyclodextrin (polar organic m odel
An alternative application of the cyclodextrin based stationary phases is the polar organic j
mode. The P-cyclodextrin column was used with a mobile phase consisting of acetonitrile : |
glacial acetic acid : diethylamine (98.3 : 0.6 : 0.1, v/v/v). Injection o f both XXI and 
8-OH DPA^ ’■esulted in a single chromatographic peak with no evidence of 
enantioselectivity.
Chiralcel CD.
A 50 X 4.6 mm i.d. column was used to conduct the screening of the Chiralcel OD stationary 
phase (JT Baker, Reading, UK). The solvent system used in table 3.5 was found after some 
initial experimentation with the concentration of the propan-2-ol and the acid and base 
concentrations. The conditions used were, column temperature 40 °C, mobile phase 
propan-2-ol : hexane : triethylamine : trifluoroacetic acid, (17.5 : 80.5 : 1 ; 1, v/v/v/v), flow 
rate, 1 ml m in '\ Table 8 shows the results.
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Table 8
Separation of test compounds using Chiralcel OD CSP.
Compound k' 
Peak 1
k' 
Peak 2
a P V Peak
shape^
I 1.46 2.07 1.42 0.83 G
II 0.94 0.94 1.00 0 G
III 2.52 2.52 1.00 0 G
IV 0.61 0.77 1.25 0.32 G
V 0.41 0.77 1.90 0.67 A
VI 1.65 1.81 1.09 0.1 G
VII 1.27 1.73 1.37 0.83 G
IX 0.85 1.18 1.40 0.78 A
X 0.72 1.03 1.44 0.67 G
XI 6.27 12.18 1.94 0.98 P
XII 0.25 0.46 1.84 0.48 G
XIII 1.17 2.03 1.73 0.98 G
XIV 1.97 3.01 1.52 0.9 G
XVI 1.07 1.50 1.40 0.78 G
XVIII 2.07 2.28 1.10 0.09 G
XIX 1.29 1.60 1.24 0.38 A
XX 1.41 1.93 1.37 0 ^ 3 G
XXII 1.34 2.53 1.89 0.97 G
XXIII 4.66 4.66 1.00 0 A
XXIV 1.92 1.92 1.00 0 G
XXV 2.79 4.45 1.59 0.97 A
XXVI 0.22 0.22 1.00 0 G
XXVII 0.78 1.22 1.57 . 0.8 G
XXVIII 0.58 1.00 1.73 0.85 G
XXIX 0.76 1.34 1.76 0.91 G
expressed as a fraction of the mean peak height of the enantiomers, (see figure 21).
 ^Due to the difficulty of accurately measuring peak tailing where enantiomers were not fully 
resolved, the shape of the peaks was determined by subjective (visual) assessment. A peak 
that appeared to be essentially symmetrical was labelled G (good), a peak with limited tailing 
(<4) was labelled A (acceptable) and a peak where significant tailing (>4) had occurred was 
labelled P (poor).
97
Figure 21
Examples of the calculation o f the peak valley parameter
PV= 1.0
PV = 0 PV = 0.7
A
Approximately half the test compounds tried were resolved sufficiently to allow approximate 
quantification of the individual enantiomers, PV>0.5. With this degree of separation it would 
be possible to show that the enantiomers were metabolically cleared from an in-vitro 
incubation at stereoselective, or essentially, equal rates. The 50 mm column used was shorter 
than those columns used for screening other CSPs (for example, the phenylglycine and 
cyclodextrin columns) and the retention times were consequently shorter. Figure 22 shows 
PV in relation to the capacity factor for the first eluting enantiomer. The relationship for a  
was equally random.
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Figure 22
Stereoselectivity versus the capacity factor for the earlier 
eluting enantiomer using Chiralcel QD.tdata from Table 3.5^
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In theory, there is nothing to suggest that the longer an analyte is retained on the column, 
the greater the possibility of enantioselectivity. There is, however, a certain “comfort” in 
the misconception. Figure 22 clearly shows that chiral selectivity (measured by PV, a  
gave similar results) was not dependent upon the retention on the column. Good 
separations have been obtained at capacity factors of less than 1 whilst no separation was 
obtained for some compounds with capacity factors greater than 4. Vandenbosch 
noted that retention of P-blockers on the protein CSP, Chiral AGP, was related to C log P 
and that longer retained analytes demonstrated the greatest enantioselectivity, a .
The random scatter in figure 23 demonstrates that neither retention nor the column 
enantioselectivity (measured by a )  for a compound was related to the hydrophobicity of 
the compound as measured by C log P.
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Figure 23
k' of peak 1 Txl and a  O  for the test compounds 
versus C log P using Chiralcel OD fdata from Table 2.1 and 3.5^
œ - B
A Chiralcel OJ (250 x 4.6 mm i.d.) column was tried with a number of the above analogues 
using propan-2-ol as the mobile phase modifier without success. The OJ column lacks the 
nitrogen function (figure 24) and the ability to donate a hydrogen atom for hydrogen bonding. 
It was assumed therefore the hydrogen donor was a vital element for enantioselectivity seen 
with the OD phase for the 2-aminotetralin analogues.
Figure 24
Structure of OD and OJ Chiralcel CSP derivatives.
CH3 H
R_K|_V/ V -C H
CH.
OD OJ
The hydrogen bonding may be affected by the mobile phase solvent. Three solvents, with 
hydrogen bonding capability but differing lipophilicity, were tried as mobile phase modifiers. 
The mobile phases used were, 1) ethanol : diethylamine : trifiuroacetic acid : hexane 
(10 : 0.1 : 0.1 : 89.8, v/v/v/v), flow rate 2 ml min'% 2) propan-2-ol : diethylamine : 
trifiuroacetic acid : hexane (25 : 0.1: 0.1:74.8, v/v/v/v), flow rate 1 ml min ' and 
3) butan-l-ol ; diethylamine : trifiuroacetic acid : hexane (25 ; 0.1: 0.1:74.8, v/v/v/v), flow 
rate 1 ml m in '\ Each set of conditions was chosen to give practicable retention times o f less 
than 30 minutes. Table 9 shows the results obtained.
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Table 9
Separation (oO of test compounds versus organic solvent modifier of mobile 
phase using Chiralcel QD CSP t250 x 4.6 mm i.d.V
Solvent modifier
ethanol propan-2-ol butan-l-ol
Compound a
I 1.28 1.37 1.33
V I 1.14 1 1
IX 1.15 1.32 1
X I 1.36 1.47 1.7
X III 1.57 1.74 1.49
XIV 1.61 1.47 1.41
XV 1.30 1.27 1
XVI 1.42 1.41 1.40
x v in 1.24 1.29 1.16
XIX 1.11 1.18 1.29
XX 1.52 1.31 1.49
XXI 1.87 1.42 1.99
X X III 1
XXVII 1.38
XXX 1.61 1.66 2.29
8-OH DPAT 1 1 1
It was difficult to draw specific conclusions about analyte structure and enantioselectivity 
from the data in table 3.6, however, they show that the choice of modifier, even from similar 
solvents, provides a means of fine tuning a separation. For example, no separation of IX was 
found when using butan-l-ol limited separation was observed with ethanol, but near baseline 
separation was possible when propan-2-ol was added to the mobile phase. The separation of 
compound XVI, however, was essentially identical under all three conditions. Further 
modifiers could have been examined. Alcohols with shorter chain length, for example 
methanol, or longer chain length such as pentan-l-ol (solubility permitting) could have subtle 
effects. The effect of a modifier less able to disrupt hydrogen bonding, such as acetonitrile 
could also have been be tried.
The Chiralcel OD column did not represent a universal separation system for the substituted 
2-aminotetralins and further HPLC CSPs were examined.
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Chiral AGP.
Chiral AGP has been shown to be effective in the separation of the enantiomers of many 
dissimilar analytes. A 150 x 4.6 mm i.d. Chiral AGP column was used to investigate the 
separation of a diverse selection of 2-aminotetralins. The column was heated to 40 °C and the 
flow rate gradually increased to 0.9 ml min'*. The initial mobile phase used was O.OIM 
sodium phosphate buffer at pH 5.0, table 10.
Table 10
Separation of test compounds using Chiral AGP CSP 
mobile phase as text.
Compound k" Peak 1 k' Peak 2 a PV Peak
shape’
VII 14.86 17.99 1.21 0.83 A
VIII 5.27 7.83 1.49 1 G
IX 6.25 6.69 1.08 0.29 G
XIV 8.17 9.72 1.19 0.69 P
XV 4.67 5.37 1.15 0.54 A
XVI 28.36 32.13 1.13 1 G
XVII 6.32 7.54 1.19 0.73 G
XIX 34.54 36.19 1.05 0.97 P
subjective analysis of peak tailing (see table 3.5)
Some compounds tried with the phosphate buffer mobile phase were highly retained, not 
eluting from the column until it was flushed with propan-2-ol : water (25 : 75, v/v). Of those 
compounds which did elute from the column all were separated to some degree. The Chiral 
AGP CSP unlike the Chiralcel OD column, where one mobile phase combination would serve 
for a large number of compounds with practical retention times (k' < 10), would require the 
addition of an organic solvent in order to elute some analogues. In addition the optimisation 
of a Chiral AGP separation would involve the investigation of other parameters, such as pH. 
The addition of electrolytes to the mobile phase has also been shown to affect the resolution 
of enantiomers when using Chiral AGP. The ion pair reagent dimethyloctylamine was 
commonly used for reversed phase chromatography prior to the advent of base deactivated 
silicas to reduce peak tailing seen with small basic analytes. The effect of adding 
dimethyloctylamine to the mobile phase used in the preceding screen, O.IM phosphate buffer
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pH 5.0, is shown in table 11. The buffer pH was adjusted back to 5.0 with concentrated 
phosphoric acid after the addition o f the dimethyloctylamine.
Table 11
Effect upon retention and enantioselectivity of the addition o f a cationic 
modifier fdimethyloctylamine^ to the mobile phase.
dimethyl­
octylamine 
cone. nM
x v n XVI IX
k" a k' a k' a
0 7.10 1.22 28.36 1.13 10.80 1.05
2.5 4.57 1.15 20.76 1.47 6.05 1.07
5.0 3.54 1.08 12.85 1.35 - -
* For the ear ier eluting enantiomer (peak 1).
The addition o f dimethyloctylamine reduced the retention of all the compounds investigated. 
This was consistent with retention and separation dependent to a degree on an ionic 
interactions, so that the amine competes for the anionic binding sites. An alternative 
possibility is an ion-pair mode of retention. The retention at a non-ionised site could be 
reduced by the competition from the added cation for the anion in the mobile phase, the 
phosphate ion. The non-polar “tail” of dimethyloctylamine might also compete for 
hydrophobic sites on the protein.
The enantioselectivity seen for the amide, XVI, increased at the lowest concentration of 
dimethyloctylamine used. At the higher concentration the enantioselectivity fell slightly. The 
results might indicate a second binding site with an antagonistic effect to the main binding 
site. If so, disruption of this other site by dimethyloctylamine, may have resulted in an 
increase in the observed selectivity.
The resolution of the enantiomers of XVTI was reduced as the concentration of 
dimethyloctylamine was increased. The separation of IX under these conditions was very 
limited and the effect of amine was not significant.
A further screening experiment was conducted in which the sodium phosphate buffer was 
replaced by an ammonium acetate solution. Ammonium acetate is a volatile salt used
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routinely for mass spectrometric detection. Using this salt to provide limited control of pH 
would allow easy transfer of a Chiral AGP method to mass spectrometric detection. To 
increase the mobile phase elution strength, propan-2-ol was added, and the mobile phase pH 
raised (from pH 5.0 to 6.7) to increase the degree of ionisation of the CSP. Acetonitrile was 
also tried as an alternative solvent strength modifier. The results o f these experiments are 
shown in table 12.
Table 12
Comparison of the effect of propan-2-ol or acetonitrile as the mobile phase 
organic solvent upon retention and selectivity.
Compound
15% propan-2-ol 
85% ammonium acetate 
O.OIM, pH 6.7
15% acetonitrile 
85% ammonium acetate 
O.OIM, pH 6.7
k ' ’ a PV k' a PV
I 4.75 1.00 0.00 3.97 1.00 0.00
V I 5.15 1.00 0.00 4.36 1.00 0.00
IX 3.23 1.20 0.98 3.60 1.00 0.00
XI 8.07 1.08 0.60 7.33 1.21 1.00
XIII 0.00 1.00 0.00 0.00 1.00 0.00
XIV 0.00 1.00 0.00 3.01 1.00 0.00
XV 3.31 1.00 0.00 5.26 1.00 0.00
XVI 3.53 1.00 0.00 3.178 1.00 0.00
XVIII 3.49 1.24 0.98 2.58 1.00 0.00
XIX 5.96 1.00 0.00 4.97 1.00 0.00
XX 8.23 1.22 1.00 10.63 1.53 1.00
XXI 11.29 1.30 1.00 15.07 1.79 1.00
XXX 7.49 1.00 0.00 5.16 1.00 0.00
8-OH DPAT 4.56 1.00 0.00 3.867 1.10 0.67
The results obtained from the use of different modifiers with Chiral AGP were consistent 
with those found when using Chiralcel OD. No specific conclusions can be drawn about 
structure / modifier combination and neither solvent is significantly better than the other. 
Again, modifier choice can be used to fine tune a separation.
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The retention mechanism for Chiral AGP is believed to be, in part, due to a non-polar 
interaction. Figure 25 shows the relationship between retention and the C log P of the 
analytes.
Figure 25
Capacity factor for peak 1 for each of the analytes shown in table 3.9 versus 
their calculated lipophilicity (C log Pi when using propan-2-ol as the mobile
phase modifier.
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In contrast to Chiralcel OD there was a limited degree of correlation between lipophilicity 
and retention when using Chiral AGP. The line in figure 25 has been fitted to the data 
labelled ■, excluding those labelled X, correlation was found to be r  ^= 0.5982. Using the 
whole propan-2-ol data set from table 3.9 the correlation falls to r^= 0.2345. However, one of 
the unretained analytes, X III (C log P = 4.278), would be negatively charged under these 
conditions and hence unlikely to be retained by the negatively charged CSP. This analyte was 
removed from the data set. The other unretained analyte XIV was expected to have been 
retained under these conditions and was retained (k' = 3.01) by the acetonitrile based mobile 
phase. The value was also excluded from the data set. The retention o f XXI was longer than 
predicted from the rest of the data. No obvious explanation could be found for this difference, 
but the keto-pyrrol substituted compounds exhibited consistently high stereoselective 
separation, regardless of mobile phase conditions, compared to other 2-aminotetralins. This 
compatibility with the Chiral AGP CSP may be reflected in its retention characteristics.
The Chiral AGP column, like the Chiralcel OD CSP, did not appear to offer the “core” 
(universal) metliodology sought. However, the aqueous mobile phases possible with the
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protein based columns offered advantages over the normal phase solvents required for the 
Chiralcel OD column. With this in mind, another protein column, Ultron ES OVM was 
examined.
I Jltron ES OVM.
This CSP (Hichrom, 150 x 4.6 mm i.d.) has been used to separate the enantiomers of 8-OH 
DPAT Table 13 below shows the separation achieved for a number of
2-aminotetralin analogues using similar conditions to those published for 8-OH DPAT. 
HPLC conditions were; mobile phase composition, acetonitiile : potassium phosphate buffer 
(O.IM, pH 6.00) (6 : 94, v/v), flow rate 1 ml min’  ^and column temp 40 °C.
Table 13
Separation of the enantiomers of the test compounds 
using Ultron ES OVM CSP.
Compound k' o f  peak 1 a
I 5.28 1.00
XIII 1.83 1.00
XVI 3.04 1.00
XX 6.52 1.44
8-OH DPAT 3.55 1.69
No separations were obtained for I, X III and XVI under any of the mobile phase conditions 
subsequently tried. Acetonitrile resulted in better column efficiency than propan-2-ol but had 
little affect upon the separation (a) achieved. Compound XX, a keto-pyrrol substitution, was 
separated under all of the mobile phase conditions tried.
None of the CSPs tried appeared able to provide a single “core” methodology for the 
separation of the enantiomers of the 2-aminotetralin analogues. The Chiralcel OD and Chiral 
AGP CSPs were able to separate the enantiomers of at least half of the test compounds. It was 
wondered if the two columns, between them could, provide a suitable methodology which 
would be particularly useful if a structure / separation / CSP relationship could be found.
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Comparison of the chiral selectivity of Chiral AGP and Chiralcel OD.
The use of a  to describe the quality of an enantiomeric, or achiral, separation is not always 
helpful as the calculation does not take account of the peak shape. The use of the resolution 
R s, would be better, but for partially resolved peaks, and for peaks with significant tailing Rs 
is difficult to measure. In these circumstances PV is ideal.
Figure 26 shows the distribution of PVs obtained for the best separation achieved using either 
Chiralcel OD or Chiral AGP (without the addition of charged organic modifiers) for the 
enantiomers of each of the compounds.
Figure 26
Distribution of PVs for the enantiomers of the 2-aminotetralins 
using Chiralcel OD and Chiral AGP CSPs.
</)
■ DcZJoQ .E8
0.QE3
1 2 . 
10 
8 J
6 -
2 J 
0
0.00 - 0.02
□ Chiralcel OD 
H Chiral AGP
0.21-0.40 0.41-0.60
PV
0.61 -0.80 0.81-1.00
The phases show similar characteristics. Approximately one third of the total number of 
2-aminotetralin analogues are poorly separated by either column, one third are well 
separated, and the remaining third are somewhere in between. If a PV greater than 0.5 is 
sufficient for the analysis of the in-vitro screening experiments, then each column was able to 
adequately resolve approximately 50 - 60% of the compounds tried. However, some 
compounds were well resolved using Chiralcel OD and not with Chiral AGP. Table 14 lists 
the PVs obtained for the enantiomers of those compounds which were analysed using both 
columns.
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Table 14
Chiral selectivity (PVl comparison for Chiral AGP and Chiralcel OD CSPs.
Compound Chiralcel OD 
p v '
Chiral AGP 
PV
I 0.83 0.12
11 0.00 0.00
III 0.00 0.00
IV 0.32 0.00
VI 0.10 1.00
VII 0.83 0.83
X 0.67 0.29
XI 0.98 0.94
XII 0.47 0.74
XIII 0.98 1.00
XXIV 0.00 0.31
XIV 0.90 0.69
XXVI 0.00 0.92
XVIII 0.09 0.28
XIX 0.38 1.00
XX 0.83 1.00
a x i i 0.97 1.00
XXIII 0.00 0.00
XXV 0.97 1.00
XXVII 0.80 1.00
XXVIII 0.85 0.06
Using propan-2-ol mobile phase.
Eight compounds were separated sufficiently well (PV>0.5) using either Chiral AGP or 
Chiralcel OD. Six compounds had PV values of less than 0.5 using either column. Seven 
compounds were separated by PV>0.5 for one column but by PV<0.5 by the other.
Neither of these columns met the “universal” separation criteria of the project. Between them, 
however, the two columns were able to resolve the enantiomers of approximately 80 % of the 
test compounds tried. Common characteristics of those analytes which were separated well 
by both columns were not obvious, except that each had atoms other than hydrogen at the C8 
position, and the substitution had the ability to form a hydrogen bond with the stationary 
phase. Those compounds which had no C8 substitution were not separated by either column
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with the exception o f I, for which a separation was recorded under all conditions with 
Chiralcel OD. This separation was not tested using either diode array UV detection or mass 
spectrometry but was considered to be an artefact.
Discussion.
The objective of the column screening experiments was to discover if a single column was 
capable of separating the enantiomers of the majority of test compounds. Such a column was 
not found.
The Pirkle type phenylglycine column failed to resolve any of the analytes tried. The 
dinitrophenyl (7c-acid) group o f the stationary phase is an electron accepting (electron 
withdrawing) function. The C8 position substitutions of the test compounds are generally 
electron withdrawing groups added to improve the analytes metabolic stability. These two 
groups give rise to a possible repulsive force between an analyte and stationary phase. Whilst 
repulsive forces may conceptually represent one of a three point interaction, at least one of 
the remaining two interactions would need to be strongly attractive. There are limited 
opportunities for strong interactions between the analytes and the phenylglycine CSP. The 
mechanism responsible for the observed retention was most likely due, at least in part, to 
interaction with the silica support matrix, evidenced by the effect of the addition of either 
acid (protonation of the silica silanol groups) or base (competitive interaction).
A Pirkle type CSP with either Tc-basic or both %-basic and acidic functionality might have 
been a better choice. The Whelk-O 1 phase would possibly provide two attractive forces for 
the test compounds; n-n interaction with the tetralin ring and hydrogen bonding with 
appropriate C8 position substitutions. Steric interaction arising from the basic nitrogen 
substitution would be necessary to provide enantioselectivity.
Cylodextrins when bonded to silica, or used as mobile phase additives exhibit relatively 
specific structural requirements if inclusion complexes and enantioselectivity is to occur. The 
tetralin portion of the test compounds is small enough to enter the cavity of the (3-CD 
molecule. As the substitution at the C8 position grows in size it is less likely that inclusion 
would take place. The nature of the substitution is also important, as polar groups would be ' 
less likely to enter the hydrophobic core of the CD. If the tetralin portion o f the molécule can 
enter the CD cavity, enantioselectivity would arise from a hydrogen bonding interaction
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between the tertiary amine and the rim hydroxyl groups. From the retention data it is likely 
that nitrile substituted test compounds were able to enter the CD cavity and were retained on 
the column longer than those analytes with the more polar groups such as the amide. The C8 
position substitutions affect the position of the analyte in the CD cavity. Without the correct 
orientation the necessary hydrogen bonding interaction can not occur, as appears to be the 
case with the analytes tried here. The separations where enantiomers were initially thought to 
have been resolved were found to be chromatographic artefacts. These system peaks may 
have arisen from the disruption of the equilibrium of triethylamine in the mobile and 
stationary phases.
In the polar organic mode for CD CSPs interaction is thought to rely on the hydrogen 
bonding o f the analyte to the rim hydroxyls. Both XXI and 8-OH-DPAT have two groups 
capable of hydrogen bonding, one, the tertiary amine, is attached to the asymmetric centre. It 
must be assumed that the relative position of these two groups did not allow two 
simultaneous bonds, or that there was insufficient steric hindrance to give rise to a separation 
of the enantiomers.
Other strategies could have been used to further examine the CD based stationary phases. 
The larger cavity of the y-CD might have allowed both inclusion and the correct orientation 
of the analyte to facilitate hydrogen bonding. A different approach would be to introduce 
flexibility to the hydrogen bonding groups at the rim of the p-CD molecule. This flexibility is 
obtained by derivatising the hydroxyl groups with hydroxypropyl ether.
The mode of interaction between the analyte and the stationary phase of the derivatised 
cellulose column, Chiralcel OD, is similar to that of the Pirkle type phenylglycine column. 
The Chiralcel OD derivative has a it-basic substituent and this can be expected to form an 
attractive interaction with the majority of the substituted aminotetralin test compounds. 
Almost half the analytes tried were resolved by the Chiralcel OD column. The obseiwed 
enantioselectivity did not correlate with the retention of the analyte on the column. Since 
retention may arise from many interactions with the CSP and the average strength of these 
interactions is unlikely to be predictive of enantioselectivity, this is unsurprising. However, 
this observation clearly demonstrates that short columns (50 mm) can be used for column 
screening experiments with a significant saving in time and solvent use relative to the more 
common length of analytical columns (150 - 250 mm).
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Retention and selectivity were not related to the lipophilicity of the analytes as measured by 
C log P. The presence of an hydrogen acceptor at the C8 position of the analyte was essential 
for a stereoselective separation. The Chiralcel OJ CSP does not have the ability to donate a 
proton and no selectivity was seen for any of the analytes tried using this CSP.
The protein based Chiral AGP demonstrated broad enantioselectivity when used with the 
sodium phosphate mobile phase. The enantiomers of all eight analytes tried were resolved to 
some degree. However, peak shapes were poor compared to that commonly seen with achiral 
chromatography, and column efficiency was low, less than 3000 plates metre"’ for some 
analytes. The retention of some compounds was excessive under the “buffer only” conditions 
and it was unlikely that this type of mobile phase would be effective for the analysis of 
extracts of biological origin. The effect of addition of dimethyloctylamine to the mobile 
phase indicates ion exchange is responsible in part for the Chiral AGP’s retention 
characteristics and, to a lesser extent may be involved in the enantioselectivity.
With the addition of an organic solvent, propan-2-ol or acetonitrile, retention could be 
reduced to practicable levels, indicating a reversed phase interaction. Approximately 60 % of 
the variance of the measured retention could be accounted for by the calculated lipophilicity 
of the analyte (after the removal of assumed outliers). Additional contributions to retention 
would arise from other possible interactions such as the ion exchange noted or hydrogen 
bonding. In some cases enantioselectivity appears to have been compromised by the addition 
of the organic solvent.
The Ultron ES OVM was the first column tried which produced a separation for the 
enantiomers of 8-OH DPAT. The analyte with the carboxylic acid group (XIII) was retained, 
indicating a retention mechanism different to Chiral AGP, but, no enantioselectivity was 
seen. The two remaining analytes (I and XVI) produced chromatograms very similar to those 
recorded using Chiral AGP.
For each of the CSPs tried there were many further optimisation experiments that could have 
been carried out to improve the enantioselectivity or efficiency of the CSP, but this was not 
necessary, since the separation needed only to be sufficient to determine the approximate 
relative amounts of the enantiomers. When used to assay in-vitro incubates this would 
indicate whether the two enantiomers were metabolised at similar rates or not. The Chiralcel
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OD CSP was able to resolve a number of analytes with the same mobile phase conditions and 
with practicable retention times. This column was chosen to analyse the incubation samples 
from a simple screen o f metabolic stability using freshly isolated rat hepatocytes. {In-vitro 
Metabolism Screening).
During these initial metabolic stability experiments one group of compounds, the keto-pyrrol 
substituted analogues, displayed interesting stereoselective behaviour, however, the 
chromatography obtained using the Chiralcel OD was not ideal. Given the advantages of 
reversed phase chromatography, such as the compatibility with aqueous sample matrices and 
mass spectrometry, the Chiral AGP was considered the best CSP to develop further. The 
objectives were, to determine if, by optimisation of the Chiral AGP mobile phase conditions, 
the CSP could be used for a greater proportion of the test compounds and (primarily) to 
produce a rugged and reproducible stereoselective separation for the keto-pyrrol substituted 
2-aminotetralins.
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OPTIMISATION OF THE CHIRAL AGP SEPARATIONS FOR 
THE KETO-PYRROL SUBSTITUTED ANALOGUES.
Introduction.
For each experiment a number of other analogues were included for comparison. The 
variables that affect separations on Chiral AGP have been documented in the general 
introduction and some of these were examined during the column screening process. The 
effect of temperature and a broader examination of the role of pH are included in this section.
R e s u lt s .
Temperature of analytical column.
The effect of temperature upon the resolution of the enantiomers was investigated using the 
test substances and conditions given in table 15.
Table 15
Retention and resolution of XVTf. XX. XT and 8-OH DPAT 
with vai-ying column temperature.
Temp. 8-O H  D PA T ’ XX XV IT XT
°C k' a k' a k' a k' a
10 15.2 1.19
20 3.35 1 8.94 1.30 12.5 1.19 6.74 1.15
30 3.15 1 6.85 1.26 9.2 1.20 6.15 1.1
40 2.81 1 5.19 1.22 6.8 1.19 5.03 1.07
50 2.68 1 4.46 1.19 4.55 1.05
60
1-------m —
2.56 1 3.80 1.14 . 4.04 1.00 
L_-----------------
mobile phase O.OIM sodium phosphate buffer pH 5.0
The retention of all solutes decreased with increasing column temperature, which was 
consistent with a reversed phase interaction. The change in retention appeared to be greater 
for those compounds showing the greater enantioselectivity. The differences between 
enantiomers seen in response to increasing temperature may arise from additional retention 
mechanisms susceptible to temperature such as hydrogen bonding. The strength of the
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hydrogen bond would vary according to the hydrogen acceptor of the analyte and the distance 
from the hydrogen donator of the protein binding site, assuming the same binding site was 
used for all three analytes. The enantioselectivity seen for both XX and XI was reduced as the 
column temperature increased presumably via the disruption of the hydrogen bonds necessary 
to the stability of the diastereomeric complex.
The retention of the enantiomers of XVII, an amide C8 substitution, reduced by an equal 
amount in response to the rising temperature and hence a  did not change over the 
temperature range investigated. The mobile phase differences may have had an effect upon 
the enantioselectivity of the enantiomers. Complexes of XVII enantiomers and the stationary 
phase may have been more stable in the aqueous environment relative to the 15% organic 
content of the mobile phase used for both XX and XI. Low column temperature provides an 
additional means of improving the resolution of some analogues under some mobile phase 
conditions. The measurement of a  with varying column temperature and organic solvent 
strength would, with hindsight, have been an interesting experiment. Low column 
temperatures introduce practical difficulties. Mobile phase viscosity increases and the 
pressure limit for the CSP is reached at lower flow rate. Reducing the flow rate of the mobile 
phase would help at the expense of an increase in retention time. All subsequent 
chromatography was carried out at elevated column temperature to reduce the effects of 
ambient temperature during analysis, reduce mobile phase viscosity and shorten 
chromatographic run times.
Another mobile phase variable pertinent to Chiral AGP is pH, since the protein structure has 
many ionisable groups. Both retention and chiral selectivity of analytes using Chiral AGP has 
been shown to be dependent upon the control of pH.
Mobile phase pH.
The affect of altering mobile phase pH upon the retention and enantioselectivity o f XXVII is 
shown in figure 27. The mobile phase used was O.OIM sodium phosphate buffer, flow rate 
1 ml min"’ and column temperature 40 °C.
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Figure 27
Log k' and a  for XXVII with varying mobile phase pH
K' alpha
- 0.2 .
- 0.6
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- 1.4
-  1.2
mobile phase pH
The results show that the retention increases with increasing mobile phase pH; that is, as the 
charge on the stationary phase increases. I f  the stationary phase was able to tolerate a higher 
pH the retention would be expected to decrease as the ionisation o f the analyte begins to 
decrease. The enantioselectivity also increases with increasing charge indicating that 
ionisation plays a role in the selectivity mechanism.
The preceding optimisation experiments demonstrated those variables, mobile phase pH for 
example, which affect the resolution of the aminotetralin analogues when using Chiral AGP. 
What was not determined was the relative magnitude of those effects when compared to the 
other mobile phase variables, such as ionic strength, which may be expected to affect 
selectivity. An experimental procedure capable of efficiently investigating the relative 
importance of variables is the factorial design.
Mobile phase optimisation for Chiral AGP using a factorial experimental design.
The factorial experiment described below investigated two of the variables shown to be 
relevant to the separation of the test compounds on Chiral AGP, mobile phase pH (factor A) 
and the proportion of propan-2-ol in the mobile phase (factor B). The molarity of the mobile 
phase buffer (sodium phosphate) was selected as the third variable (factor C) to examine its 
impact on the separation. The levels were chosen to include those thought to be optimal, and 
determine the limit of the factorial space but do not represent the extremes possible for each
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factor. The levels chosen and the results obtained (k \  a , and PV) for this experiment are 
given in table 16.
Table 16
Results of 2- factorial design using XXVII as the test compound.
Experiment Factor Factor Factor Retention Separation
number A B C k' o f  1st eluting peak a P
1 7.0 12 0.05 2.27 1.54 0.94
2 7.0 12 0.005 9.09 1.61 1.00
3 7.0 8 0.05 7.05 2.09 1.00
4 7.0 8 0.005 14.58 1.95 1.00
5 5.4 12 0.05 1.25 1.44 0.86
6 5.4 12 0.005 3.07 1.43 0.90
7 5.4 8 0.05 1.72 1.67 1.00
8 5.4 8 0.005 2.08 1.51 0.96
Previous best 6.0 10 0.01 6.09 1.61 0.91
For experiment one and five the factors B and C have been kept constant and the value o f A 
has been altered. The difference in retention and separation between the two experiments was 
a result of the effect of A. There were three further experimental pairs where the value o f A 
was different but the values of B and C were constant. The mean of these differences was a 
measure of the average effect of factor A on the chromatography. Similar treatment was 
applied to the other variables and also combinations of factors.
The simple analysis presented here assumes that the relationship between the factors and the 
measured parameters is linear. With this approximation in mind the ranges chosen for the 
mobile phase pH and propan-2-ol concentration were kept relatively narrow. The high and 
low levels for the buffer concentration were sufficient to encompass those concentrations 
reported in the literature. It is important to remember that optimisation approaches such as 
factorial design, search only a limited factor space and therefore may find local optimum 
conditions not the global, or “best” combination of the factors examined.
The measured relative effects of the three factors considered in isolation, on the retention and 
separation functions is given in table 17 (see General Introduction for calculations).
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Table 17
Magnitude of effects of the three factors investigated upon the 
three measured chromatographic parameters.
Factor Magnitude o f  effect for 
k' a  PV
pH o f  mobile phase buffer 6.22 0.29 0.06
% propan-2-oI in mobile phase -2.44 -0.30 -0.07
molarity o f  mobile phase buffer -4.13 0.06 -0.02
The results for both separation parameters (a  and PV) showed a similar magnitude of effect 
for both factors. The value obtained for the effect of mobile phase pH upon retention (6.22) 
was positive, reflecting that with increasing pH, within the range examined, retention of the 
analytes increased. Similarly the negative value obtained for the effect of mobile phase buffer 
molarity (-4.13) results from the reduction in retention as the buffer molarity was increased. 
The data was consistent with chromatography where ionic interactions play an important role. 
In contrast, if an ion-pair interaction were dominant, then an increase in the mobile phase 
buffer concentration, and hence in the phosphate counter ion, would result in increased 
retention. In achiral ion-exchange chromatography an increase in salt concentration is used to 
reduce analyte retention. The reduction in retention times seen with increasing propan-2-oI 
concentration implies hydrophobic interactions, as seen for other compounds separated using 
the Chiral AGP CSP.
Manipulation of the buffer concentration could be used to further improve chromatographic 
performance. A gradient starting with ammonium acetate (pH 6.5, 0.01 M) : propan-2-ol 
(88 : 12, v/v) and finishing with ammonium acetate (pH 6.5, 0.1 M) : propan-2-ol (88 : 12, 
v/v) 20 minutes after injection was tried. Figure 28 shows the improvement in peak efficiency 
compared to isocratic elution using ammonium acetate (pH 6.5, 0.05 M) ; propan-2-ol 
(88 : 12, v/v). The overall run time could be controlled by selecting the starting buffer 
concentration and altering the slope of the gradient. This approach gave an increase in 
sensitivity, greater peak capacity for the column and more accurate integration with little 
disruption of baseline. Gradient elution methods require two HPLC pumps or a single pump 
with low pressure partitioning valves. The additional equipment means that gradient elution 
methods may be less robust.
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Figure 28
Effect of salt gradient elution upon peak shape and 
enantioselectivity of XXVII.
Discussion.
The retention mechanism of the keto-pyrrol 2-aminotetralin analogues on the Chiral AGP 
CSP is clearly the result of multiple interactions, which include ion exchange and reversed 
phase non-polar interactions. The buffer salt was not significant for these compounds, 
although, selectivity differences (as seen with achiral ion exchange chromatography) might 
have been expected.
The mechanism of enantioselectivity is not clear. The enantioselectivity results from the 
difference in stability of the diastereomeric complexes formed between each enantiomer and 
the CSP. Conditions which affect the stability of these complexes will affect the observed 
enantioselectivity. The ionic interaction, which increases with mobile phase pH, was not 
paramount for the enantioselectivity because its modification and disruption did not lead to a 
loss o f enantioselectivity. Hydrogen bonding between the CSP and the C8 position 
substitutions of the analogues may be the primary interaction which results in the 
stabilisation of the diastereomeric complex. Steric, hydrophobic or charge transfer 
interactions could provide the third interaction required for a three point interaction. 
Disruption of hydrophobic or charge transfer interactions between the tetralin portion o f the 
analytes and the stationary phase might also be involved in the reduction of enantioselectivity 
seen with increasing propan-2-ol concentration.
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Increasing the temperature of the mobile phase will affect the hydrogen bonding or non-polar 
interactions that stabilise the complexes thus reducing the difference between them. The 
addition of an organic solvent with hydrogen bonding potential, such as propan-2-ol, might 
have a similar effect. The pH of the mobile phase can affect the formation of hydrogen bonds. 
The concentration of hydrogen ions is lower at higher pH. An excess of hydrogen ions may 
inhibit the formation of the diastereomeric complexes.
The factorial design experiment produced data which tested assumptions made about the 
nature of the retention and stereoselective mechanism of Chiral AGP. It also provided key 
information to develop the application of the salt gradient. Factorial design, however, 
assumes the interaction between two variables is linear. To overcome the limitation of this 
assumption further levels are required. The additional data allows a smooth surface to be 
approximated for the variable space investigated. However, a 3  ^factorial design requires 27 
experiments. Modified factorial designs have been developed as a compromise, for example, 
the central composite design. This is a two level star design superimposed on a two level 
factorial design, which re q u ir e 15 experiments (with a single central point which can be 
repeated a number of times to provide a measure of the variance of the analytical system) to 
fit a smooth surface to the interaction between two levels.
The composite factorial design was used to investigate and optimise the separation o f XX and 
8-OH DP AT using an Ultron ES OVM column. The Ultron ES OVM column is also protein 
based, therefore retaining the advantages of a reversed phase separation. It had also been 
shown to separate the enantiomers of 8-OH DP AT. The data generated by this design would 
allow comparison of the Ultron ES OVM CSP with Chiral AGP and whether the additional 
experiments produced significant additional information about the separation.
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MOBILE PHASE OPTIMISATION FOR THE ULTRON OVM CSP 
USING A COMPOSITE FACTORIAL EXPERIMENTAL DESIGN.
Introduction.
The addition of the star design also allowed a larger space to be explored, as can be seen in 
tables 18 and 19.
Results. 
Table 18
Variable values for the 2~ factorial design.
Factors
Level % acetonitrile mobile phase pH molarity o f  
mobile phase buffer'
Low 6 4 0.01
High 14 6 0.1
potassium phosphate buffer
Table 19
Variable values for the star design.
Factors
Level % acetonitrile mobile phase pH molarity o f  
mobile phase buffer'
Low 2 3 0.005
Centre 10 5 0.05
High 18 7 0.25
potassium phosphate buffer
The experiments were conducted in a random order and a number of chromatographic 
performance figures calculated for each peak or peak pair. The analysis of the data collected 
for retention (k ') and selectivity (a) was carried out using the SAS (Statistical Analysis 
System) procedure “RSREG”. The program generates information on the best line fit and the 
relative effects and significance of the fit for each variable and combination of variables, 
table 20.
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Table 20
Magnitude of effects of the three factors investigated upon 
the retention and selectivity of XX and 8-OH DP AT.
* value is significant at the 5 % level.
** value is significant at 10 % level, 
remaining values were not statistically significant.
XX 8-OH DPAT
Factor k' a k' a
% acetonitrile -2.43^ -0.13 -1.48 -0.18
mobile phase pH 1.88' 0.22" 1.35' 0.32 '
buffer molarity -0.30 -0.01 -0.11 -0.08
The effect of the combination of the variables pH and acetonitrile concentration appeared the 
most significant interaction for retention and separation of both compounds, however, the 
values produced for the interactions can be hard to interpret if the interaction is not constant. 
The equation fitted to the data can be used to produce three dimensional plots (via a further 
SAS program procedure “GPLOT”) showing the interaction between any two factors,
figure 29.
Figure 29
Response surface plot for a  of the enantiomers of 
TOH DP AT versus the factors acetonitrile and pH.
1.2
im .o
12.0
B.CÏC H  3 Cl 7 .3
Figure 29 demonstrates why the interaction between factors may be difficult to understand 
from the tabulated effects data. The reduction in a , due to increasing acetonitrile
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concentration, was most significant at high mobile phase pH. The effect was less pronounced 
at lower pH values. The buffer concentration had no significant effect upon either retention or 
separation of either of the test compounds. The acetonitrile concentration was not significant 
with respect to the separation of the enantiomers of either compound and only significant in 
the retention of XX, possibly due to the more lipophilic nature of XX with respect to 
8-OH DPAT. The pH of the mobile phase was an important variable for the retention and 
separation for both compounds. Very little retention was seen at low pH values and 3D plots 
predicted that a reduction of the acetonitrile content would not result in significant retention 
or separation of either compound without increasing the mobile phase pH. The limited effect 
upon retention of increasing the mobile phase buffer salt concentration implies that retention 
does not include an ionic component as seen with Chiral AGP. The analytes would be 
charged (the basic amine, pkg «10) at all the mobile phase pHs used, therefore it was the 
effect upon the stationary phase which resulted in the increasing enantioselectivity of the 
CSP.
Discussion.
Effective chiral separations were achieved for the keto-pyrrol substituted 2-aminotetralin 
analogues and for 8-OH DPAT. The two factorial design experiments were conducted to see 
if better optimisation of the two assays was possible by this approach. This might then have 
had broader applicability to other analogues in this class. However, the drawback of factorial 
design strategies to support screening programs is that they are generally not rapid enough. 
The number of experiments required is very large if a significant factor space is to be 
explored for a number of compounds. The application of the factorial design approach to 
these assays was basic, though adequate, and a more thorough manipulation of the data 
produced is possible
An experimental strategy to provide insight into the mechanism of retention and 
enantioselectivity, reduces the number of experiments, required to develop an assay for a new 
analogue. As an initial step it is difficult to see that the composite design offered sufficient 
additional information, in this instance, to warrant the additional work required. Given the 
results already obtained it would be possible to concentrate on just two factors, mobile phase 
pH and % organic solvent, because the third factor, buffer concentration, was unimportant for 
enantioselectivity using either CSP. Replacing the buffer concentration with a new variable 
might be valuable. The use of a shorter chromatographic column would make a significant
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reduction in total run time, particularly if automation could be used to select the solvent 
concentrations. However, the greatest impact would be made if more than one analogue could 
be injected for each point of the design.
Two difficulties arise when two or more compounds are analysed concurrently, the separation 
of one analyte may be affected by the presence of another, and the identification of the peaks 
in the chromatogram. The structure o f some of the test compounds varied sufficiently for 
there to be significant differences in their UV absorption spectra so that peaks which do not 
co-elute could be assigned. Mass spectrometiy coupled to liquid chromatography (LC-MS) 
can provide selectivity, as compounds with different molecular mass can be selectively 
detected in the eluent of the HPLC. A question remains, however, “would the presence of 
multiple analytes affect the observed chromatographic behaviour”?
The Chiral AGP column was chosen for the following experiment because it was closer to the 
“universal” column objective than the Ultron ES OVM. There was also evidence that the 
Chiral AGP column was more robust for use with extracts of biological material than the 
Ultron ES OVM when the enantioselectivity of the latter was irreversibly affected after the 
analysis of extracts of in-vitro incubation media.
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SIMULTANEOUS FACTORIAL DESIGN OPTIMISATION.
Introduction.
The objective of this experiment was to demonstrate that with LC with MS detection it was 
possible to greatly increase the utility of the factorial design approach to improve the speed at 
which chiral assays could be developed. Ideally, a short column would have been used, but 
one was not available. The column used was Chiral AGP (150 x 4.6 mm i.d.). Flow rate was 
1 ml min’  ^ and the column was held at 45 °C.
Hydrogen bonding has been assumed to be an important factor in the enantioselectivity of the 
Chiral AGP CSP for the 2-aminotetralin analytes. Variation of solvents able to affect 
hydrogen bonding were used in place of buffer concentrations. The “high” value was chosen 
to be propan-2-ol and the “low” value acetonitrile, to give the eight experiments listed in 
table 21.
Table 21
Eight mobile phase combinations for the simultaneous 2~ factorial design
Experiment
number
Effect
measured
Factor A  
pH
Factor B 
H bonding
Factor C 
% organic
1 4 acetonitrile 3
2 A 7 acetonitrile 3
3 B 4 propan-2-ol 3
4 AB 7 propan-2-ol 3
5 C 4 acetonitrile 8
6 AC 7 acetonitrile 8
7 BC 4 propan-2-ol 8
8 ABC 7 propan-2-ol 8
The twelve analogues chosen for this experiment are given in table 22 with their respective 
pseudo molecular ion (m + 1, molecular weight (assuming a single charge) of free base plus 
one proton).
124
Table 22
Test compounds used for simultaneous factorial design 
and the m/z ratio expected for each.
Compound
number
m + 1
8-OH DPAT 248
VI 246
IX 269
XI 310
XIII 276
XV 275
XVI 313
XVIII 311
XIX 299
XX 325
XXIII 326
XXX 299
The mass spectrometer (PE SCIEX) was set to scan six discrete mass/charge ratio (m/z) 
ranges, 247.0, 267.0, 275.5, 299.0, 311.5 and 325.0, each ± 5.0 m/z units wide. Before 
conducting the factorial design, an experiment was carried out to assess analyte interaction 
during chromatography. Each analogue was injected separately (100 ng on column) and in 
combination with the other eleven analytes (equivalent to 8 ng each on column). The mixture 
was injected on three occasions and injections were carried out in random order. Two 
compounds had identical molecular ions. They did, however, possess dissimilar UV 
absorbance profiles and consequently were resolved using an in-line UV detector. The results 
for k' and a  for the enantiomers of each compound are given in table 23.
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Results.
Table 23
Retention and enantioselectivity for twelve test compounds 
using pH 7.0 (0.05M ammonium acetatel : 2-propan-1-ol (92 : 8. v /v \ 
injected individually and as a mixture.
Compound
number
Individual
runs
Mixture
k'
Mixture
a
k' a Run 1 Run 2 Run 3 Run 1 Run 2 Run 3
8-OH DPAT 2.4 1 2.1 2.1 2.1 1 1 1
VI 2.5 1 2.5 2.5 2.6 1 1 1
IX 2.3 1 2.1 2.1 2.1 1 1 1
XI 5.4 1.14 5.6 5.5 5.5 1.09 1.13 1.13
XIII 0.4 1 0.4 0.4 0.4 1 1 I
XV 1.2 1 1.2 1.2 1.2 1 1 1
XVI 1.6 1 1.6 1.6 1.6 1 1 1
XVIII 1.6 1 1.5 1.5 1.6 1 1 1
XIX 3.6 1 3.6 3.7 3.7 1 1 1
XX 10.7 1.4 10.7 10.8 10.9 1.35 1.36 1.35
X X IIi 3.8 1 3.9 3.9 3.9 1.04 1 1
XXX 3.7 1.03 3.6 3.7 3.7 1 1 1
There appeared to be no interaction between the analytes in the mixture sample. Two low a  
values (1.04, XXIII and 1.03, XXX) were recorded due to short term noise at the apex o f 
these peaks which were not seen in subsequent analyses.
Having determined that interaction between the analytes was unlikely, the remainder of the 
experiments to complete the experimental design were conducted. The calculations were 
carried out using the Yates method and the resulting factor effects are
summarised in figures 30 and 31.
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Figure 30
Magnitude of factor effects upon the capacity faclQi-cecorded 
for the earlier eluting enantiomer of each analogue.
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The capacity factor for all but one compound (XII, a carboxylic acid substitution) increased 
with increasing mobile phase pH. In all cases an increase in the organic content of the mobile 
phase reduced retention, with propan-2-ol was more effective than with acetonitrile. These 
results were consistent with those obtained earlier.
Figure 31
Magnitude of factor effects upon the enantioselectivity 
recorded for each analogue.
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It can be seen in figure 3.13 that four compounds were not resolved under any o f the 
conditions tried. For those analytes where separation was seen, increasing the pH of the 
mobile phase from 4.0 to 7.0 improved the separation of the enantiomers. Only one 
compound was resolved best by propan-2-ol. Table 24 summarises the main factor effects 
upon the separation of the enantiomers of each analyte and the number of mobile phase 
combinations with which a separation was obtained.
Table 24
Mobile phase factors required to achieve resolution of enantiomers and the 
number of mobile phase combinations under which separation was obtained.
Compound Comment Number o f  
separations
VI separated only at high pH 4
8-OH DPAT separated at high pH, not propan-2-oI 4
IX no separation under any conditions 0
XV no separation under any conditions 0
XIII no separation using propan-2-ol 3
XXX no separation under any conditions 0
XIX separation with high pH but not with propan-2-ol 3
XI separation requires both high pH or acetonitrile 6
XVIII separation at high pH and low concentration o f  acetonitrile 1
XVI no separation under any conditions 0
XX separation best at high pH, low % organic particularly acetonitrile 8
XXIII one separation at high pH and low concentration o f acetonitrile 1
Discussion of experimental design approaches to Chiral AGP optimisation.
The object of the optimisation strategy was to enable the rapid development of 
enantioselective analytical methods for use with the isolated rat hepatocyte metabolic 
stability model. The speed of LC-MS makes this approach possible. Similar experiments 
could have been conducted with diode array UV detection, but the application would be 
limited to compounds with sufficiently different UV absorbance spectra, and the number of 
analytes which could be tracked in a single analytical run would still be restricted. With LC- 
MS, however, the difference between molecular ions of even close analogues are much more 
likely to be sufficient.
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The use of multiple scans of limited m/z range (± 5 units) rather than scanning the whole 
range required by the molecular ions, resulted in a reduction in noise arising from the 
detection of unwanted masses. Due to the allowable increase in the dwell time (20 msec.) of 
the mass spectrometer detector an increase in sensitivity is also seen. This increase in 
sensitivity could be utilised by injecting a smaller amount of each of a larger number of 
analytes.
Some of the mobile phase combinations led to large capacity factors (k' > 35), and a shorter 
Chiral AGP column would have reduced the overall time required to complete the factorial 
design. Long run times would not be necessary to produce adequate enantioselectivity and, if 
using the mass spectrometer, selectivity from the biological matrix. However, if UV detection 
was to be used for the analysis of in-vitro preparations, some of the separations obtained 
would not have been acceptable without further development of the chromatography. These 
separations would not have had sufficient resolution from endogenous components or 
metabolites to allow accurate measurement of the parent enantiomers or had impractical long 
retention times. A number of options are possible to improve the initial separations, for 
example, the salt or buffer concentration of the mobile phase could have been increased. This 
has been shown previously to reduce retention but not enantioselectivity. As described 
earlier, the parameter that determines whether a separation would be adequate for in-vitro 
clearance determinations is the enantiomer resolution, described here as PV for simplicity. 
Alpha (a) has been used for the calculations above because it is not limited to a maximum 
value and the calculations alone would not indicate whether a separation was indeed 
adequate.
Data generated by these experiments can be used to improve the experimental design of 
experiments for future analogues in the series. In this example all of the separations obtained 
would have been possible using acetonitrile and a pH of 7.0. Exploration of the hydrogen 
bonding factor (factor B) could therefore be replaced by the exploration o f a new factor, for 
example, the addition of a charged modifier such as dimethyloctylamine I**®*'™®®®'*"’ *^ *^ 1 w ith 
sufficient data for a series of analogues, and different chiral stationary phases, it may be 
possible to include stationary phase as a factor, as long as both phases were compatible with 
the remaining two or more factors, for example, both reversed phase. The objective is to 
develop acceptable methods quickly, and under these circumstances factors without a linear 
relationship, as would be the case for different stationary phases, may be appropriate. Those
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compounds not separated in the evolving factorial design experiments can be examined 
separately with alternative chiral stationary phases, or other stereoselective methods. It is 
important that molecules that behave differently from the rest of the series are identified 
quickly.
The conditions used for the initial mixture experiments resulted in resolution of two 
compounds, XI and XX. However, an additional six separations (VI, 8-OH DPAT, XIII, 
XIX, X V in and XHI) had been achieved after the completion of the factorial design.. The 
number of analytes that can be monitored simultaneously is limited by practical 
considerations. The twelve analytes used here produced ninety six chromatograms from 
which the k' and a  values were calculated manually.
Two predominant obstacles to the easy and routine application of simultaneous factorial 
designs are the requirements for sophisticated (and hence expensive) detection techniques, 
and perhaps, the lack of software to calculate k' and a  automatically and reliably.
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CONFIRMATION OF THE SEPARATION OF ENANTIOMERS.
Introduction.
Many of the 2-aminotetralin analogues used for this study were produced in limited 
quantities, less than 100 mg, and very few as pure enantiomers. During the column screening 
experiments a separation was judged to have occurred if two peaks of equal peak area were 
recorded using UV detection, and a  and PV were subsequently calculated. This approach was 
acceptable for the column screen but a number of the analogues had more than two peaks and 
were therefore not pure materials. Additional evidence to confirm enantiomeric separation 
was required before further analytical development was embarked upon.
Results.
Diode array UV detection.
Enantiomers should have identical UV spectra. It has been shown earlier (cyclodextrin 
separations of IX) that it is possible to be misled when using a single wavelength to 
determine a stereoselective separation. The diode array UV detector overcomes these 
problems, figure 32.
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Figure 32
Contour plot for XXVIT from diode array UV detector.
Mass spectrometry.
The following figures show that further evidence of a chiral separation for XXVII was 
obtained from the mass spectrometer where the m/z ratio for both peaks was identical 
(figure 33).
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Figure 33
Total ion current and single ion chromatogram for XXVII 
using Chiral AGP and mass selective detection (Finnigen TSO 70^
% 1
'A 11
Circular dichroism.
UV absorption, diode array spectra and the very selective mass spectrometric detection do not 
confirm that two peaks are enantiomers. Circular dichroism was considered the method most 
appropriate to provide the proof of an enantiomeric separation with the additional possibility 
of providing evidence for the conformation of the enantiomers by reference to similar 
enantiomers of known conformation. 8-Hydroxy dipropyl 2-aminotetralin was available 
commercially, unfortunately only as the racemate, and therefore the pure enantiomers had to 
be prepared. Two published methods were available describing the separation of the 
8-OH DPAT and ascribing the absolute configuration to the individual enantiomers
1988. Ackland, 1991]
Preparation of individual enantiomers of 8-OH DPAT.
The separation system described by Ackland was used. The method utilises a chiral
counter ion, ZGP, in a non-aqueous mobile phase, chloroform : triethylamine : ZGP
(500 : 0.17 ; 1.53, v/v/w). The HPLC column used was a Licrosorb DIOL, 250 x 4.6 mm i.d.
8-OH DPAT was detected using UV absorbance at 278 nm. The chromatography was
conducted at ambient temperature. Some initial difficulties were experienced equilibrating
the normal phase column. The flow rate was 1.0 ml m iif' rather than the published
2.0 ml min'*. The capacity of the separation was investigated by injecting increasing amounts
of 8-OH DPAT onto the column until the chromatographic separation became unacceptable.
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The chromatogram in figure 34 shows the separation obtained after the injection of 100 pg of 
8-OH DPAT on to the column.
Figure 34
Chromatogram of 8-OH DPAT separation after 
the injection of 100 pg of racemate.
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The areas of the two peaks were approximately equal. At higher column loading the peak 
shape behaves in an unusual but reproducible way, figure 35. The later eluting, 
(S)enantiomer, appears to split into two peaks. The combined peak areas for the two peaks 
were approximately equal to that recorded for the first eluting enantiomer and if collected 
would on injection at a lower concentration produce only a single peak.
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Figure 35
Chromatogram of 8-OH DPAT separation showing the peak splitting 
of the later eluting (S^ enantiomer.
R 8 OH DPAT
S 0 OH DPAT
2 6 8 10 16
A number of injections of approximately 100 pg were made and the collected fractions 
combined and reduced to dryness under a gentle stream of air. After dissolving in methanol a 
small aliquot (5 pi) was diluted with mobile phase and injected. Figure 36 shows the resulting 
enantiomeric purity obtained from the isolation.
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Figure 36
Chromatogram overlay for the two isolated 8-OH DPAT 
enantiomer fractions.
R  Q OH DPAT
M i n u t e s
Only a trace of the first eluting enantiomer, (R), was present in the isolate for the second 
eluting enantiomer. The tailing peak obtained for the isolate of the second eluting enantiomer 
makes accurate measurement very difficult. An estimate of the peak area o f the underlying 
later eluting enantiomer was that it represented a maximum of 9 %.
These experiments have shown that the isolated 8-OH DPAT was sufficiently 
enantiomerically pure for the circular dichroism experiment, however, the amount of ion pair 
reagent, ZGP, also present in the sample was not known. Each isolate was dried and 
dissolved in 1 ml of 1% glacial acetic acid in water. This was washed with 2 x 5 ml of diethyl 
ether. The ether extracts were combined, dried and retained for later investigation. The ZGP 
has a free carboxylic acid function which is not ionised under acidic conditions allowing it to 
be extracted from the aqueous environment. The 8-OH DPAT, by contrast, is basic and would 
remain charged at acid pH thereby remaining in the aqueous phase. The isolate was then 
made basic by the addition of 0.25 ml of IM sodium hydroxide, thus allowing the 
8-OH DPAT to be extracted with a further 2 x 5 ml of diethyl ether. Both ether extracts were 
then injected on to an achiral reversed phase HPLC system set up to check the purity of the 
isolate prior to investigation by circular dichroism spectroscopy. A Zorbax RX 08 (250 x 4.6 
mm i.d.) column was used with a mobile phase consisting of acetonitrile ; trifluroacetic acid : 
water (20 : 0.1: 79.9 v/v/v ). The flow rate used was 1.5 ml min’  ^ and the column kept at 
45 °C. The raw normal phase isolate contained an excess of ZGP when measured at 214 nm
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UV, see figure 37. The wavelength was chosen after a UV spectra o f the isolate was taken. 
The UV maxima measured for the isolate was approximately 210 nm.
Figure 37
Chromatogram of 8-OH DPAT enantiomer fractions using an achiral 
stationary phase and low UV wavelength detection.
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The small peak with a retention time of 14 minutes corresponded to that found for a reference 
injection of the 8-OH DPAT racemate starting material.
The ether extract of the acidified isolate and that of the subsequent base extract resulted in the 
following chromatograms, figure 38.
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Figure 38
Overlay chromatogram of the acid and base extracts of 
the enantiomer fraction.
ZGP
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The extract clearly was not yet pure although a considerable amount of the ZGP had been 
removed by the acid / base extraction process. A chromatographic step was used for the final 
purification step prior to spectroscopy. The new isolate (the ether extract from the basic (pH) 
original isolate) was dissolved in the mobile phase and injected on to the column resulting in 
an overloading of the column’s capacity. The solvent volume corresponding to the peak was 
collected , sodium hydroxide added and re-extracted.
To improve the resolution of the ZGP and the 8-OH DPAT the acetonitrile was replaced with 
methanol (methanol : trifluroacetic acid : water) (30 : 0.1 ; 69.9, v/v/v ). Figure 39 shows the 
chromatogram of the re-extracted peak 1 from which the 8-OH DPAT peak was isolated.
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Figure 39
Chromatogram of original 8-OH DPAT extract 
using methanol mobile phase.
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The elution order of the two peaks had been reversed and the re-extraction has served to 
further reduce the amount of ZGP present, table 25. The methanol containing mobile phase 
resulted in better chromatography when the amount of 8-OH DPAT exceeded 100 jug. The 
solvent was collected, made basic and extracted with diethyl ether prior to spectroscopy. The 
above, rather lengthy, procedure ensured that the samples to be used as the reference spectra 
for the possible assignment o f configuration was as pure as reasonably possible.
Table 25
Effect of acid followed by base extraction on the level of ZGP contamination
in the isolate of peak 1.
Sample Peak area measured for 
ZGP®
Peak area measured for 
8-OH DPAT
% o f  ZGP to 
8-OH DPAT  
present in isolate
Isolate o f  peak 1 from Licrosorb 
/ ZGP isolation 27013061 1503640 94.7
Extraction o f  acidified isolate 2176989 11596 99.5
Extraction o f  basic (pH) isolate 28825 131693 18.0
The amounts injected were not equivalent
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Preparation of the enantiomers of XX. XXVTI and XXI.
Such was the capacity of the chiral counter ion method of chromatography that the isolation 
of sufficient 8-OH DPAT enantiomers (« 100 pg) to obtain an accurate CD spectra was a 
trivial manual task. If  the enantiomers of the keto-pyrrol substituted 2-aminotetralins could 
be similarly separated, then their preparation would be equally trivial. A sample of XXI was 
dissolved in methanol and diluted with the mobile phase used for the isolation of the 
enantiomers of 8-OH DPAT. The sample was injected on to the Licrosorb column but only a 
single peak was obtained, with no evidence of enantioselectivity. An alternative separation 
capable of semi-preparative application was required.
The low capacity of protein based chiral columns is often cited as a limitation to their use in 
preparative work. However, as there appeared to be no better resolution of this group of 
analogues, a series of injections were carried out to find the maximum capacity of the 
Chiral AGP analytical column (150 x 4.6 mm i.d.). The amount of drug that could be injected 
on to the Chiral AGP column whilst maintaining adequate chromatography for isolation of 
the enantiomers was found to be approximately 30 pg. This implies approximately ten 
chromatographic runs per compound in order to isolate the target of 100 pg of each 
enantiomer.
The collected fractions for each peak were combined. The separated enantiomers were 
contained in approximately 50 ml of mobile phase, and required concentration and removal 
of the buffer salts. Solid phase extraction using a non-polar C2 extraction matrix was tried 
initially but recovery was poor. The remaining samples were extracted using diethyl ether 
after made basic by the addition of IM Na OH. A sample of each final isolate was 
chromatographed using the Chiral AGP column in order to establish the enantiomeric purity, 
table 26. Figure 40 shows the result for XXI.
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Figure 40
Overlay o f chromatograms obtained for the enantiomer fractions of 
compound XXI obtained from Chiral AGP separation.
Peak 1 Peak 2
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Table 26
Amount and purity of 2-aminotetralin analogue enantiomers isolated using
Chiral AGP.
Sample
Amount recorded for 1st 
eluting enantiomer 
pg total
Amount recorded for 2nd 
eluting enantiomer 
pg total
Relative amounts for 
“other” peaks 
pg total
XXI peak i 130 0.6 2.1
X X I peak 2 1.2 133 2.7
XX peak 1 152 0.3 0
X X  peak 2 2.5 138 1.8
XXVII peak I 100.5 0 0
XXVII peak 2 0.3 113 0
Contamination of one enantiomer with its antipode, will reduce the measured optical rotation. 
The highest level of contamination of this type was less than two percent and considered 
insignificant. A small unknown peak was present in some samples, maximum two percent 
based upon area, measured at 315 nm. The absorbance at other wavelengths was not
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measured. Only one enantiomer of XX was contaminated with the unknown peak. If  there 
were found to be differences between circular dichroism spectra for the enantiomers of XX, 
other than sign, then further purification would be conducted.
Confirmation o f optical activity of isolates and assignment of absolute configuration using 
circular dichroism spectroscopy.
A number of spectra of each of the isolated enantiomers were made between 190 to 400 nm. 
The two 8-OH DPAT enantiomers had circular dichroism spectra showing strong optical 
activity (see figure 41).
Figure 41
Circular dichroism spectra of the enantiomers of 8-OH DPAT
0
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The circular dichroism spectra of each enantiomer sample was the opposite of its antipode. 
The amount of optical rotation was high and there was no ambiguity about the identification 
of the isolated peaks as enantiomers. Figure 42 shows a typical spectra.
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Figure 42
Circular dichroism spectra of the enantiomers o f XX.
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The CD spectra for the two test compounds (XX and XXI) were equally clear, proving that 
the separations achieved were stereoselective. To use the circular dichroism spectra of the 
8-OH DPAT enantiomers to assign the configuration of the two test compounds required the 
spectra to be compared in a region where the UV absorption would be similar. The absorption 
at the higher wavelengths, above 240 nm, were different because of the different 
substitutions on the C8 position. The spectrum for 8-OH DPAT had a significantly different 
spectra from the test compounds at low wavelengths (figure 43), where similarities might be 
expected. Because of these differences it was not possible to assign a conformation to the test 
compounds, but it was possible to conclude that the earlier eluting enantiomer of both test 
compounds were the same, either both(R) or both(S).
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Figure 43
Circular dichroism spectra of the enantiomers of 8-OH DP AT 
between 190 and 240 nm.
o
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Discussion.
Circular dichroism spectroscopy has shown that the separations achieved for the keto-pyrrol 
substituted analogues were chiral. The technique was not, however, able to provide any clues 
about their absolute conformation. A more thorough investigation of the chiroptical 
properties of other 2-aminoteti’alin analogues found no correlation between
rotation and structure.
Whilst X-ray crystallography is the method of choice for the assignment of absolute 
configuration, a number of factors made x-ray crystallography impractical for the assignment 
of configuration of the test compounds. Growing the crystals necessary for x-ray 
crystallography requires expertise, particularly if very small amounts of the enantiomer are 
available. The preparation of sufficient pure enantiomer (at least tens of milligrams) to give a 
reasonable probability of successful crystal growth would require a chiral separation capable 
of being scaled up to separate a milligram or more per injection. Chiral crystallisation of the 
racemate would be possible, however, insufficient material was available to provide a high 
probability of success.
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COMPUTATIONAL MODELS OF CHIRAL AGP 
ENANTIOSELECTIVITY.
Introduction.
There would be considerable benefit in a computational technique which could predict the 
extent of chiral recognition and enantiomeric separation by a CSP. Some o f the studies 
which have sought to do this have been discussed in the general introduction. The least 
complex approach is the construction of rules or guidelines for the analyte sub-structure most 
likely to lead to enantioselectivity when using a particular CSP. This has been done by a 
number of workers, each of which used a close set of structural analogues. For example, 
Maguire demonstrated the importance of the size of the 5-alkyl substituent of 
5-alkyl-5-phenylhydantoin analogues for enantioselectivity using p-cyclodextrin. Other 
studies, for example that of Norinder sought a mathematical relationship (in this
example using partial least squares regression, PLS) between physicochemical descriptors of 
N-aminoalklysuccinimides and enantioselectivity with Chiral AGP, Quantitative 
structure-activity relationships (QSAR) for enantioselectivity using computational chemistry 
techniques were a natural progression from these experiments, see, for example, Kaliszan 
11992] sjji^jjarly, computational chemistiy tools such as, molecular graphics, molecular 
mechanics and molecular orbital techniques have been used in the elucidation of the QSAR 
of many important drug-receptor binding studies The forces studied in these
QSARs, for example hydrogen bonding, dipole and n-n interactions are analogous to those 
that occur in analyte-CSP interactions.
O f the CSPs studied, two. Chiral AGP and Chiralcel CD, were found to be effective in the 
separation of the enantiomers of the 2-aminotetralins. In theory, any of the above techniques 
could be applied to these, but in order to do so, some problems must be considered. The 
conformation of neither Chiral AGP nor Chiralcel CD is known, the chemical composition of 
Chiralcel OD is similar to that of Chiralcel OC. The latter has been modelled to evaluate 
differences between the diastereomeric complexes possible between Chiralcel OC and the 
enantiomers of oxiracetam, a small molecule with limited steric interaction with the 
stationary phase The more retained enantiomer was able to form an additional
hydrogen bond with the CSP. To apply this approach to the 2-aminotetralin
analogues, two problems were foreseen. First, the effect of binding the derivatised cellulose
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to the silica support on the CSP conformation is unknown, so that the importance of steric 
factors would be difficult to estimate. Furthermore, the 3,5 dimethylphenyl carbamate sub­
units of the Chiralcel OD phase possesses a degree of flexibility due to bond rotation. Whilst 
the structure of the binding site or sites of Chiral AGP are also unknown, studies have shown 
that the protein conformation bound to the silica support, appears to be stable i990ai
For this project Chiral AGP was chosen for investigation because the nature of the retention 
and enantioselectivity of the 2-aminotetralins was indicated by the column screening and 
chromatographic optimisation experiments. A rule based model of the enantioselectivity of 
Chiral AGP for the 2-aminotetralins requires consideration of two structural features. First, 
for the substitution of the C2 position nitrogen. A secondai-y, rather than a primaiy or tertiary 
amine resulted in better chiral discrimination, though the overall effect appeared limited. This 
can be seen with the chromatography of the keto-pyrrol analogues and their metabolites 
(-NH2  , a  = 1.2; -NHR, a  = 1.5 and -NRR, a  = 1.1). This data implies that molecular volume 
of the basic nitrogen substituents are, to some degree, important. Secondly, the more 
important structural requirement was the presence of a group at the C8 position capable of 
forming an hydrogen bond. The model of the Chiral AGP chiral discrimination now consisted 
of two rules (the presence of a basic nitrogen and C8 substitution) which were sufficient to 
reject those analogues lacking suitable C8 substitutions. However, the presence of a 
substitution capable of hydrogen bonding was not sufficient to enable predication of an 
enantiomeric separation. Refinement o f the model was therefor required.
Molecular modelling methods.
Molecular modelling can investigate the electronic and structural properties of compounds 
via mathematical algorithms. The “building” of computational molecular models helps the 
three dimensional structure of the 2-aminotetralins to be visualised and the electronic nature 
(molecular obitals) of the molecule to be revealed. The computational chemistry program 
used in this project was MOSAIC
Starting structures.
The 2-aminotetralin structures used to initiate the modelling process were based upon a 
conformation of 8-OH DP AT, created from an x-ray crystallograph of 8-OH DP AT which 
was obtained from the Cambridge crystallographic database This ensured that the
process started with an accurate, low energy conformation, albeit in the crystal phase. Energy
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minimisation by MOSAIC of a free hand drawn 8-OH DP AT molecule resulted in a very 
similar conformation (and energy) to that obtained from the energy minimisation of the 
structure obtained from the crystallographic database. This implied that the algorithms within 
MOSAIC used for the energy minimisation were effective.
Each o f the 2-aminotetralin analogues were modelled by modification as shown in figure 44 
of the C8 and C2 nitrogen of the 8-OH DPAT crystallographic structure.
Figure 44
Modification to 8-OH DPAT structure to generate starting structures.
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Substitutions of the C2 nitrogen were similar for the majority of the analogues (propyl or 
cyclopropyl), and the chromatographic data generated with the Chiral AGP CSP did not 
indicate that these substitutions played a “make or break” role in the stereoselectivity 
observed. The aryl chains would, in any case, be very flexible and effects would most likely 
arise from their molecular volume. To minimise the computational time, only the atoms 
directly attached to the basic nitrogen were modelled.
Molecular mechanics.
Molecular mechanics (MM) treats the atoms and bonds of the molecule as a series of balls 
connected with springs. A force field (derived from experimental data) consisting of data 
relating to bond stretching and angles, torsional rotation, van der Waals radii and elccfronic 
interactions is used to calculate the three dimensional shape of the molecule. This results in a 
conformation which is lower in energy than the starting structure. Particular force fields are 
used for particular types of molecule, for example small molecules or large molecules, and no 
one force field can be parameterised for all types of molecules. In this case each structure was 
energy minimised using by a molecular mechanics (MM) algorithm, Alinger’s 
MM2
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Molecular Orbital methods.
Molecular orbital methods (MO) treat molecules very differently to the analysis used by MM. 
MO involves a partial solution to Schrodinger’s wave function for a particular molecule. The 
wave equations cannot plot precise electron orbits or atomic position but provides a 
probability, based upon energy, of finding an electron in a given place. The space in which 
the electron is likely to be found defines an orbital.
The MM minimised structures were examined using a geometry optimisation MO algorithm. 
This resulted in structures with a low conformational energy. It is important to remember that 
this represents only one energy minimised conformation for each molecule, and this is not 
necessarily the lowest energy (global minimum) possible. In addition, these calculations 
provided data on the electronic nature of the individual atoms in each molecule. This can 
include, for example, electrostatic data (electrophilic and nucleophilic reactivity - Fukui 
reactivity indices partial charge (net Mulliken charge electron orbital
information for the highest and lowest occupied orbital (HOMO and LOMO), and dipole 
moments. There are several published algorithms incorporated into software packages for 
MO calculations. The Restricted Hartree-Fock AMI was used here.
Mathematical model of Chiral AGP enantioselectivity.
There are many possible methods for the calculation of QSARs Linear regression
analysis is probably the simplest. Data from twenty one analogues was used to produce a 
mathematical model of the chiral discrimination of Chiral AGP. Each analyte had been 
separated under essentially similar conditions using the Chiral AGP column. The result of the 
MO calculations was, for each compound, a low energy conformation (with the co-ordinates 
o f the atoms relative to an arbitrary fixed point), and electronic data. Some of this calculated 
electronic data for the C8 substitution and the aromatic ring of the tetralin sub-structure was 
used by the mathematical model to try to describe the chromatography obtained when using 
Chiral AGP. The data, either direct or derived such as the sum of the partial charge for the 
C8 position substitution, was extracted from this data. The C log P for each molecule was 
added to the data set as an additional variable.
A statistical model, essentially an equation describing the interaction of the analytes and the 
Chiral AGP CSP, was built using a multivariate linear regression model (SAS, statistical
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analysis system'). The dependent variable was either a  or PV and each of the other variables 
was fitted in turn according to a least squares linear model. The variable (a) with the best fit 
was then selected. To this regression each of the remaining variables was fitted in turn, and 
again the variable (b) which improved the correlation coefficient most was added to the 
equation. This process continued until all the variables were used or the effect of an 
additional variable on the correlation was not significant (increase in r<0.15). The following 
equation was the result for the analysis of PV as the independent variable (equation 29 and 
figure 45);
’ SAS/Windows V6.08, SAS Institute Inc., SAS Circle, Box 8000, Cary, NC, USA.
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Equation 29
where a = 
b = 
c =
d = 
Figure 45
PV = 0.1654a - 1.7133b + 0.2974c + 0.945 Id -1.677 
n = 21, Y" = 0.6816
C l o g P
sum of the partial charge on the aromatic ring
sum of the lone pair donation characteristic of the C8 position substitution 
(electrophilic superdelocalizability)
lone pair acceptance character of the C8 hydrogen acceptor if present 
(nucleophilic superdelocalizability)
Predicted peak valley separation value versus actual value
0.6
0.41 0.21
- 0,2
-0.4
-0.4 -0.2 0 0.2 0.4 0.6 0.8 1,2
A ctual peak v a lley  separation
Equation 3.1, describes 68% of the variance of the data (r^=0.6816). The inclusion of the 
hydrophobicity as measured by C log P (a) was consistent with the proposed non-polar nature 
of the protein binding site. The partial charge of the aromatic portion of the molecule (b) may 
also be relevant to the fit of the molecule into the hydrophobic binding site. The lone pair 
donation characteristics (c) of the atoms attached to the C8 position was consistent with the 
presence of a hydrogen bonding group. The lone pair acceptance characteristics (d) was 
contrary to that expected. However, the variable (d) was positive if a hydrogen acceptor 
group was present and zero if not. With hindsight, this variable was inappropriate.
If  the peak valley parameter was replaced by a , the resulting equation accounted for less than 
50 % of the variance. The relative retention (a) of the two enantiomers describes only 
retention characteristics of the two peaks. The PV value, in a limited manner, reflects other
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aspects of the chromatographic performance such as peak shape. The measurement of the 
resolution (R J of the two peaks might have been the most appropriate measure but the peak 
shapes (peak tailing and overlap) obtained for some of the chromatograms made accurate 
measurement of Rg impossible.
The mathematical model (equation) provided only a limited correlation. An assumption of 
the mathematical model was that the key element that differentiated between the structures of 
the 2-aminotetralin analogues was the substitutions at the C8 position, and data pertaining to 
substitutions at this position was used to generate the equation. Although an element of 
distance from the amine was implied, insufficient positional information, distances and 
angles was included in the model to describe the three dimensional shape of the analytes.
The MO calculation provided atomic positions for one low energy conformation of the 
molecule. This conformation may not be the one that was taken up by the analyte when 
bound to the protein of the stationary phase. Nor did it allow for the changes in conformation 
of the analyte, and the “region or volume” of space that the hydrogen acceptor could occupy 
under chromatographic conditions. The development of methods (for example, molecular 
dynamics simulations or algorithms capable of defining three dimensional volumes) to 
quantify the positions that the hydrogen acceptor may take up was beyond the scope of this 
work. A simpler method of expressing the relationships of the hydrogen acceptors to the 
2-aminotetralin substructure was required.
Template model of Chiral AGP enantioselectivity.
Template modelling is a tool used in medicinal chemistry for drug design. The essential 
strategy is overlaying structures with similar properties (e.g. binding to a specific receptor) 
whereby differences and / or similarities between the molecules may become apparent. 
Similarly, an image of a binding site, for example the 5-HTia agonist recognition site 
[Hilbert,19871 built up ffom the volume occupied by the structures, and the
characteristics related to regions of the binding site. For this approach to be successful, the 
molecules must be superimposed using key structural elements, for example those known (or 
assumed) to be important for binding to occur. The lone pair of electrons of the basic nitrogen 
and the aromatic nucleus of each agonist was arranged to occupy the same co-ordinates.
From this regions of the receptor binding site were inferred from the common character of the
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superimposed structures. The template model was refined as new structures with 5-HT]a 
activity were included. The activity of proposed structures could then be tested against the 
template model.
The template model approach for the investigation of stereoselective chromatography has 
some difficulties, for instance, the assumption that a single binding site is responsible for the 
response measured. In fact, the chromatography may be the result of two or more binding 
sites acting synergistically or antagonistically. A further assumption is that the binding site is 
static at least whilst the analyte is bound, and that analytes bind in the same manner. A 
similar assumption relating to the analytes, is that these are assumed to bind to the protein in 
a conformation very similar to the low energy conformations modelled. However, unlike the 
mathematical model where the data was generated for a single low energy conformation, the 
template model can very easily include structures of higher energy.
To create the 2-aminotetraIin / Chiral AGP template, two assumptions were made, that the 
basic nitrogen was the anchor to the stereoselective site, and, that the aromatic structure of 
the analytes occupied the same portion of the hydrophobic binding site. The positions of the 
hydrogen acceptors, under these assumptions, became the essential difference between the 
overlaid structures. For each analogue, the MM energy minimised structure generated prior to 
further optimisation by MO calculation, resulted in a single low energy conformation of each 
molecule. Again it should be stressed that these conformations represent only a local energy 
minimum which may not be the lowest possible. Molecules may be able to flex and twist 
depending upon the energy available to them. In order to generate structural conformations 
with possible lower energy states, a further series of calculations were conducted. Each MM 
energy minimised compound was displayed, and a number of the bonds in the molecule 
capable of rotation were rotated through 360 degrees in steps of 30 degree generating 
approximately 200 to 400 different conformations, see figure 46.
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Figure 46
Example of bond rotations.
OCH3 I
N
Each of the new structural conformations was energy minimised and the unique 
conformations stored. All conformations no more than 0.5 kcals moF* above the lowest 
energy state were manually superimposed, the alignment being maintained by superimposing 
the aromatic rings. Each set of structural conformations was then coloured according to the 
separation (a) achieved using a single Chiral AGP column (mobile phase: propan-2- 
okammonium acetate (O.IM, pH 6.85) 1:99 to 10:90 v/v, flow rate 1 ml min"', 40°C), 
table 27.
Table 27
Colour code used for overlaid structures.
Colour used for overlay Chromatographic 
separation, a
Compounds
purple 1.0 II, III, IV, IX, X, x x n i, XXV
green <1.1 >1.0 V, v n , XVIII, xxrv , x x v n i
blue < 1.2^ 1.1 XI, XIV, XXVI
red >1.2 VI, VIII, x n , x n i, x v i, 
XXII, XXVII
The low energy sets for each compound were overlaid with others of the same colour, from 
other analogues, producing four compilations of structures, see plates 1 to 4. The atom 
symbols have been removed for clarity. The final step was the superimposition of all four sets 
of compounds. The picture was simplified by leaving visible only those groups capable of 
acting as a hydrogen acceptor The 2-aminotetralin sub-structure was included
for scale and position see plates 5 and 6 (looking down upon the vertical plane o f the 
2-aminotetralin substructure).
Those compounds with a  values greater than 1.2 (resulting in complete resolution) using the 
Chiral AGP column, coloured red, have the hydrogen acceptor located in a circle centred 
about the C8 position of the tetralin when viewed along the plane of the aromatic group (plate
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6). All of these compounds have a single CC bond between the 8 position substitution and the 
aromatic ring. This bond allows rotation in the horizontal plane of the H acceptors.
For the two compounds which were not resolved, coloured purple, one hydrogen acceptor is 
placed far from the red group. The position of the hydrogen acceptor of the other compound 
is less distinct from that of the red set, but the additional ring structure of this compound does 
not allow any flexibility and tlie group lies close to the plane of the tetralin. The hydrogen 
acceptors of the blue group (a  <1.2 > 1.1 ) are found in a number of different regions. Few 
were found in the area defined by the red set of structures. For the final group of compounds, 
those which demonstrated only very small a  values, coloured green, the hydrogen acceptor 
can be seen in a discrete group closer to the C8 position, and directly above the tetralin.
The similarities of, and differences between, the structures can be more clearly seen using a 
CPK representation of the molecules. Plate 7 is the CPK'^’^  (Corey-Pauling-Koltun) 
representation of plate 6. Plate 8 shows the same set with those atoms further than 
approximately one carbon fron - the C8 position of the 2-aminotetralin taken out. The relative 
positions of the purple, blue and red groups can be clearly seen. Plate 9 is the CPK 
representation of plate 5. Plate 10 has had the small cluster of blue hydrogen acceptors in the 
centre removed. This view is not as useful as the previous plates. However, the green set can 
now be seen. Plates 11 and 12 are the view from the aromatic end of the tetralin substructure. 
Again, plate 12 has had the blue and purple acceptors removed to show the distinct area 
occupied by the red coloured hydrogen acceptors. Plates 13 and 14 show a different 
representation of plates 7 and 8, where the surface of the hydrogen acceptors have been 
defined using coloured dots. This has the advantage of allowing the atoms to be displayed, 
clearly showing the location of the green sub-set.
Discussion
The mathematical model gives a correlation with separation not that much different to that 
obtained using C log P alone (see chromatography development). The structural variation of 
the 2-aminotetralin analytes was greater than those used to generate mathematical models for 
the N-aminoalkylsuccinamides and 1 -alkyl-2%6' -pipecolxylidides IHermansson, i987i ggj.jgg 
compounds described in the general introduction. The limited variables used to define the 
positions of the hydrogen acceptor has compromised the usefulness of equation.
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The template model was more successful in highlighting differences in the aminotetralin
structures, allowing some explication of what structural factors were common to those
compounds which are well separated when using Chiral AGP. This approach did have a
number of additional difficulties. All the calculations used to generate the conformations
were conducted in the gas phase and in the absence of other molecules. The actual
conformation of the molecules when bound to the receptor may be quite different from those
generated by the computer. A further assumption implied by the experimental design was that
the aromatic portion of each analogue would occupy the same position in the binding site. It
is unlikely that this is the case, and that some flexibility in the position of the tetralin
substructure is possible. It is important to remember that the observed chromatographic
resolutions were the result of a number of interactions between the analyte and the CSP. !
Different conformations of the analyte (other than the minimum energy conformation) might I
result in binding with different strengths of chiral discrimination. |
I
I
Despite the difficulties, limitations and assumptions above, the resulting images appear to I
offer useful insights. The substitutions included in the model were quite varied, and the 1
essential stmctural difference, the position of an attached hydrogen acceptor can be extracted |
from the data. The chromatography optimisation data suggests that the 2 position basic '
nitrogen is, in part, responsible for the binding of the molecule to the CSP. The hydrogen I
acceptor, takes part in a further interaction in a position away from the plane of the aromatic i
ring and at a specific distance in the vertical plane. The aromatic portion of the molecule may 
take part in an hydrophobic attractive (7t-7c) interaction with the binding site. Alternatively, ;
the tetralin core structure might also result in a steric interaction by restricting access to the 
CSP hydrogen donor group for those analytes without the necessaiy “reach”. The three point 
interaction necessary to produce an enantioselective separation arises from interactions of the 
basic nitrogen, hydrogen bonding and, probably, a n-n interaction with the aromatic 
substructure. This conclusion is consistent with the generally accepted views of Chiral AGP 
stereoselectivity.
An alternative template could of course, have been constructed using different assumptions.
By overlaying the basic nitrogen and the hydrogen acceptor group another multi structure 
data set could have been created. For this, the difference between the groups of analytes 
would relate to the volume of space occupied by the tetralin fragment of the molecule. The 
interpretation of this data would have been more difficult than for the template used. In
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addition, the direction of the hydrogen bond, the possible length of the bond and the degree of 
flexibility of the C8 substitutions would need to have been accounted for.
The importance of the basic nitrogen and the hydrogen bonding interactions is quite clear, but 
ultimately, the relative importance of these, and that of the aromatic n-n interaction, for the 
enantioselectivity of the 2-aminotetralins, is not known. This alternative modelling approach 
could be successful if the structures used to initiate the template were not as flexible as the 
tetralins, which would allow the two positions of the ionic and hydrogen bonding sites to be 
determined. Otlier aspects of the binding site might then be inferred from the addition of 
subsequent structures upon these fixed positions. Literature data (structure, Chiral AGP 
separation and chromatographic conditions) could be used to generate such a model.
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SAMPLE PREPARATION FOR BIOLOGICAL MATRICES.
Introduction.
Chiral columns are generally not robust enough to analyse biological samples that have not 
undergone some form of clean up. Solvent extraction using diethyl ether has been shown to 
be effective for the extraction of both 8-OH DPAT and the keto-pyrrol substituted analogues 
from aqueous media. This method was used to prepare samples obtained from protein 
precipitated aliquots of hepatocyte incubation media (first examination of the metabolic 
stability of some of the test compounds, see In-vitro Metabolism screening) for analysis using 
Chiralcel OD.
The chromatography obtained with these extracts was poor, with co-eluting endogenous 
materials. Consequently the column was replaced by Chiral AGP, which being reversed 
phase, was likely to be more tolerant of aqueous derived samples. The extraction technique 
was also changed to solid phase extraction, which is common in all areas of chromatographic 
analysis, particularly for extraction of biological matrices.
Results.
Solid phase extraction tSPEV cartridge screen.
Rat plasma was judged to be the most complex biological matrix to be investigated, and was 
used to develop a suitable extraction method. This method would then be expected to be 
effective for the incubation media derived in-vitro samples. During the initial hepatocyte 
incubation experiments, the analogues with the keto-pyrrol substitution appeared to show 
interesting differences in the metabolic stability of their enantiomers. For this reason, the 
extraction was developed for this sub-group of the test compounds. When an effective 
extraction method had been developed it would be tested using other 2-aminotetralin 
analogues.
Bond Elut cartridges were used for screening. The phase (100 mg) was packed into 1 ml 
barrels and retained by polypropylene frits. The solvents and sample were drawn through the 
cartridges by the application of a mild vacuum. Each SPE phase required solvation (priming)
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before it could be effectively used with aqueous samples. The extraction scheme in table 28 
was used for the initial cartridge screen.
Table 28
Extraction scheme used for solid phase extraction cartridge screen.
Extraction step Solvent
Prime 2 X 1 ml acetonitrile
Prime 2 X I ml water
Sample loading 1 ml water containing analytes o f  interest
Wash 2 X 1 ml water
Elution 1 X 1 ml o f  acetonitrile ; trifluroacetic acid : water (60 : 0,1:39.9 v/v/v)
The elution solvent was chosen to address two of the possible retention mechanisms of the 
cartridges screened. An acetonitrile concentration was used which was sufficient to overcome 
non-polar interactions present. The addition of acid was used to suppress the ionisation of the 
residual silanol groups present and therefore break any ionic interactions with the basic 
analytes. The extraction screen above was used with the cartridges in table 29. The extraction 
recovery was determined by reference to a direct injection of equal concentration to the 
extracted sample. The sample was an aqueous standard of XXVII and XXI and the extract 
was analysed using Chiral AGP.
Table 29
Recovery of the enantiomers of XX and XXI 
from a selection of SPE cartridges.
Cartridge XXVII
% recovery
XXI
% recovery
Peak 1 Peak 2 Peak 1 Peak 2
C8 104 99 98 99
Phenyl 103 98 100 100
Cyclohexyl 101 97 99 99
C2 103 98 101 101
nitrile 99 96 99 99
Diol 109 104 110 111
CBA ‘ 100 96 101 101
carboxylic acid phase.
158
The spiked aqueous sample was collected after it had passed through each of the cartridges 
(breakthrough sample). In the event of a low recovery from the final elution, the analysis of 
these breakthrough samples would show which step, retention or elution, was not effective. 
The same cartridges were used in a second screening experiment where an additional wash 
step (2 X 1 ml methanol : water, 50 ; 50 v/v) was added prior to elution. The recovery from all 
cartridges was again essentially complete. That 50% methanol does not elute the test 
compounds suggests that secondary interactions, that is interaction with the unbonded silanol 
groups of the solid phase matrix, were occurring.
A further extraction screen was conducted using 50p,l of plasma, containing either XXVII or 
XXI, diluted to 1 ml with water. Complete recovery was recorded for each cartridge type and 
the chromatograms were free from interference. The UV absorption characteristics of the 
keto-pyrrol analogues allowed a detection wavelength of 315 nm to be used. This was high 
enough to provide additional selectivity from co-extracted (and co-eluting) biological 
material.
Each of the cartridges screened was effective in the extraction of the analytes. It was unlikely 
that much advantage would have been gained from continuing to use all the phases used in 
the initial steps, so one cartridge, the C2 phase, was chosen for further investigation. The 
limited non-polar interaction of the C2 phase would reduce the retention of unionised 
components in the sample matrix. Those non-polar components which were retained would 
then be washed from the cartridge by the rinse steps prior to elution. Other cartridges which 
might also have had similar properties to the C2 were the polar phases, CN, DIOL and CBA.
The cartridge screening experiments had shown that whilst the recovery of the analytes was 
complete using the trifluroacetic acid containing eluting solution, the chromatography on 
Chiral AGP was compromised if trifluroacetic acid remained in the injection matrix. 
Trifluroacetic acid is a strong acid and an effect on the pH dependent chromatography was 
not unexpected, trifluroacetic acid is a volatile acid and was removed from the extract as the 
elution solution was reduced to dryness using vacuum evaporation (GyroVap, nominal 
temperature 40 °C). Evaporation under air or nitrogen was insufficient to completely remove 
the trifluroacetic acid.
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A further experiment was conducted, comparing the recovery ffom rat plasma and protein 
precipitated rat isolated hepatocyte suspensions, with direct injection and spiked elution 
solution, table 30.
Table 30
Affect of sample matrix upon the recovery of XXVTI H pg ml—f 
using C2 phase SPE cartridge.
Sample Parameter
% Recovery 
1st eluting 
enantiomer
% Recovery 
2nd eluting 
enantiomer
Spiked mean 99.9 100.0
tube C V n=5 1.2 1.1
Eluting mean 98.6 99.3
solution CV n=5 1.0 1.8
Rat mean 92.8 92.1
hepatocytes C V n=5 2.3 2.1
Rat mean 92.6 94.2
plasma C V n=5 1.8 2.5
The spiked tube samples were used to test the effectiveness of reconstituting SPE extracts . 
This was completely effective, as shown ffom a comparison of chromatograms from these 
and the direct injection of standards. Spiked eluting solutions tested the recovery o f analytes 
after they had been dried onto the surface of the collection tubes. The reconstituting of dried 
extracts can be a source of sample loss, as can volatility during the vacuum step. The 
recovery from protein precipitated rat hepatocyte suspensions (250 jiil of cell suspension + 
250pl of methanol + 750 pi of water) and rat plasma was excellent at approximately 92%.
The extraction data has been presented for just one sub-set of the test compounds 
(8 keto-pyrrol substitution), however, most 2-aminotetralins would behave similarly because 
the primary retention mechanism appeared to be via the residual silonal groups. The 
compound with the acidic C8 substitution, XIII, might not be effectively retained by this 
mechanism, if the ionic repulsion exceeds the nitrogen - silanol interaction. Table 31 shows 
the extraction recoveiy for a range of analogues.
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Table 31
Recovery of test compounds from C2 SPE cartridge using initial extraction
screen conditions.
Compound % recovery from cartridge
8-OH DPAT 101
I 110
VI 113
IX 103
XI 115
XIII 95
XIV 99
XV 87
XVI 90
XVIII 99
XIX 103
XXIII 96
XXX 104
The C2 SPE -extraction scheme was effective for all the test compounds tried including the 
acid substitution, XIII.
Quantification of analyte in biological materials - Calibration using rat hepatocytes fortified 
with XXVII.
A calibration curve in heat deactivated rat hepatocytes was constructed. The concentration 
range of XXVII was 107 to 2610 ng m f \  An aliquot (250 pi) of the spiked hepatocyte 
suspension was taken and 250 pi of methanol added. After briefly hand mixing, 750 pi of 
water was added before the sample was spun using a small bench top centrifuge (12000 rpm 
for 2 minutes). The supernatant was transferred to a primed C2 SPE cartridge and extracted 
as described earlier. The final extract was reconstituted in 50pl of water : mobile phase 
(50 : 50, v/v). Analysis was carried out using a Chiral AGP column (150 x 4 mm i.d.) fitted 
with a Brownlee C2 guard cartridge (15x3  mm i.d.), maintained at 40 °C. The mobile phase 
used was propan-2-oI : sodium phosphate buffer (0.0 IM, pH 6,62), (10 : 90, v/v) at a flow 
rate of 1 ml min‘\  The injection volume was 20pl. Peak area data for both enantiomers is 
shown in table 32.
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Table 32
Calibration data for XXVII extracted from heat deactivated 
control rat hepatocytes using SPE extraction.
Concentration
XXVII
ng m l'
peak area 
peak 1 CV%
peak area 
peak 2 C V %
0 - - - -
7732 7290
107 8564 6.5 10586 23.5
7612 11782
57417 64290
534 56097 1.8 45522 22.0
55411 44007
113286 94187
1059 109594 5.5 85680 24.6
121837 133792
192586 217145
2098 201753 2.4 170659 13.3
195354 217025
282951 312529
2610 284492 0.9 224184 17.7
279628 308318
The precision for the peak area of the first eluting enantiomer was excellent, CV < 6.5% . 
Sensitivity was good as the peaks at the lowest concentration were easily integrated. The 
addition of an internal standard would not have improved the data significantly. The precision 
of the peak area data recorded for the second peak was poor with an average CV of 
approximately 20%.
Some of the samples gave split or multiple peaks for the later eluting enantiomer and the 
integrator had measured these peak groups in an inconsistent way. When the total area for the 
peak group has been calculated, the precision of peak area measurement improved 
significantly to CV<8.5% . The calibration curve data was now very similar to that achieved 
for the first peak as shown by the slope and intercept data in table 33.
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Table 33
Result of weighted H/x-) least squares linear regression of spiked control 
hepatocyte standards after manual integration of last eluting enantiomer.
Peak slope intercept r'
Peak 1 10816 -333 (3 ng ml") 0.9934
Peak 2 11831 1235 (-10 ng ml ') 0.9945
The robustness and efficiency of the SPE procedure meant that the inclusion of an internal 
standard for the analysis of these analytes was not important for the analysis o f the in-vitro 
incubation medium.
To further examine the peak splitting another experiment was carried out, combining all the 
remaining sample for the calibration samples and making three injections of 25, 35 and 50pl. 
The chromatograms below (figure 47) clearly show a enantioselective peak splitting 
phenomenon related to injection volume.
Figure 47
Effect of injection volume on the degree of peak splitting observed for the 
later eluting enantiomer.
J VJ
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This phenomenon was similar to that seen when isolating 8-OH DPAT using ZGP. Peak 
splitting in achiral chromatography is not uncommon. Columns may develop channels 
through the stationary phase bed or, the injection of the analyte in an inappropriate solvent 
may result in splitting. These figures show only one peak splitting, which could not be
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caused simply by mechanical problems, since this would effect both peaks equally. The peak 
splitting seen with high loading of 8-OH DPAT was reproducible, particularly when using the 
Gilson Model 231 autosampler. Similar, but less distinct peak disturbances were seen when 
using other autosampler, for example, a Waters WISP. The peak splitting seen with biological 
extracts and Chiral AGP was not seen again, although, high column loading was used for the 
isolation of enantiomers of the same analytes, however, not in the presence of biological 
material.
Calibration using rat plasma.
Calibration curves were constructed by fortifying control rat plasma with XX and XXI. The 
extraction o f 50pl of sample (diluted with 1 ml of water) resulted in curves that were linear 
and repeatable over the range 0.12 to 100 pg ml*’. Extraction efficiency was calculated to be 
68 to 87% (by comparison to the peak area of a direct injection of known concentration). The 
lowest extraction efficiency was seen for the lowest calibration standard (0.12 pg m f' ) 
where the low recovery may have been due to integration difficulties o f a small wide peak. 
The calibration experiment was carried out on three separate occasions with reproducible 
results. The back calculated accuracy for all calibration standards was better than ± 15% of 
the nominal concentiation for each spiked sample, and correlation coefficients r  ^>0.98. 
Results for XX and XXI and their respective enantiomers were similar.
The stability of the analytes in plasma and the final sample extract was measured after 24 
hours by reference to a freshly prepared calibration curve. Both analytes were found to be 
stable. The stability of the analytes in fresh whole rat blood was also examined. Analytes 
were stable for at least 30 minutes, the maximum time taken to prepare plasma from blood 
samples
The development and validation of a bioanalytical procedure is never complete without the 
analysis of real samples. During the analysis of samples taken during the incubation of XX 
and XXI, some chromatographic issues arose, which are briefly discussed below.
Chromatography of XX and XXI after incubation with freshly prepared rat hepatocytes:
Figure 48 shows a typical chromatogram of a sample of XXI after incubation with freshly 
prepared rat hepatocytes. The mobile phase was propan-2-ol : sodium phosphate buffer 
(O.OIM, pH 6.62), (10 : 90, v/v) at a flow rate of 1 ml min‘* at 40 °C .
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Figure 48
Optimised chromatogram of an extract of XXI after 
incubation with freshly prepared rat hepatocytes.
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The two parent enantiomers were well resolved and putative metabolites can also be seen 
(approximately 10, 11.5, 13 and 18 minutes). The results of the analysis of extracts of XX, 
however, were not reproducible. The relative amounts of the parent enantiomers of XX 
measured in aliquots taken during incubation with in-vitro preparations was variable. A 
peak, presumed to be a metabolite of the (-) enantiomer, peak 2, was variously co-eluting or 
interfering with the integration of the (+) enantiomer, peak 1. Figure 49 (A) shows this 
metabolite peak co-eluting with the parent enantiomer when using the mobile phase 
conditions above. The second chromatogram (B), shows the result of reducing both the pH 
and the propan-2-ol concentration, propan-2-ol : ammonium acetate (O.OIM, pH 5.3), (8 : 92, 
v/v).
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Figure 49
Chromatogram of an extract o f XX after incubation with freshly prepared rat 
hepatocytes.(A=pH 6.6. B=pH 5.3V
The reduction in the mobile phase pH alone, resulted in short analytical times with poor 
resolution. The reduction in the propan-2-ol concentration restored the chromatogram to a 
robust and complete separation of the parent enantiomers. Better resolution of the putative 
metabolites was not achieved.
Protein precipitation.
SPE proved to be a fast, efficient and reliable sample preparation technique. However, the 
direct injection of an incubation sample would be even simpler. The 100,000 g microsome 
preparations had little biological material present, and the samples were essentially protein 
which was denatured when the methanol was added to arrest metabolism. Direct injection of 
protein precipitated 100,000 g microsome incubates was investigated. Samples were 
prepared by transferring the supernatant of the protein precipitated incubation medium to a 
test tube and reducing to approximately half volume under a gentle stream of air (TurboVap). 
The samples were then transferred to suitable vials for injection.
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Test injections of a XXI solution were made prior to injecting the in-vitro samples. The 
retention times recorded for the test injection were approximately 17 and 25 minutes for the 
parent enantiomers. The first sample injection, a 2 minute incubation sample, resulted in two 
small peaks at approximately 22 and 30 minutes. These peaks were much smaller than 
expected for the parent enantiomers. A further injection of the standard solution was made 
and the retention times were as previously recorded. The injection matrix of the standard was 
water, for the sample the matrix was approximately 0.5M sodium phosphate buffer pH 7.4. 
Dilution of the standard solution with the buffer used for the microsome incubation resulted 
in increased retention times (see table 34). The propan-2-ol content of the mobile phase was 
increased to reduce excessive run times.
Table 34
Effect of injection matrix upon the chromatographv of XXI.
Injection
solvent
Retention 
time k'
Separation
a
Peak efficiency Peak
skew
mobile
phase
5 6.5 1.3 3834 4581 1.4 1.2
0.5M  
bu -i
10 12.5 1.3 9771 12317 1.2 1.1
17.5% propan-2-ol in 0.0 ammonium acetate pH 6.7
The injection of the standard in buffer increased not only the retention time but also the 
efficiency as well. Selectivity, a , had not significantly altered. The efficiency of this 
particular Chiral AGP column was good but the efficiency seen with the buffer matrix was 
unprecedented with the 2-aminotetralin group of compounds using isocratic elution. The 
initial optimisation o f the Chiral AGP column investigated the effect of the buffer 
concentration. The test used peak separation as the quality parameter and the above results 
confirm that the buffer concentration is not significant. However, no visible difference in 
peak efficiency was seen. To test this, the mobile phase was changed to propan-2-ol : sodium 
phosphate buffer (0.5M pH 7.4) (15 : 85 v/v), table 35
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Table 35
Chromatographic performance of XXI when using 
a phosphate buffer mobile phase.
Injection solvent Retention time 1 Separation Peak efficiency Peak
k' a N skew
0.5M  buffer 6 8.5 1.4 2052 2557 1.6 1.3
The peak efficiencies were lower than found with ammonium acetate, although, the pH is 
higher and this may have had an effect. The mobile phase was changed back to ammonium 
acetate and the effect of injection volume when using 0.5M phosphate buffer investigated, 
table 36.
Table 36
Effect of injection volume of 0.5M phosphate upon injection matrix affects.
Injection 
volume |il
Retention time 
k'
Peak efficiency N Peak skew
25 10 12 9518 11362 1.4 1.0
150 10 12 9629 11540 1.4 0.9
Retention, efficiency, skew or separation were unaffected by the injection volumes tried, 
however, it is assumed that a critical injection volume must exist somewhere below 25 |l i1. The 
increase in efficiency would lead to increased peak capacity for the column via improved 
resolution, and sensitivity would increase if the propan-2-ol content was increased to 
maintain similar retention times to those seen when using mobile phase as the injection 
matrix.
The same experiment was conducted using the close analogue of XXI, XX, table 37.
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Table 37
Effect upon the chromatographic performance of XX 
of the sample injection matrix.
Injection
solvent
Retention time 
k'
Peak efficiency 
N
Peak skew
mobile phase* 4.4 5.7 1881 207 1.3 1.3
0.5M  buffer 13.7 9758 0.9
ammonium acetate (O.OIM, pH 5.9) (10 : 90 v/v).
The mobile phase pH used above was the optimum found for the quantification of XX 
enantiomers when analysing in-vitro incubation samples. The loss of enantioselectivity was 
the same when using the pH 6.7 mobile phase. Direct injection of in-vitro samples was 
considered inappropriate and all further analysis utilised SPE.
The use of the buffered injection matrix poses two questions. The increase in column 
efficiency, when using 0.5M phosphate buffer as the injection matrix with the ammonium 
phosphate mobile phase, might be explained by a form of gradient elution. It has been shown 
that a gradient elution using salt concentration can provide the increase in efficiency. The 
high salt concentration in the injection matrix must alter the local solvent conditions upon 
introduction into the column. This disruption may have continued in a discrete way during 
the chromatography of the analyte. If this view of the chromatography is correct then the 
different effects upon the two very similar analytes is difficult to reconcile with the data 
collected during the development of the chromatography, where the buffer concentration was 
shown to be unimportant for enantioselectivity of either analyte, either isocratically or via 
gradient elution. If  the mechanism of this effect can be controlled, and shown to be robust, it 
could be used as an additional optimisation variable for chromatography using Chiral AGP.
Sensitivity enhancement.
The sensitivity (« 5 ng on column) obtained for the keto-pyrrol substituted compounds at 
315 nm UV was adequate for the analysis of samples from the envisaged in-vitro 
experiments. However, for analysis in-vivo samples, or for analogues without significant 
absorbance above 220 nm greater sensitivity was required so other forms o f detection were 
investigated.
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Fluorescence detection.
A number of the 2-aminotetralin analogues were screened for fluorescence activity. No 
fluorescence could be detected with excitation wavelengths above 220 nm. The Perkin Elmer 
fluorescence detectors used (LS40 HPLC detector and LC5 fitted with a cuvette holder) 
allowed excitation wavelengths down to 190 nm to be used. The fluorescence output obtained 
by this approach is small and does not usually improve upon the UV absorbance response. 
However, where excitation at low excitation wavelengths did produce a fluorescence 
response the increase in selectivity over low wavelength (210 - 220 nm) UV can be 
significant
Electrochemical detection ŒCDT
The indole of XXI and its close analogues (XX and XXVII) was considered a possible 
electroactive group. To discover whether XXI was electroactive, and, if so, what voltage 
would be required to obtain maximal response the ESA Coulochem detector was set up as 
described below;
Mobile phase: propan-2-ol : ammonium acetate (O.OIM, pH 6.65) (5 : 95, v/v).
Flow rate: 1 ml min'*
Column: Brownlee C2 15x3  mm i.d. at ambient temperature.
The short column provided sufficient retention to resolve the analyte peak and the solvent 
front (injection matrix) disturbances. Before use the detector cell had been flushed, off-line, 
with 6M nitric acid to clean the electrode surface. The system was allowed to stabilise for 
approximately two hours at 0.4V, the lowest voltage tried. When changing the applied 
voltage, the measured baseline current rose rapidly and slowly fell back to a new but slightly 
higher baseline current. Injections were made in duplicate when the current had stabilised 
after increasing the electrode voltage, figure 50.
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Figure 50
ESA Coulochem detector response to XXI 
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The detector response had not reached maximum at 0.75V but at higher electrode voltages 
the background current had risen to unacceptable levels, leading to increased baseline noise 
and instability. In addition, with increasing electrode voltages more co-extracted biological 
material will begin to react at the electrode surface. The increase in background noise seen 
when using high applied electrode voltages can result in a reduction in the signal to noise 
ratio of the analyte and thereby reduce system performance.
A Chiral AGP analytical column was added to the system, with both guard column and 
analytical column placed into a forced air oven set at 45 °C. The mobile phase was changed 
to propan-2-ol : ammonium acetate(0.01M, pH 6.68) (12 : 88 v/v). The Kratos 773 UV 
detector was placed downstream of the electrode since the high back pressure created by the 
porous carbon electrodes would rupture the UV flow cell. The system was left to equilibrate 
overnight at a flow rate of 0.2 ml min"' with 0.7V applied to the electrode. The flow rate was 
increased to 1.0 ml min"' and a number of test injections of XXI where made. With the BCD 
gain set to give a similar peak height response (gain = Ix) to the UV detector, the noise 
measured during a baseline plot was many times less than that seen for the UV signal
The system was used to measure aliquots from hepatocyte suspensions incubated with XXI. 
The suspension matrix used for the cells was phosphate buffered saline (O.IM, pH 7.4). 
Initially sample preparation was limited to protein precipitation of the suspension aliquot
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with an equal volume of methanol. After centrifugation the supernatant was reduced to 
dryness under a gentle stream of air. The sample was then reconstituted in the desired 
injection matrix, table 338.
Table 38
Effect of injection matrix on BCD and UV detector responses obtained after 
incubating XXI with rat hepatocytes in phosphate buffered saline.
Sample Injection matrix ‘ BCD response 
at 0.7 V
UV response 
at 315 nm
15 pg ml" XXI 0.25M large solvent front clean chromatogram
15 pg ml ' XXI O.IM large solvent front clean chromatogram
15 pg ml" XXI O.OIM clean chromatogram clean chromatogram
control hepatocytes O.IM large solvent front clean chromatogram
Injection matrix was sodium phosphate buffer (pH 7.4) at the concentration specified in the 
table.
 ^The low molarity buffer resulted in a clean chromatogram with peaks corresponding to the 
parent XXI enantiomers only. No response was seen for the N-dealkylated metabolite, see 
figure 51.
 ^The BCD response was approximately 9 times greater than that recorded by the downstream 
UV detector, BCD gain set at 5x.
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Figure 51
Comparison of ECD and UV response for a sample from a rat hepatocyte 
incubation with XXI prepared by protein precipitation.
J
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The functional group of the test compound which was expected to be electroactive was the 
nitrogen in the indole C8 substitution, which would have detected any metabolite which still 
contained the indole group. The indole was possibly only weakly electroactive at the applied 
voltage. The " T-dealkylated metabolite produced very little ECD response, indicating that it 
was the tertiaiy amine group that was responsible for the BCD response. Once one of the 
alkyl groups had been removed from the amine, electrochemical activity was effectively lost. 
The lack of response to the N-dealkylated metabolite presented a new opportunity. Long 
chromatographic run times were necessary when using Chiral AGP to produce selectivity 
between the first eluting enantiomer of the parent compound and the N-dealkylated 
metabolite of the later eluting parent. This was particularly true o f XX when using a mobile 
phase pH of 6.7. Sensitivity could be increased by reducing the retention o f the parent 
compounds. The lower k ' would result in a higher peak height response and a rate of change 
of baseline slope which would make the task of integration easier. For experiments where the 
measurement of the N-dealkylated metabolite was not required faster and more sensitive 
chromatography would be possible. There were, however, difficulties with applying ECD to 
the analysis of XX and XXI from biological extracts.
The use of a high concentration buffer as the injection matrix resulted in very large solvent 
fronts making integration of the analytes difficult and therefore peak compression could not 
be used for XXI The baseline response of the ECD, when used with biological extracts, was
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disrupted by long term noise. The oscillating baseline made integration difficult. A number of 
possible causes of the baseline instability were considered. Biological material from the 
in-vitro preparations which was not detected at 315 nm UV may have been eluting from the 
column, but improving the sample clean up by adding a SPE step did little to improve the 
long term baseline instability. The grade of mobile phase reagents used with ECD can be 
important. The reagents used were the highest analytical grades generally available, but 
specialist grades of ECD buffer salts were not tried. Recirculation of the mobile phase is a 
common practice when using ECD. A guard cell was fitted after the HPLC pump and before 
the autosampler and the mobile phase outlet from the UV detector returned to the mobile 
phase reservoir. The guard cell voltage was set to 1.0 V. The objective of the guard cell was 
to oxidise any labile component of the mobile phase and any compound in the now 
“contaminated” mobile phase before they reach the detector cell for a second time. Whilst 
recirculation improved the baseline fluctuations it did not remove them completely. A further 
objection to recirculation was that a build up of contaminants in the mobile phase would 
eventually compromise the low capacity protein based analytical column regardless of 
whether or not they were detected. With time the electrode surface became fouled leading to 
a reduction in detector response. An internal standard would have compensated for the 
gradual loss of signal.
A further difficulty was purely mechanical in nature, the Coulochem detector cells and the 
0.5 fim filters used in conjunction with the cell blocks were liable to blocking. The back 
pressure would mount until the pump closed down or some upstream part of the system 
failed, for example, an autosampler seal. The analysis of all but very small numbers of 
samples were carried out using an autosampler which in the event of a pump shut down 
would continue to inject the samples regardless. The ECD system was not developed further.
Liquid chromatography with mass spectrometry detection. H.C-MS and l.C-MS-MSV
Due to limited availability of either the PE SCIEX or Finnigen mass spectrometers, very little 
method development and optimisation of the MS detector response was possible. Single ion 
monitoring for the detection of XX and XXI was found to be approximately an order of 
magnitude more sensitive than HPLC UV at 315 nm.
Some problems were manifest when using LC-MS. The signal to noise ratio tended to 
increase with time. The loss of signal can be adjusted for by using an internal standard. As no
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internal standard had been used for analysis by UV absorption, and time to fully develop a 
LC-MS assay was not available the UV method was used with a limited number of standards 
in order to reduce the overall run time. Without optimisation and using the least sensitive of 
its detection modes the LC-MS assay was approximately twenty times more sensitive than 
the UV method. The stability of the detector was far better than the equally sensitive 
electrochemical detector. Calibration standards used throughout the analysis of study samples 
demonstrated that the detector was linear over the time period used.
The use of daughter ion monitoring (LC-MS-MS) would have been the preferred detection 
technique because the selectivity would have been improved. Also the reduction in noise 
associated with MS-MS would have increased sensitivity.
Discussion.
Three sample preparation techniques were examined, solvent extraction, SPE and protein 
precipitation. Solvent extraction can be a powerful extraction method but it is more labour 
intensive than the alternatives. SPE methods are easier to develop, following procedures 
described above, than a robust and selective liquid extraction method. Protein precipitation 
for samples with very limited biological material can be effective, however, the ease of SPE 
and the production of an extract in an “ideal” injection matrix outweigh the additional effort 
involved. For the protein based commercial chiral columns to be applicable to routine 
biolanalytical samples the sample must be presented in as pure a solution as possible. SPE 
was able to meet this requirement.
The keto-pyrrol 2-aminotetralins which showed enantioselective differences in metabolic 
stability have distinctive UV absorption spectra. Monitoring the HPLC eluent at 315 nm 
produced adequate sensitivity and selectivity for all the in-vitro metabolism experiments 
conducted. The selectivity was also adequate for the analysis of the compounds in rat plasma. 
The sensitivity was also thought to be adequate for the in-vivo investigations. This was found 
not to be the case in practise. Electrochemical detection could have been developed further to 
improve the sensitivity obtained with the UV method but at the expense of not measuring the 
major in-vitro metabolite. The detection method of choice would be LC-MS either single ion 
monitoring or preferably single reaction monitoring (LC-MS-MS).
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IN-VITRO METABOLISM SCREENING
FRESHLY ISOLATED RAT HEPATOCYTES.
Initial Screening.
Introduction.
As discussed in the general introduction, the use of in-vitro models of metabolism may be an 
aid to the selection of molecules for the development of new medicines. Resistance to 
metabolic attack, lack of toxic metabolites or the absence of polymorphic metabolism are 
examples of the characteristics to be looked for when screening new candidates.
Rats ai e a common source of biological material for in-vitro studies. This is (in part) due to 
the ease of obtaining the material, and has led to the extensive knowledge of rat metabolism 
and toxicology. Incubation with freshly isolated rat hepatocytes is a common model used to 
examine metabolic stability of compounds. In contrast to microsomal preparations, 
hepatocytes can carry out both phase I (oxidative) and phase II (conjugation) reactions and 
may more fairly represent in-vivo metabolic processes. Freshly isolated hepatocytes maintain 
full cytochrome P450 function and are viable for a number of hours depending upon 
incubation conditions. Sufficient cells can be obtained from a single preparation to allow a 
number of experiments to be conducted in parallel. Hepatocytes can be cultured, hence a 
single population of cells may remain viable for many days. However, without careful culture 
conditions, P450 activity rapidly declines
Results.
A selection of the 2-aminotetralin test compounds chosen for their varied C8 substitutions, 
was incubated with freshly isolated rat hepatocytes (5x10^ cells m l" \  Three millilitres of 
hepatocyte suspension at 37 °C in 20 ml glass vials were spiked with a total of 30 pg of test 
substance. The samples were mixed by gentle swirling of the vial and returning to the shaking 
water bath. Aliquots (500 pi) were drawn at timed intervals (up to 32 minutes) and added 
immediately to 500 pi of methanol. The methanol was removed from the supernatant under a
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gentle stream of air. After evaporation the dried extracts Avere reconstituted in 200 pi mobile 
phase.
The analysis of the extracts was carried out using a Chiralcel OD column (250 x 4,6 mm i.d., 
40 °C). The mobile phase used was ethanol : trifluroacetic acid : diethylamine : hexane 
(10 : 0.05 : 0.05 : 89:9 v/v/v/v) at 1.0 ml min'% 100 pi of the extract was injected. The 
concentration of test substance in each sample was determined using an external standard 
method. The data was plotted and the half life measured (table 39) as described in the general 
introduction.
Table 39
Half life of test compounds during incubation 
with freshly isolated rat hepatocytes.
Compound Half life (minutes) of measured peak area
Peak 1 Peak 2
XIII not detected* not detected
XIV 187 poor integration"*
XV 49 44
XVI 289 co-elution"*
XX 10 10
XXI 25 10
XXII 173 239
standard injection was well resolved and detected with adequate sensitivity but analyte was 
not extracted from biofluid.
 ^ integration of peak was made unreliable by co-eluting peak but little change in peak area 
was seen.
 ^peak 2 was hidden by co-eluting endogenous peak.
Discussion.
Compound XIII, a carboxylic acid C8 substitution, was not extracted. The compounds, XIV, 
XVI and XXII were all shown to be stable when incubated with isolated hepatocytes. XV 
was less stable than these and enantiomers were cleared at similar rates. The enantiomers of 
XX were cleared rapidly and at an equal rate, hence no enantioselectivity was seen. The 
enantiomers of a close analogue of XX, XXI were cleared at different rates. The faster of the
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two was cleared at a rate equal to that of the enantiomers of XX, its antipode was cleared at 
approximately one third of the rate.
The simple solvent extraction and normal phase chromatography was not adequate for the 
measurement the 2-aminotetralin from the protein precipitated hepatocyte suspension. 
However the results obtained did reveal an interesting difference in enantiomer stability 
between the two similar analogues, XX and XXI.
The chromatography obtained for standard solutions of these compounds using the Chiralcel 
OD column was good with near baseline resolution. However, chromatography of sample 
extracts was less acceptable. A peak, whose area increased with time, a possible metabolite of 
XX was retained more strongly than the parent enantiomers. The long retention of 
metabolites more polar than their parent presented a problem if they were so retained that 
they interfered with subsequent injections. No peaks appeared in the chromatograms of the 
extracts of the XXI incubation mixture. Possible explanations for the absence of 
“metabolites” of XXX included, poor extraction, different UV absorption characteristics or 
very different chromatographic behaviour. To examine these two analogues further, a more 
appropriate chromatographic method was required.
Stability o f the enantiomers of XX and XXI during incubation with freshly isolated ra t 
hepatocytes.
Introduction.
The enantiomers of each of the keto-pyrrol substituted 2-aminotetralins were well resolved 
using the Chiral AGP CSP, and the reversed phase mechanism was more likely to allow 
metabolites more polar than their parents to be eluted from the column earlier. Indeed XXVII 
(N-despropyl XX), was resolved into its constituent enantiomers and, with careful control of 
the mobile phase pH, from the enantiomers of XX.
The Chiral AGP stationary phase is protein based. The use of proteins tend to result in 
phases which are easily compromised and have limited peak capacity. A simple, single step 
solvent extraction scheme was unlikely to be a suitable sample preparation for use with the 
Chiral AGP column, and an SPE process using 100 mg C2 Bond Elut extraction cartridges
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was developed. The development of the method has been described in the chapter, 
Chromatographic Development. The new analytical method was used to analyse samples 
from a repeat incubation of the keto-pyrrol analogues.
Results.
The three C8 keto-pyrrol substituted analogues were incubated at a concentration of 10 pg 
ml'^ with 5x10^ hepatocyte cells ml'* (figure 52).
Figure 52
Log concentration of enantiomers of XX. XXI and XXVIl versus incubation
time.
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The data shows the enantioselective metabolism of just one of the keto-pyrrol substituted 
analogues. XX was cleared from the incubation medium quickest with no measurable 
difference in rate of clearance of enantiomers. The enantiomer of XXI which was cleared 
fastest was metabolised at a similar rate to XX, after a delayed start. Using Chiral AGP, the 
rapidly metabolised enantiomer eluted from the column earlier than its antipode, in contrast 
to the Chiralcel OD, where it was the later eluting enantiomer. XXVII, a putative metabolite 
of XX, was cleared slowest of all, with no enantioselectivity apparent. The chromatograms 
for XX and XXI contained peaks which grew in size as the parent enantiomers diminished, 
and themselves diminished when no parent remained, evidence that they were drug related 
(metabolites).
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The stability of the three compounds in heat deactivated hepatocytes had already been 
demonstrated during the development of the sample extraction method. The results obtained 
during the incubation with viable cells were not, therefore, an artefact o f instability in the 
incubation matrix. The stability o f the individual enantiomers in solution had been examined 
during the preparation of samples for circular dichroism spectroscopy, where no evidence of 
racemization was seen over a period of three months in methanol at -20 °C. However, 
racemization via a metabolic process might be possible and this was examined by incubating 
the enantiomers of XXI individually with 5 x 10  ^cells ml'*. No evidence of racemization 
during incubation was seen, and the enantioselectivity of the clearance of the enantiomers of 
XXI was maintained.
Discussion.
The solid phase extraction and Chiral AGP chromatography proved robust if not particularly 
efficient in comparison to achiral reversed phase chrorhatography. The results show that 
when incubated individually, the enantiomers of XXI were still cleared at different rates. No 
evidence of the opposite enantiomers was seen demonstrating that the compound was 
conformationally stable during metabolism. An alternative possibility was considered for the 
observed differences in clearance. The incubation medium used for the hepatocyte model 
includes plasma proteins. Enantioselective protein binding might result in different rates of 
metabolism for the individual enantiomers because only unbound drug (free) can be 
metabolised. This possibility was investigated by incubating XX and XXI using phosphate 
buffered saline as the suspension medium. Although the clearance rate of the two compounds 
was reduced, similar differences in enantioselectivity were seen as when using the protein 
fortified medium. It was concluded, therefore, that the observed enantioselectivity was not 
artefactual and was a result of differences in in-vitro metabolism.
The chromatograms obtained from extracts of both XX and XXI after incubation with the 
hepatocytes show significant differences in the number of peaks which were believed to be 
metabolic products. The identification o f these putative metabolites might help explain the 
difference in enantioselectivity.
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Identification of metabolites formed during incubation of XX and XXI with freshly 
isolated rat hepatocytes.
Introduction.
Further incubations of XX and XXI were carried out at 10 pg ml * with 5x10^  cells ml '. 
Aliquots were taken and extracted as previously and the eluate of the Chiral AGP column was 
directed into the source of the TSQ 70 mass spectrometer. A “make-up” flow of 0.5 ml min * 
of O.IM ammonium acetate (pH 7) was added to improve ionisation of the analytes. The first 
two minutes of each chromatographic run were directed to waste to avoid saturating the MS 
detector. From two to thirty minutes the column eluent was scanned for analytes with a m/z 
ratio 50 to 500.
A number of metabolites for XX and XXI were postulated as shown in figure 53.
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addition o f oxygen to 
tetralin fragment
side chain
Postulated metabolites for XXI (m/z 349).
X X I iii (m/z 365) OH
addition o f oxygen to
loss of one side chain
X X I i (m/z 295)
’ loss o f second side chain
X X I iv (m/z 365)
NH
X X I ii (m/z 241)
addition o f oxygen to 
tetralin fragment
Postulated metabolites for XX  (m/z 325).
I
X X  iii (m/z 341)
addition of oxygen to 
side chain
loss o f one side chain
XX  i (m/z 283)
X X  iv (m/z 341)
loss o f second side chain
NH,
X X i(m /z 2 4 1 ) i
182
Results.
Three time points were examined, 3, 10 and 15 minutes of incubation. The major metabolite 
visible by UV (315 nm) detection had a m/z ratio corresponding to the molecular ion of the 
XXI i metabolite (figure 54). The m/z 365 ion, the molecular ion for the hydroxylated parent 
(XXI iii and or XXI iv) was seen in the 3 minute sample only.
Figure 54
Extracted ion chromatograms for XXI 
enantiomers and postulated metabolites.
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No peaks corresponding to the XXI ii metabolite (m/z 241) were seen. This may have been 
due to limited retention and therefore the signal was lost when the solvent front was directed 
to waste. The areas recorded for the parent compound clearly show enantioselective clearance 
but little difference could be seen in the areas recorded for the XXI i metabolite. The area of 
the two peaks recorded for the m/z ratio corresponding to the hydroxylated parent 
enantiomers (m/z 365) indicated that there may have been a significant difference between 
the amount of the enantiomers present. However, no information was available as to the 
position of the additional oxygen molecule and it was possible that these two peaks resulted 
from hydroxylation of the parent at different positions.
The capacity and sensitivity of the Chiral AGP LC-MS method was not good enough for 
LC-MS-MS particularly as each metabolite was split into two enantiomers. In addition the 
capacity of the Chiral AGP column was low and the injection of more material (to improve
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detection) would lead to degradation of the columns performance. To improve sensitivity and 
selectivity the analysis of samples was repeated using achiral chromatography.
A further set of incubations and extractions was carried out. The extracts were analysed using 
a Zorbax RX C8 250 x 4.6 mm i.d. column at 40 °C with a mobile phase consisting of 
acetonitrile : water : trifluroacetic acid (25 : 74.9 : 0.1 v/v/v) at 1.5 ml min No make-up 
flow was used. The UV (315 nm) response was recorded in addition to the m/z range 50 - 500 
(figure 55).
Figure 55
Achiral chromatogram of XXI after 10 minutes incubation 
with UV and extracted ion monitoring.
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The noise seen in the MS chromatograms was due to the low amount of material injected 
onto the column and the full scan parameters used. A chromatogram containing a single peak 
was obtained for the m/z 365 ion. The co-eluting m/z 295 seen at the parent compound 
retention resulted from fragmentation (loss of side chain) taking place in the mass 
spectrometer interface. A further aliquot of the extract was injected and the mass 
spectrometer set to scan for the daughter ions of m/z 295 (figure 56).
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Figure 56
Daughter ion mass spectrum of m/z 295 Tpeak 1 in figure 55V
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The molecular ion (m + 1, m/z 295) can be seen and the major fragment corresponds to the 
loss of the amine and the cyclopropyl chain (m/z 224). A fragment of the correct mass for 
this lost fragment (m/z 72) was present. Other minor fragments were seen, for example the 
loss of the cyclopropyl chain only (m/z 241). This data was adequate to confirm the presence 
of the XXI i metabolite. A further aliquot was injected and scanned for the daughters of m/z 
365 (figure 57).
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Figure 57
Daughter ion mass spectrum of m/z 365 (peak 2 in figure 551
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The spectrum has been enlarged (relative to m/z 365) to show the detail present in the smaller 
fragments. A molecular ion for the hydroxylated parent (m/z 365) was seen in the daughter 
ion spectrum. The smaller ion at m/z 347 represents the loss of water (m/z 18) from the larger 
fragment. The loss of the amine and cyclopropyl chains (m/z 125) has occurred leaving the 
tetralin fragment with the additional hydroxyl group. The fragment can be seen at m/z 126 (m 
+ 1). The oxidation had not occurred on either of the cyclopropyl side chains. The tetralin 
fragment had a smaller fragment corresponding to the loss of water. The loss of water 
suggests that the hydroxylation had occurred on the saturated ring o f the tetralin group, 
metabolite XXI iii. Other small fragments correspond to the loss of one cylopropyl chain 
with (m/z 311) and without (m/z 293) the hydroxyl group. Due to steric factors, the probable 
position of hydroxylation was the at C4 position. NMR could have been used to determine 
the exact position of the hydroxylation had sufficient material been produced.
In a similar fashion, XX was incubated with hepatocytes, and a 10 minute aliquot analysed. 
The extracted ion MS and UV (315 nm) chromatograms showed a pattern of postulated 
hydroxylated parent peaks different to those obtained with XXI (figure 58).
186
Figure 58
m / z : 2 8 3
Achiral chromatogram of XX incubation sample with 
UV and selective ion monitoring.
Peak 1
m / z  : 3 2 5
Parent
peaic 2 A peaks 3 and 4
U V 3 1 5 n m
2 : 0 0 4 : 0 0 6 : 0 0 8 : 0 0 1 0 : 0 0 12: 00 14:00 16:00
Time (minutes)
Peak 1 was assumed to be the XX i metabolite of the parent compound and no daughter ion 
spectrum was taken. One of the postulated hydroxyl metabolites of the parent XX co-eluted 
with the XX i metabolite. A number of reversed phase HPLC systems was tried to resolve the 
two peaks without success. Ion exchange chromatography using a Spherisorb SCX column 
resulted in a partial separation, but was less robust than the original Zorbax RX C8 column. 
For the purpose of the MS investigation resolution of these two components was not required. 
A further aliquot of the extract was injected and the daughters of m/z 341 examined. The 
large peak resulted in the fragmentation pattern shown in figure 59.
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Figure 59
Daughter ion spectrum for m/z 341 rpeak 2 in figure 58Y
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The molecular ion was present and the major fragment (m/z 224) represented the loss of the 
amine and propyl side chains. No evidence of an hydroxylated tetralin fragment was visible, 
hence metabolite XX iv. A fragment corresponding to the amine and side chains (m/z 118) 
was present with a very small fragment corresponding to the loss of water from the amine / 
propyl side chain / hydroxyl fragment (m/z 100). The fragmentation patterns for peaks 3 and 
4 were identical (figure 60).
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Figure 60
Daughter ion spectrum for m/z 341 Tpeak 3 or 4 in figure 58).
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The hydroxylation has again occurred on the dipropyl amine fragment but in this case there 
were clear signs of the loss o f water from the metabolite. The similarity between the two 
small hydroxylated peaks suggests the formation of a diastereomeric metabolite which could 
separate into its two diastereomeric pairs on an achiral column. This could be the result of 
hydroxylation of the a ’  ^ carbon. Hydroxylation at the carbon might also explain the loss 
of water from the fragment. No evidence was found for a metabolite with two additional 
oxygens, that is, hydroxylation of each side chain.
The position of the hydroxylation of the larger m/z 341 metabolite is more difficult to assign. 
Initially it was felt that hydroxylation of the ct cai’bon might result in the loss of water, which 
was not seen. Therefore an N-oxide metabolite was proposed. Further experiments using 
titanus chloride to reduce the N-oxide back to parent compound were unsuccessful. Because 
of this, and the generally held belief that N-oxides do not survive the ionisation process in 
mass spectrometry, it was assumed therefore that the larger hydroxylated metabolite was the 
result of oxidation of the o carbon.
Discussion.
There was a clear distinction between the metabolism of the two compounds. The 
enantiomers of XX which were cleared equally well by the hepatocyte suspension underwent
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more hydroxylation than its analogue XXI (both quantitatively, and qualitatively, based upon 
the UV chromatographic data). The use of UV data for making comparisons of concentration 
where the chromophore is possibly being modified by the metabolic conversions is always 
suspect without test substance to refer to. However, the UV extinction coefficient for XX and 
XXVII (N-despropyl XX) are very similar. Quantitative comparisons using the UV derived 
areas of peaks for the XX hydroxylated metabolites (where hydroxylation occurs on the 
propyl chains) appears reasonable. The same comparison may not hold for the hydroxylated 
metabolite of XXI where the hydroxylation has taken place on the tetralin portion of the 
molecule. This was examined using diode array detection. DAD demonstrated that the UV 
maxima at 315 nm seen for the parent compounds had been shifted to a higher wavelength 
(360 nm) for the hydroxylated metabolite of XXI, XXI iii.
Both hydroxylation and N-demethylation are forms of oxidative metabolism. The group of 
enzymes responsible for much oxidative metabolism are those belonging to the membrane 
bound cytochrome P450 family, which are located in the membranes of the endoplasmic 
reticulum.
The P450 group of enzymes are characterised into families and sub-families based upon the 
degree of amino acid sequence homology. Two P450s belong to the same family if they have 
more than 40% sequence homology, and the same sub-family if they share more than 60% 
sequence homology. The degree of homology between the species results in similar 
qualitative metabolic reactions in, for example man and rat. However families and sub­
families can show differing degrees of expression, and this results in quantitative metabolic 
differences between the species In general the activity o f the CYP isozymes show
a high degree of overlap in the metabolic reactions which they catalyse. Of the various 
isozymes, the sub-family CPY3 A is possibly the most important drug metabolism isozyme in 
humans representing about 60% of the total P45G
The CPY3A sub-family catalyse a number of N-dealkylation reactions.
spatzencgger, 1995. Vasumori, 1993] the substrate Specificity of CYP3A overlaps with that of
the CYP2C sub-family. Both isozymes are preferentially expressed in the male rat and 
therefore male / female differences would be expected in the metabolism for substrates of 
these isozymes. Other isozymes capable o f N-dealkylation in rat and man are members of the 
CYP2 family , Substrates for the CYP3 A sub-family are lipophillic with positive
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log Dy 4  values. Substrates may be bulky, but metabolism often occurs on small exposed 
substituents of molecules such as N-methyls. The isozyme can be induced by compounds 
such as phenobarbitol 1®""***» There is some evidence that the activity of CYP3 A (N- 
demethylation and 4-hydroxylation of Mephenytoin) may be enantioselective
The isozymes often credited with enantioselective metabolism are found in the sub-family 
CYP2D. These isozymes are not reproducibly expressed in humans (polymorphism) with 5 to 
10% of Caucasians consistently showing a genetic “deficiency” in CYP2D6 activity 
[Gibaidi, 1993) activity of the CYP2D sub-family in rat is much greater than that in dog or 
man 1®"”*‘‘’ Substrates for the CYP2D isozymes require a basic nitrogen, and binding to 
the enzyme is ionic. This results in a higher affinity for the substrate (low k^) and renders the 
isozymes readily saturable. The isozyme is not inducable. The active site of the CYP2D 
isozymes in man and rat show spatial differences demonstrated by the fact that in rat quinine 
inhibits the isozymes whereas in humans its antipode, quinidine, is the more potent inhibitor.
The keto-pyrrol substituted 2-aminotetralins are possible substrates for both these isozyme 
sub-families. Evidence for the involvement of CYP2D6 might be found in the response o f the 
metabolism to increasing drug concentrations.
Metabolic clearance with increasing concentration of XX and XXI.
Introduction.
Further incubations of XX and XXI were conducted at 2, 5, and 15 pg m f^. Timed aliquots 
were taken, extracted and analysed using Chiral AGP with UV detection. All the incubations 
were conducted in parallel with cells from a single preparation.
Results.
The concentration data obtained from the six incubations was plotted and the half lives 
estimated by least squares linear regression (tables 40 and 41).
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Table 40
Half life ( t^ )  of XX enantiomers during incubation with 
freshly isolated rat hepatocytes.
Starting concentration tj/2 (mins) tj/2 (mins) ratio o f  half lives
XX ug ml"' peak 1 peak 2 p2/pl
2 19.4 22.1 22.1
5 28.8 29.6 2&6
15 79.7 81.5 81.5
Table 41
Half life (tjn^ of XXI enantiomers during incubation with 
freshly isolated rat hepatocytes.
Starting concentration tj/2 (mins) tj/2 (mins) ratio o f  half lives
X X I pg m f' peak 1 peak 2 p2/pl
2 10.6 17.9 17.9
5 14.6 21.3 21.3
15 51.0 73.4 73.4
Further incubations were conducted with XXI using an extended concentration range 
(table 42).
Table 42
Half life ( t^ )  of XXI enantiomers during incubation with freshly isolated rat 
hepatocytes - extended concentration range.
Starting concentration 
XXI pg m r‘
ti/2 (mins) 
peak 1
ti/2 (mins) 
peak 2
ratio
p2/pl
1.08 4.3 19.1 4.4
2.14 8.5 20.2 2.4
5.98 23.5 50.5 2.1
11.9 51.6 »
23.57 98.6 123.5 1.3
* Some samples lost due to pump failure and insufficient sample remained for re-injection.
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Discussion.
The enantiomers of XX were cleared at similar rates for each of the three concentrations, and 
no evidence of saturation of the metabolism was seen. This contrasts strongly with the results 
from the incubation of XXI. The clearance of peak 1 ((+) enantiomer) was similar to that for 
the enantiomer of XX at the same concentrations. Peak 2 ((-) enantiomer), however, was 
cleared more slowly. In both experiments the clearance of peak 2 was very similar for the two 
lowest concentrations, indicative o f saturation of one or more routes of metabolism. These 
results are evidence of the possible involvement of CYP2D6 in the enantioselective route of 
metabolism. Further evidence for the involvement of enzymes CYP2D6 and CYP3A in the 
metabolism of XXI may be obtained by using specific P450 inhibitors in the hepatocyte 
incubation medium.
Incubation of XX and XXI in the presence of specific P450 inhibitors.
Introduction.
Triacetyloleondomycin and quinine are specific inhibitors of rat CYP3A2 and CYP2D6 
respectively I®™'***’ Spatzenegger, 1995] incubations were carried out at 2 pg ml'* to 
maximise enantioselectivity. The inhibitors were added to the incubation medium 5 minutes 
before the addition of XXI to allow the inhibitors an opportunity to equilibrate (table 43).
Results. 
Table 43
Incubation of XXI in the presence of specific P450 inhibitors.
P450 Inhibitor Present Half Life (minutes)
Peak 1 Peak 2 Ratio
None (control) 10.1 15.9 1.6
Quinine 24.6 36.8 1.5
Triacetyloleondomycin 10.9 18.0 1.7
Discussion.
The half lives of the enantiomers measured for the control incubation were similar to that 
obtained previously (tables 4.3 and 4.4). The pre-incubation with quinine halved the rate of
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clearance for both the enantiomers with little change in the enantioselectivity. 
Triacetyloleondomycin appeared to have little effect on either rate or enantioselectivity. The 
compound was difficult to dissolve and may have come out of solution in the incubation 
medium. Or possibly, the compound was unable to cross the cell membrane. Although the 
overall clearance was no different to that of the control, the production of the N-dealkylated 
metabolites was reduced by approximately 25% after 20 minutes (chromatograms not 
shown). These results show that CYP2D6 was involved in the metabolism of XXI but limited 
additional evidence o f enantioselectivity was obtained.
One difficulty presented by the use of freshly isolated hepatocytes is that the preparation 
must be used immediately, and any subsequent experiments require a fresh preparation. This 
might lead to a variability, both qualitatively and quantitatively in the results obtained due to 
differences in P450 expression between animals.
Sub-cellular fractions prepared from homogenised liver have the advantage that they can be 
stored at low temperatures for a period of months. Two forms of preparation are common. 
The 89 or 9,000 g fraction (post-mitochondrial supernatant) has had the membrane fragments 
and the cell nucleus pelleted and discarded. The more common, microsomal preparation, is 
prepared at 100,000 g and the pellet retained. This form of preparation consists of, in the 
main, the endoplasmic reticulum and hence, is more specific for P450 activity.
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RAT LIVER MICROSOMES.
Reproducibility of microsomal incubations.
A significant advantage of sub-celiular preparations is the ability to store material from a 
single animal. This means that the reproducibility of the rate and extent o f the clearance of 
the enantiomer can be examined under varying conditions.
Two experiments were conducted, the first examining the reproducibility of incubation on 
successive days (table 44), the second investigating the difference between individual 
animals, (table 45)
Results.
Table 44
Reproducibility of measured half lives for the enantiomers of XXT incubated 
with 100.000 g microsomes from two animals (incubated three times on two
separate occasions).
Rat 1 - Male 
H alf life in minutes 
enantiomer 1 /  
enantiomer 2
Ratio Rat 8 - Female 
H alf life in minutes 
enantiomer 1 / 
enantiomer 2
Ratio
Occasion 1 4.82 /  6.60 1.37 8 .3 4 /1 6 .4 0 1.97
4 .3 9 /5 .8 1 1.32 8 .1 1 /1 6 .3 8 2.02
5.09 / 7.22 1.42 8.71 /  17.96 2.06
Occasion 2 4.96 /  6.72 1.35 8 .3 8 /1 7 .9 9 2.15
4 .8 8 /6 .8 8 1.41 8 .2 9 /1 6 .3 8 1.98
4.68 /  6.84 1.46 8 .1 6 /1 6 .0 2 1.96
Mean 4.8 / 6.67 1.39 8 .3 3 /1 6 .8 6 2.02
Standard dev. 0.24 /  0.53 0.05 0 .2 1 / 0.88 0.07
Coefficient o f  
variation
5.1 / 7.9% 3.7% 2.6 / 5.2% 3.6%
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Table 45
Reproducibility of measured half lives for the 
enantiomers of XXI incubated with 100.000 g microsomes 
from four male and four female animals.
Sex Rat No. H alf life (mins) 
enantiomer I /  
enantiomer 2
ratio 
o f  half lives
protein 
mg ml"'
protein 
nMolar P450
Male 1 4.82 /  6.70 1.39 10.8 1.8
2 12 .65 /16 .51 1.31 10.1 1.0
3 3 .6 9 /5 .5 3 1.50 12.4 2.8
4 3.68 /  5.03 1.37 14.1 2.4
Mean 6 .2 1 /8 .4 4 1.39
Std.Dev. 4.33 /  5.42 0.08
CV 69.7 / 64.00% 5.7%
Female 8 8 .2 7 /1 3 .5 9 1.64 9.8 1.2
9 1 3 .1 3 /2 3 .1 5 1.76 10.2 0.9
10 8 .3 4 /1 7 .7 3 2.13 9.7 1.3
11 3 5 .4 0 /5 1 .0 0 1.43 9.3 0.7
Mean 1 6 .2 9 /2 6 .3 7 1.74
Std Dev. 1 2 .9 4 /1 6 .8 8 0.29
CV 79.5 / 64.0% 16.9%
The reproducibility of the incubation and analysis was excellent with coefficients of variation 
of 2.6 - 7.9% for rate, and 3.7% for the ratio of rates. The female rats had a slower metabolic 
rate but shov'ed more enantioselectivity. The slower rate of clearance was expected because 
of the lack of CYP3A and CYP2C in females, both of which were expected to produce the 
N-dealkylated metabolite.
The results for the reproducibility between animals (table 45) show a significant degree of 
variation in metabolic rate for both male and female. The differences seen correlate well with 
the measured concentration of P450, figure 61. The reproducibility of the ratio of half lives, 
for male rats, was similar to that obtained in the previous experiment. The variation in the 
ratio of half lives seen when using microsomes from female rats was greater.
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Figure 61
Mean clearance of XXI enantiomers from control microsomes 
with varying concentration of P450 protein.
0.25 n
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^  0.2 - I^ 0.15 -
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Two characteristics of the results obtained from the incubation o f XXI with microsomes 
obtained from female rats were; i). the metabolic profile (chromatographic peaks obtained 
using Chiral AGP with detection at 315 nm UV) was similar to that seen with the male rat 
microsomes (and freshly prepared rat hepatocytes), but ii), in contrast to incubation o f XXI 
with microsomes from male rats, quantitative differences were seen in the amount of 
N-demethylated metabolite present, particularly in rat 10.
The results suggest that the obsei-ved enantioselectivity in the metabolism of the enantiomers 
of XXI does not result exclusively from the activity of CYP2C or CYP3A because these are 
poorly expressed in females.
In-vitro metabolism after P450 induction.
A further approach to the investigation of P450 metabolism is the use of liver microsomes 
from animals that have received known P450 inducers. Table 46 shows the results o f the 
incubation of XXI with microsomes from induced rats.
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Table 46
Incubation of XXI with 100.000 g microsomes prepared 
from rats dosed with known P45Q inducers.
Inducer * Sex H alf life in minutes 
enantiomer 1 / enantiomer 
2
Ratio o f  half 
lives
P450 isozymes 
induced
Control Male
Female
4.01 Z4.92 
8 .2 2 /1 7 .0 6
1.23
2.07
Phénobarbital Male
Female
0 .9 9 / 1.93 
4 ,4 7 /1 2 .0 8
1.96
2.69
2 A 1 ,2 B 1 ,2 B 2 , 2C
(limited extent) and 
3A
P-naphthoflavone Male
Female
46.73 /  105.21 
25.63 /  53.54
2.25
2.09
lA  and 2A
Pregnenolone- 16a- 
carbonitrile
Male
Male
1 .3 6 /1 .8 5
1 .6 3 /1 .9 9
1.36
1.22
3 AI and 3A2
‘ Animals were inc uced by dosing at 80 mg kg i.p. for tliree days.
With respect to the control incubation, the rate of metabolism of the enantiomers was 
increased by induction with phenolbarbital and pregnenolone-16a-carbonitrile (PCN) (male 
rats only). The overall rate of metabolism was lower in the microsomes produced from the rat 
induced with P-naphthofiavone. With respect to enantioselectivity the only notable increases 
were seen for the males induced with phénobarbital and P-naphthoflavone (see figure 62). A 
small increase (relative to the earlier experiments) was also seen in the female rat induced 
with phénobarbital, figure 63.
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Figure 62
Chromatograms of samples taken 12 minutes after incubation o f XXT with 
microsomes from control and induced male rats.
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Figure 63
Chromatograms of samples taken 12 minutes after incubation of XXT with 
microsomes from control and induced female rats.
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Discussion.
Careful inspection of the chromatograms (see figures 62 and 63) produced by these 
experiments revealed some interesting differences. In the control animals very little of the 
XXI ii metabolite was seen in the male rats and none in the female rats. This metabolite was 
also absent in the P-naphthoflavone induced female and found in very small amounts in the 
phenobarbitol induced female. The PCN induced male had a slight increase of the XXI ii 
metabolite over the control animal, but the phénobarbital induced male had large amounts of
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accumulated XXI i i . No enantioselective differences were seen in the amounts of XXI ii. By 
contrast the XXI i metabolite produced unexpected differences in enantioselectivity. Control 
male animals, and those induced using PCN, show similar amounts of the XXI i metabolite.
A small difference (ratio of areas P2/P1 = 1.1) was seen with the phénobarbital induced male.
The relative amounts of the XXI i enantiomers were similar in all females, and the ratio was 
0.6 - 0.7. It was not clear whether the enantioselectivity seen in the relative sizes of this 
metabolite arise from its production (from the parent XXI) or from their subsequent 
metabolism.
However, similar chromatograms would have been obtained if the clearance of the 
N-dealkylated enantiomers was enantioselective. There was no evidence of different amounts 
of the R-NH2  metabolite being formed, but other metabolic processes may have been present.
The metabolism of XX and XXI in 100,000 g microsomes was found to be qualitatively 
identical to that seen in freshly prepared hepatocytes and S9 preparation. The increase in the 
production of R-NH2  seen with the phenobarbitol induced male is likely to be partially due to 
induction of CYP3A. CYP2C has been shown to be capable of N-dealkylation and
is not expressed in females. However, the increased amount of N-dealkylation in the 
phénobarbital induced female appears to be, at least in part, responsible for the increase in the 
rate of metabolism of the parent enantiomers. CYPIA has been shown to be capable of 
N-deakylation and may be responsible for the enantioselectivity seen with the
male rat induced with p-naphthoflavone. The sex and age of rats has a significant effect upon 
the P450 make up
The routes of metabolism seen so far have all been phase 1 reactions. No evidence was found 
for conjugated metabolites in either the freshly isolated rat hepatocytes or S9 fractions. Phase 
2 reactions do not occur in microsomal preparations. To investigate the possibility of 
conjugated metabolites a further in-vitro model was examined, that of incubation with 
precision cut liver slices.
201
RAT LIVER SLICES.
Introduction.
The production of good quality (constant thickness and without torn edges) liver slices 
requires more practice (and technique) than the preparation of either hepatocytes or sub- 
cellular fractions. In addition only a limited number of slices can be produced from a single 
liver. One liver slice contains approximately 5 million cells and the incubations were carried 
out using one slice per millilitre of incubation medium.
Results.
As expected the enantiomers of XX when incubated with rat liver slices were metabolised at 
a similar rate. The chromatographic profiles obtained from incubations of XX and XXI with 
liver slices were qualitatively similar to those obtained from incubation with microsomes and 
hepatocytes. The parent enantiomers of XXI were metabolised enantioselectively but the 
clearance rates were lower than seen with the isolated hepatocytes or sub-cellular fractions.
An incubation (5 pg ml"’) of XX and XXI was carried out. At 30 minutes the incubation was 
cooled on ice to slow metabolism. The slices were disrupted using glass rod homogenisers 
(kept on ice) and the whole samples spun to remove the cell debris. An equal volume of 
methanol was added to an aliquot of the supernatant to precipitate the protein. After further 
centrifugation, the supernatant was dried under a gentle stream of air and the extract 
reconstituted using water. The extracts were analysed using achiral chromatography. The 
column used was a Zorbax RX C8 (150 x 4.6 mm i.d.) at 40 °C. Gradient elution (10 - 80% 
acetronitrile in water containing 0.1% triflouroacetic acid) at a flow rate of 1.0 ml min"' was 
used. The eluate was directed into the heated nebuliser source of the TSQ 700 mass 
spectrometer. The mass spectrometer was set to scan the m/z range 50 - 600. Both incubates 
contained peaks corresponding to the parent enantiomer, the XXI i and XXI ii metabolites. 
The ion corresponding to the parent plus oxygen (XXI iii and or XXI iv) was present for XX 
(2 peaks with a 4 : 1 ratio of intensity) and XXI (1 peak). Peaks corresponding to the two N- 
dealkylated metabolites plus oxygen were seen for XX, but not for XXI. No peaks were seen 
which might be sulphate conjugates for either compound, but 0-glucuronides were seen. For 
XXI, a peak corresponding to the m/z of a N-glucaronide was seen. This lends some weight
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to the earlier observation of an N-oxide seen with the hepatocyte incubates. However, 
insufficient material was available for LC-MS-MS analysis, and the peak identities must 
remain tentative.
Discussion.
The experiments described here to demonstrate enantioselective in-vitro metabolic activity 
were preliminary experiments, unlikely to provide conclusive evidence of the involvement of 
specific P450 isozymes in specific metabolic paths. None of the incubation conditions used, 
or the models themselves, were optimised and substrate saturation was occurring, even at low 
concentrations. The inhibitor and induction experiments were carried out, in the main, only 
singly and consequently variation between animals could have masked minor quantitative 
and qualitative differences in metabolites. None of the preparations were characterised, 
except for the P450 content of the 100,000 g preparations.
Better methods for the investigation of P450 metabolism are available, for example sub- 
cellular fractions can be characterised for P450 both quantitatively and qualitatively using 
probe substrates chromatographic techniques can be used.
Comparison of the probe substrate activity with metabolic formation o f the compound under 
investigation using multivariate regression can be made to highlight the involvement of 
specific isozymes *®*®''®"®’ , Other techniques involve the use of isolated isozymes, cDNA
- expressed isozymes or antibodies to isozymes as specific inhibitors. These techniques 
preclude the use of freshly isolated hepatocytes or liver slices.
For comparison of metabolic profiles, liver slices appear to offer the most relevant model of 
those examined, because they most resemble the intact organ. However, the value of any 
in-vitro model is determined by how well it predicts the fate of the test compounds in-vivo.
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IN-VIVO PHARMACOKINETICS OF XX AND XXI 
AFTER INTRAVENOUS DOSING IN THE RAT.
Introduction.
In-vitro metabolic clearances of the two test compounds XX and XXI have been 
reproducible. The metabolism of XX exhibits very limited enantioselectivity whilst its close 
analogue XXI undergoes enantioselective clearance from incubations with microsomes, 
isolated hepatocytes and liver slices. The in-vitro experiments have provided a measure of the 
metabolic stability of the two compounds, and have shown subtle differences between their 
metabolic paths. In order for these observations to be of value in the development of new 
medicines, they should provide insight into the metabolic behaviour o f these compounds 
in-vivo.
Notes on study conduct.
There were a number of considerations in planing the in-vivo experiments. Firstly neither of 
the test compounds had been tested in animals and consequently, no information regarding 
adsorption was available. However, the bioavailability of 8-OH DP AT was low when given 
orally to rats due to extensive first pass metabolism by the liver. The in-vitro metabolism of 
the test compounds by rat hepatocytes was extensive, and first pass metabolism by the liver 
could be expected if the animals were dosed orally. A further consideration was that the 
experimental protocol could specify the collection of urine and faeces or blood samples, but 
not both, as would have been preferable. Dosing by an intravenous (iv) route overcame most 
o f the uncertainty of drug delivery. The dose was chosen by reference to those used 
previously for 8-OH DP AT and its analogues and to the relative pharmacological activity of 
the test compounds. During the in-vitro metabolism experiments using rat liver microsomes 
obtained from female rats demonstrated a greater degree of enantioselectively for the 
enantiomers of XXI. However, early metabolism and pharmacokinetic studies have 
historically been conducted in male rats and this was the case here.
The number of blood samples and the total volume which can be drawn from a rat is 
controlled by the United Kingdom Home Office. A compromise, therefore, between the 
number of samples taken in order to define the pharmacokinetic profile of the drug and the
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volume of sample taken, which determines the sensitivity of the analytical method, was 
made. The rate of clearance of the drug from the system was expected to be high, and 
therefore the number of samples that could be collected during the period immediately after 
dosing was maximised. A total of 14 samples of 100 to 150 pi of blood was taken from each 
animal, starting 2 minutes after dosing with a final sample at 24 hours.
Dosing.
The animals were divided into two groups and the first group were administered XXI at 
5 mg kg“^ (dose solution concentration approximately 3 mg mf^). The animals showed 
immediate signs of typical response to a compound showing 5-HT activity, specifically a flat 
body posture, fore paw treading, and mild convulsions. Within a few minutes the animals 
reactions had reduced to a gripping motion and a loss of co-ordination. After 5 minutes the 
rats had become very subdued. Thirty minutes after dosing the animals were returning to their 
normal condition.
The second group of animals was dosed with XX at 2 mg kg"\ Rat number 4 showed 5-HT 
response similar, but less severe, than the first group of animals. The two remaining animals 
were subdued with signs o f disorientation. One animal, rat 5, had a pilo-reaction (hair 
standing on end) for a few minutes, twenty minutes after dosing. By thirty minutes all rats 
were returning to normal.
(
Sampling.
Whole blood samples were centrifuged immediately and approximately 60 - 70 pi o f plasma 
was harvested and frozen. Both XX and XXI had been shown to be stable for at least 30 
minutes in whole blood.
Analysis o f plasma samples.
Plasma samples from one animal in each group were extracted, along with spiked control 
plasma in the range 0.12 to 50 pg m f '. The volume of plasma harvested at each time point 
was sufficient for a single analysis only. Each animal was analysed individually with a 
freshly prepared calibration cui*ve. This analysis scheme was chosen in order to reduce the 
risk o f losing all the study samples for a dose group due to failure of the chromatographic
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system. The data obtained from the three calibration cui'ves would also provide additional 
method validation data.
One animal from each group was analysed initially. The chromatography for each batch was 
reproducible and the calibration data for both compounds was acceptable. However, drug 
could only be detected in the first six samples (up to 0.75 hours), before the limit of detection 
was exceeded (0.06 pg ml'^). Consequently, the samples for the other two animals in each
group were analysed by LC-MS. The detection limit for the mass spectrometer was 
approximately 3 ng ml ' of each e 
plasma up to 6 hours after dosing.
nantiomer, which was sufficient to measure XX or XXI in
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PHARMACOKINETICS FOR THE ENANTIOMERS OF XXI.
Table 47 gives the concentrations found for the enantiomers of XXI. Data for samples from 
rat 1 was obtained by HPLC-UV detection.
Table 47
Concentration (ng ml of XXI in rat plasma after intravenous dosing.
Time
(hours)
Rat 1 
dose 5.06 mg kg"' 
peak 1 peak 2
Rat 2 
dose 5.22 mg kg ' 
peak 1 peak 2
Rat 3 
dose 5.12 mg kg'' 
peak 1 peak 2
predose n.d.' n.d. n.d. n.d. n.d. n.d.
0.033 1561 1722 1214 1235 1751 1732
0.067 1093 1121 687 698 1111 1190
0.133 680 714 791 782 1770 1689
0.267 624 703 832 1054^ 1044 1119
0.5 339 339 312 294 374 421
0.75 258 286 155 152 283 244
1 n.d.^ n.d. l.s.'* l.s. 212 253
1.5 n.d. n.d. 61 61 156 172
2 n.d. n.d. 17 13 73 79
4 n.d. n.d. 8 7 12 10
6 n.d. n.d. n.d. n.d. 3 n.d.
short term noise spike on peak results in over estimate of probable concentration.
 ^ lost sample
The mean concentration of each enantiomer of XXI at each time point (max. n=3) was 
calculated. Samples where concentrations were below the lower limit of quantification of the 
assay were not included in the calculations. Data are shown in figure 64.
207
Figure 64
Plasma concentration versus time for XXI enantiomers 
(‘peak 1 # . peak 2 O) mean of three rats.
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The exponential decay in plasma concentration can be clearly seen in figure 5.1 . The data 
were replotted using a logarithmic concentration scale (figure 65).
Figure 65
Log, plasma concentration versus time for XXI enantiomers 
(peak 1 peak 2 O) mean of three rats.
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Figure 65 indicated that the enantiomers were not cleared at a single elimination rate, as 
would be described by a single compartment pharmacokinetic model therefore the data were 
modelled according to an open two compartment model (biphasic).
Prior to fitting the appropriate equation to the data, an estimate of the parameter values had to 
be made. This was achieved using a peeling procedure. First a line was fitted through those
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points which appear to be in the linear portion at the end of the blood level time curve, which 
represents the overall elimination rate (2 to 6 hours).
The pharmacokinetic model was fitted using the software package SIPHAR'. The 
concentration time curve was fitted using a weighted least squares minimisation algoritlim. 
The weighting factor used was l/y(caic)- The weighting factor was used for reasons analogous 
to weighting calibration data, that is, to give essentially equal importance to the low 
concentration values when fitting the curve (figure 60).
Figure 66
Mean plasma level data for peak 1 with manually fitted overall fterminaH
elimination slope.
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The slope of the line was used for the estimate of (3 and the intercept as an estimate of B. In 
order to fit a line to the earlier time points the difference between the measured value and the 
value as calculated using the estimate of the elimination phase, p (figure 66). A line is then 
fitted to the new values to provide an estimate of a  and A (figure 67).
‘ SIPHAR for DOS V3.3 supplied by SIMED S.A., Creteil, France, 1989.
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Figure 67
Mean plasma level data for peak 1 with manually fitted 
distribution phase slope (concentration difference values. +).
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The parameter values (A, a , B and |3) were then used to start the minimisation algorithm, this 
resulted in final parameter values as give in table 48.
Table 48
Values for A. a . B and P calculated using mean plasma concentration data 
obtained for the enantiomers of XXI.
Enantiomer a  phase Half P phase H alf
A -a life B -P life
peak 1 1228.6 2.346 0.2954 146.4 0.654 1.0597
peak 2 1130.2 2.903 0.2388 369.7 0.936 0.7407
The mathematical equation which describes the concentration of drug in plasma with time is, 
equation 30:
Equation 30
C,. = g .g -"  + A.e
The models fitted to the mean data for the enantiomers of XXI are shown in figure 68.
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Figure 68
Log, plasma data for XXI peak 1 and 2 with fitted elimination curves.
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No plasma concentration for the second enantiomer, peak 2, was obtained for the 6 hour 
sample. This has resulted in a poor fit for the p phase of this enantiomer. Had an accurate 
measure of the plasma concentration been available ( the concentration for peak 1 was at the 
limit of detection), the half lives for the overall elimination phases would, possibly, have 
been more similar. Equally the two curves could have been fitted to only the 0.033 to 4 hour 
time period but would also have resulted in a less accurate fit for peak 1.
The mathematical model fitted the analytical data well with coiTelation coefficients of
r  ^= 0.9753 and 0.9695 for peak 1 and 2 respectively. The probability that each curve fitted by
chance was less than 1%.
The volume of distribution at time zero was 1374 and 1500 ng m f' for peaks 1 and 2 
respectively. The mean dose administered was 0.6746 mg total for each enantiomer. The 
volume of the central compartment was 491 and 450 mis for peaks 1 and 2 respectively. Both 
figures are significantly larger than the total body volume of the animal. Other volumes of 
distribution can be calculated.
The volume of distribution at steady state for peak 1 was 682 ml and for peak 2, 611 ml.
These figures can be normalised for body weights using distribution coefficient. For peak 1 
the distribution coefficient was 2.59 ml g*' and for peak 2,2.32 ml g '\
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The total exposure of the drug to the body can be obtained by measuring the area under the 
blood level time curve (AUC). The AUC to infinity for peak 1 was 746.9 ng ml'* hrs and for 
peak 2, 784.3 ng ml'* hr.
All the above calculations have been carried out using the mean plasma concentration. Given 
the limited data available it was not appropriate to fit a model to each animal and then 
compare the results, but it was possible to fit a model to all the individual data points. This 
approach would still result in an average measure for the pharmacokinetic parameters but a 
measure o f the fit for the full data set would also be calculated, figures 69 and 70.
Figure 69
Figure 70
Plasma concentration data for XXI peak 1 trat 1 O. rat 2 □. rat 3 xF
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Plasma concentration data for XXI peak 2 trat 1 O. rat 2 □. rat 3 xV
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Time (hours)
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Figure 71
Overlay o f fitted models for XXI peak 1 (---- 1 and peak 2 (-
Table 49
Time (hours)
Values for A. a . B and p calculated using individual plasma concentration 
data obtained for the enantiomers of XXI.
Enantiomer a  phase Half P phase Half
A -a life B -P life
peak 1 1350.3 3.996 0.1735 364.1 0.825 0.8805
peak 2 1199.9 4.475 0.1549 571.7 1.037 0.6684
Table 50
Summary of pharmacokinetic parameters measured for the enantiomers of 
XXI calculated from model fitted to data points from three rats.
Parameter Peak 1 Peak 2
H alf life 
terminal phase
0.88 0.67
H alf life 
distribution phase
0.17 0.15
Plasma concentration 
time 0
1714 1772
volume o f distribution 
for central compartment
394 381
volume o f  distribution 
at steady state
688 594
distribution coefficient 2.62 2.26
Area under the curve to infinity 779 819
Correlation coefficient 
o f  model fit
0.9009 0.8978
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PHARMACOKINETICS FOR THE ENANTIOMERS OF XX.
The results obtained from the analysis of plasma samples from the second group of animals 
are given in table 51
Table 51
Concentration tng ml~) of XX in rat plasma after intravenous dosing.
Time
(hours)
Rat 4  
dose 2.19 mg kg ' 
peak 1 peak 2
Rat 5 
dose 2.23 mg kg'' 
peak 1 peak 2
Rat 6 
dose 2.17 mg kg'' 
peak 1 peak 2
predose n.d.‘ n.d. n.d. n.d. n.d. n.d.
0.033 929 962 374 388 101 104
0.067 648 715 396 410 165 153
0.133 379 424 374 375 109 104
0.267 237 238 234 230 89 98
0.5 129 180 164 175 53 56
0.75 50 108 71 73 32 31
1 n.d. n.d. 72 73 25 23
1.5 n.d. n.d. 57 51 9 9
2 n.d. n.d. 30 28 10 9
4 n.d. n.d. 5 5 3 4
After obtaining initial parameter estimates, as detailed above, an open two compartment 
pharmacokinetic model was fitted to the concentration data for the individual enantiomers, 
figure 72.
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Figure 72
Log, plasma concentration data for XX peak and 2 (O) mean of three
rats.
I) '%.
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The new parameter estimates were then used to fit a curve to the individual data points for 
each enantiomer, figure 73. The data for peak 2 were essentially similar and has not been 
plotted.
Figure 73
Plasma concentration data for XX peak 1 for rat 4 ToL rat 5 and rat 6 txL
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The pharmacokinetic parameters described above were calculated from the data obtained for 
both the mean and the individually fitted data points and are summarised in table 5.6.
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Table 52
Summary of pharmacokinetic parameters measured for the enantiomers of 
XX calculated from both mean and all data points.
Parameter Mean data All data points
Peak 1 Peak 2 Peak 1 Peak 2
H alf life (hr) 
terminal phase
0.89 1.02 0.78 0.76
H alf life (hr) 
distribution phase
0.14 0.19 0.10 0.11
Plasma concentration 
time 0
526 506 784 778
volume o f  distribution 
for central compartment
553 575 371 374
volume o f  distribution 
at steady state
553 575 886 799
distribution coefficient 2.07 2.17 3.34 3.02
Area under the curve to infinity 210 228 260 281
Correlation coefficient 
o f  model fit (r )^
0.9982 0.9936 0.7440 0.7322
Discussion of pharmacokinetic results.
It was clear from the plasma concentration data that neither compound was enantioselectively 
distributed or cleared from plasma. The pharmacokinetic analysis confirms this observation. 
The enantioselectivity seen for XXI in-vitro arose from metabolic conversion of the parent 
enantiomers. This was assumed to be due to hydroxylation of the tetralin ring. It was unlikely 
that the hydroxylated metabolite o f XXI could have been detected in plasma with the 
methods used because of the limited retention time on column and insufficient detection 
selectivity by UV (315 nm) or LC-MS. However, the N-demethylated metabolite, well 
resolved from the chromatographic solvent front, would be detectable by both the UV and 
MS methods. Although the N-demethylation of the parent was not believed to be the 
enantioselective pathway it could be used as a marker for metabolism. An assumption has 
been made that the drug dissolved in the blood has access to the liver as it has when dosed 
orally with the exception that it does not pass through the liver via the hepatic portal vein 
before distribution. The circulating levels of XXI were less than 2 pg ml"' , and if metabolism 
had occurred, a difference in the circulating levels of the parent enantiomers would have been 
expected, given the data obtained from in-vitro experiments.
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No chromatographic peaks corresponding to the N-demethylated parent, were seen during the 
analysis with either UV or mass spectrometric detection. A number possibilities exist for the 
absence of the N-demethylated metabolite. The metabolite may have been excreted so rapidly 
that the levels of metabolite circulating in plasma were too low to detect, even when using 
LC-MS. A further possibility was that the metabolite was rapidly metabolised to a further 
metabolite, the molecular ion for which was not monitored for (LC-MS). This route of 
metabolism was not seen in-vitro where the N-dealkylated metabolite was subsequently 
metabolised by further N-demethylatyion to the primary amine. The rate o f this conversion 
did not exceed the rate of production.. A disconcerting possibility was that no metabolism 
took place. If  this was the case, it casts doubt upon the in-vitro in-vivo model approach. 
Without urine samples from the rats, it is impossible to say, that the metabolite was not 
rapidly excreted, or similarly, that the metabolite was not rapidly metabolised further. 
However, in-vitro, the N-demethylated metabolite was not rapidly cleared in non-induced 
rats.
If  no metabolism took place, what might have been the possible reasons? The rats underwent 
surgeiy prior to the study to insert the cannulea that were used to dose animals and withdraw 
blood samples. Although unlikely, it might have been possible that these procedures in some 
way compromised the metabolic capacity of the animals either physically or biochemically.
The calculated pharmacokinetic parameters confirm that little distinction was made between 
the enantiomers of either XX or XXI by the rats. The measured plasma concentration of the 
enantiomers of XX were more variable than those recorded for XXI, particularly at the early 
time points. No obvious explanation was found for the observed variation as no dosing or 
sampling difficulties were experienced with these animals The mean plasma concentrations 
of enantiomers of both test compounds, however, result in excellent correlation for the fitted 
lines. The model fitted to the individual data points is more appropriate than a comparison of 
the three animals modelled individually, and the parameters calculated from these models are 
discussed below.
The terminal half life for XXI peak 1 was longer than that measured for peak 2 (the reverse 
of the expected result). The difference is possibly an artefact of the 6 hour time point 
recorded for just enantiomer from only one animal and the 0.267 hr sample for rat 2, peak 2. 
The total exposure of the two enantiomers, the AUC, was 779 and 819 ng ml"' hrs for peaks 1
217
and 2 respectively an absolute difference of only 5%. The disposition o f XXI enantiomers 
was also similar with a distribution coefficient o f 2.62 and 2.26 ng g*' respectively. That the 
drug was able to distribute itself into a theoretical volume exceeding that of the whole animal 
was indicative o f a deep tissue store (the peripheral compartment). A possible explanation for 
the obsei-ved value would be partitioning into lipid or binding to tissues which is common for 
weak bases such as the test compounds. Similar parameters were found for XX with a lower 
AUC (260 and 281 ng ml"' hrs), reflecting the lower dose administered. The volume of 
distribution at steady state was higher (distribution coefficient 3.34 and 3.02 ml"') than found 
for XXI but not significantly so.
In summary, both test compounds behaved similarly without the differences in 
enantioselective clearance seen so clearly when using in-vitro preparations. The 
pharmacokinetic data has provided some further information relevant to the questions 
regarding the lack of detectable metabolism. Highly protein bound compounds are unable to 
undergo metabolism because they have no access to the enzymes responsible. Both of these 
drugs have high volumes of distribution and are not limited to the circulating plasma volume 
and therefore not highly bound to plasma proteins. Equally, the C log P for these compounds 
( C log P = 4.1) would suggest that they were able to partition into lipid and as such would 
penetrate the lipid rich smooth endoplasmic reticulum containing the cytochrome P450 
family o f drug metabolising enzymes.
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GENERAL DISCUSSION
That chirality is important in the biological and the pharmacological sense is without 
question''''®*^^'^’ Similarly, its impact upon the development of new medicines
remains beyond doubt *” “• Government
agency guidelines affecting the development of new chiral drugs have been published, for 
example from the American FDA*. These policy statements have not been as limiting (in that 
only single enantiomers could be developed or that racemic mixtures were proscribed) as 
might have been expected some views on the safety of racemic medicines. However, the 
development of racemic drugs does require additional supporting information to be generated 
and submitted to the authorities, and as a consequence, new drugs are more likely to be 
marketed as single enantiomers 1992] future. To facilitate the
development of these new drugs, the use of enantioselective pharmacodynamic and 
pharmacokinetic information in the process for the selection of candidates for development 
will hopefully result in medicines with improved potency and efficacy but fewer side effects.
Manufacturers o f chromatographic materials have not been slow to take advantage of the 
growing desire of analysts to use direct enantioselective chromatographic methods. With over 
400 stationary chiral phases identified for HPLC, it may be thought that a ready solution 
exists to every chiral analytical problem. Although it’s difficult, if not impossible, to test, 
this belief is probably unfounded. The possibility of a universal CSP (as the C l 8 column is 
perhaps perceived to be in achiral chromatography!) remains the “Holy Grail” of chiral 
chromatography protagonists. However, the proliferation of CSPs, of itself, is not helpful to 
the rapid development of chiral HPLC methods unless there is understanding of the 
mechanisms of enantioselectivity.
Though there a large number of phases available, differences between phases may be less 
than might be thought. For example, there are three sizes of cyclodextrin commonly used as 
chiral selectors in HPLC. The mechanism of enantioselectivity is identical for each, but the 
size of analyte which can be accommodated (included) into the non-polar “bucket” is varied, 
Cyclodextrin may be derivatised with, for example, napthylcarbamate and used with 
non-aqueous solvents (normal phase chromatography). Used in this mode, applicability has
' Department of Health and Human Services, Food and Drug Administration: FDA’s policy statement 
for the development of new stereoisomeric drugs. 92D-0211, 1992.
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now been altered significantly, via a change in the mechanism of the CSP-analyte interaction, 
and host-guest inclusion is thought to be no longer possible. However, the column is now 
similar to the equivalent Pirkle type phases or derivatised cellulose phases. The selectivity 
differences seen between these columns may arise from subtle alterations in the presentation 
of the functional groups to the analyte, and from steric interactions with the support matrix. It 
would have been interesting to have used the 2-aminotetralin analogues to examine two or 
more CSPs derivatised as for the Chiralcel OD phase to see if these subtleties could have 
been examined.
Another approach to a “universal” CSP which may increase the applicability of a particular 
CSP, is the use of an alternative mode of chromatography i99si Supercritical fluid 
mobile phases , for example, can improve efficiency, robustness and resolution .
However, the analyte-CSP mechanisms involved remain the same and thus, this approach can 
not be a panacea.
For this project none of the CSPs tried were able to adequately resolve the enantiomers of 
more than about half of the 2-aminotetralin analogues. A universal column was not found and 
four analogues remained unseparated by any of the columns tried. That some compounds 
from a series of similar analogues remained unresolved is not uncommon .
A further strategy to overcome the limited application of a single CSP has been to encourage 
different analyte-CSP interactions. Examples of this approach are the Whelk -01 (with both 
7î-acid and ir-basic functionality) and the macrocyclic antibiotic derived columns, such as 
Chirobiotic V (vancomycin, where multiple binding sites on the CSP can be identified). 
Regardless of the number of CSPs available, it is doubtful that a universal column will be 
developed, even for a closely related series of compounds like the 2-aminotetralins.
It is pertinent to ask that if a universal column does not exist, what alternative strategies can 
be used to achieve the necessary goal of rapid development of enantioselective 
chromatographic methods? Can extant columns be used in a better way, for example, can the 
factors influencing the chiral discrimination of CSPs be explained more thoroughly and hence 
better controlled?
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The factorial design methodology was a useful, but slow, method of optimising the 
separation of enantiomers. The simultaneous factorial design developed here, particularly if 
used with short columns, significantly improved the speed at which new methods could be 
developed. The replacement of an existing factor, or the addition of a new factor, to allow a 
choice of stationary phase, potentially broadens the application of the method further.
The development of this concurrent method development strategy was informed by the 
optimisation experiments conducted with Chiral AGP. The results obtained from these 
experiments were consistent with the accepted views of AGP enantioselectivity IHcrmansson, 
1987 and 1989) reversed phase nature of the CSP is particularly compatible with extracts o f 
biological origin but efficient sample clean-up is always required if long column life is 
wanted.
Some of the deficiencies of chiral stationary phases, such as lower efficiency and limited 
peak capacity, may be overcome with coupled column methods, some of which are 
particularly elegant . However, these techniques can not overcome a lack of
enantiomer discrimination by the CSP. The application of gradient elution techniques to 
Chiral AGP ''or other CSPs) appears to be uncommon, if not unique. The use of column 
efficiency enhancing gradients could significantly improve the applicability of protein based 
stationary phases. Whether this approach was possible with other CSP types was not tested.
A algorithm which would allow the analyst to choose the most appropriate CSP for a 
particular analyte structure would be an effective alternative to an universal column. Many 
analytical groups, with varying success, have sought computational models to fulfil this. The 
“rule” based method of the enantioselectivity of 2-aminotetralin on Chiral AGP was 
sufficient to define analytes which could not be separated using this particular column. The 
development of the rule based method into a linear regression method was still too limited to 
be effective, except to indicate that the more polar the enantiomers were, the less likely they 
were to be resolved. The colourful images of the molecular graphics template model are 
seductively simple but even so, the model was the most successful in explaining the 
enantioselectivity of Chiral AGP for the 2-aminotetralins,
A recent study, in many respects similar to that described here, examined the capacity factor 
of 52 basic drugs on Chiral AGP . A regression model using C log P, electron
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excess charge on the aliphatic nitrogen and molecular volume to describe retention was 
developed. Where a separation of enantiomers occurred, the mean capacity factor was used. 
These results underline the importance of the basic nitrogen and the non-polar interactions 
between analytes and Chiral AGP. However, the description of the binding site is not 
consistent with the results reported here. The steric restriction at the anionic site is unlikely to 
be as severe as they appear to suggest (given the results obtained with the 2-aminotetralins, 
particularly the separation of compound V m  with its large nitrogen substitution). This 
difference perhaps arises from the achiral analysis of binding to a chiral binding site. The 
authors had not included a possible hydrogen bonding region in their model.
It has been demonstrated that understanding the chiral recognition process, rather than the 
addition of another variation of a cyclodextrin or cellulose stationary phase to the columns 
available to the analyst, has more to offer the rapid development of enantioselective methods 
per se. This is not to suggest that the targeted development and production of a chiral 
stationary phase for the analysis or preparative chiral chromatography of a specific molecule 
IPirkie, 1992] inappropriate, but it is a separate issue and not within the remit of this study.
The development of enantioselective bioanalytical methods does not end with the 
achievement of a separation of the enantiomers. To support in-vitro and in-vivo studies, the 
analytes must be measured in a variety of biological matrices. Robust bioanalytical methods, 
especially chiral, require clean extracts. For this study solid phase extraction, was simple, 
robust and easy, and a single method was effective for all the test compounds. Solid phase 
extraction may be used on-line, analogous to column switching, but off-line methods tend to 
be more flexible. The SPE - Chiral AGP method was adequate for the analysis of the 
keto-pyrrol substituted 2-aminotetralin analogues in all of the biological matrices examined.
The in-vitro models all demonstrated qualitatively identical phase 1 (oxidative) reactions. 
Conjugation reactions (phase 2) were identified only in liver slices. Hepatocytes appeared to 
be the most effective preparation, showing reproducible turnover of substrates and 
enantioselectivity. Cultured hepatocytes could be an improvement upon freshly isolated cells, 
in that they might allow better characterisation of the metabolising enzymes. The in-vitro 
experiments indicated that the observed enantioselectivity was probably the result of the 
action of a number of P450 sub-families. Non-P450 reactions, for example those o f flavin 
containing mono-oxygenases  ^were not examined.
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The determination of which P450s were responsible for specific reactions would require 
experiments more sophisticated than those reported here. Achiral gradient methods were 
developed (using solvent selectivity changes, not solvent strength, unreported) which were 
able to resolve many more minor metabolites than those reported. These gradient methods 
could be used to support a variety of in-vitro methods. The analysis o f incubates of pure 
enantiomers (or racemates) and probe substrates; purified P450s or recombinant P450 
isozymes could be used to determine the involvement of specific P450 families. With this 
information, informed decisions could be made as to the relevance of the observed 
metabolism to that expected in humans, for example, CYP2D polymorphism.
The results from the pharmacokinetic experiment were disappointing. The limitations upon 
the conduct of the study meant that is now impossible to tell whether the model was in some 
way compromised with respect to metabolism of the analytes. The measurement of first-pass 
effects, renal clearance and the identification of metabolites excreted into urine would be 
required before the relevance of the observed in-vitro metabolism could be determined.
In summary, it was clear that whilst a universal chiral chromatographic procedure for this 
series of compounds was unlikely, it was possible to use strategies to quickly develop 
suitable chromatographic separations. The use of solid phase extraction techniques produced 
extracts of biological samples (cell suspensions, plasma etc.) that were sufficiently free of 
endogenous compounds to allow extended use of protein based CSPs without degradation of 
their chromatographic performance.
Data have been generated that show the degree of in-vitro metabolism of the enantiomers o f a 
number o f 2-aminotetralin analogues. A similar analytical approach could have been applied 
to a majority of the remaining members of this group of compounds. However, it remains to 
be determined whether the outcome of the present study can provide the basis for studying 
the metabolism of new aminotetralin analogues.
This project has suggested several avenues of further investigation. Of most relevance to the 
central objective of the project, i.e. rapid chiral method development, is the further 
development of the simultaneous factorial design. Two approaches would appear to be 
practical, the first being application to specific compound classes, where analogues are 
produced with minor structural modifications in the search for increased receptor activity or
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metabolic stability, etc. As more information is generated the experimental design would 
evolve, and it is quite possible that different designs would be generated which focused upon 
different structural features of the analogues. For example, modifications at one site on the 
molecule might indicate that an experimental design using a Chiral AGP column would be 
most beneficial. Conversely, modifications at a second site might indicate that Chiralcel OD 
or derivatised cyclodextrin would be more appropriate. An alternative approach might be the 
development of a number of simultaneous designs using complementary CSPs as a factor 
thereby maximising the chance of finding a separation for a disparate selection of analytes.
The development of the molecular graphics template for Chiral AGP (and perhaps other 
protein derived CSPs) has much merit in its own right as a model o f the Chiral AGP 
enantioselective binding site, and as a less strict (less defined, as reported here) model in 
conjunction with the simultaneous factorial design. Used in this way it could direct the 
analyst towards (or away from) a particular CSP / optimisation design.
In conclusion, the combination of these two methods could provide the analyst with the tools 
to generate enantioselective pharmacokinetic and pharmacodynamic information at the speed 
necessary to support the discovery of new medicines.
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